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ABSTRACT   
 The aim of this study was to investigate how to produce iron oxide nanoparticles, 
with the potential for long circulation times or the ability to preferentially reach 
particular tissues.  
The preparation of iron oxide nanoparticles was achieved using inorganic solution 
methods to prepare particles of small size using a narrow size distribution. The 
nanoparticles were coated with dextran and carboxymethyl dextran as reference 
materials using the same method as in the preparation of the iron oxide nanoparticles. 
This project investigated the use of the biodegradable polymer poly(glycerol adipate) 
(PGA) as a coating for iron oxide nanoparticles. PGA is already used in drug 
delivery systems and showed an ability to control the rate of release of the drug. 
PGA can be readily modified with pendant functional groups leading to 
modifications of the physicochemical properties of the polymer. It can also be readily 
modified to form copolymers with the hydrophilic polymer poly(ethylene glycol) 
(PEG). PGA 40% acylated with stearic acid (PGA 40%C18) and the PEGylated 
copolymer PEG±PGA 40%C18 were synthesised for this work. 
The formulation of coated iron oxide nanoparticles was investigated using PGA and 
modified PGA polymers. The coating process was optimised producing small coated 
nanoparticles were measured by TEM and the best sizes are (16 ± 5 nm with PGA 
while with, modified PGA is 23 ±7 nm and with PEG±PGA 40%C18 is 16 ± 4 in 
diameter). The PGA±IONPs were over-coated by incubation with albumin and 
Tween. The coated particles were characterised by DLS, zeta potential, and 
transmission electron microscopy. The colloidal stability of the various particle 
formulations was investigated using increasing salt concentrations.  These 
demonstrated that PGA±coated nanoparticles were more stable than the existing 
dextran formulations, and that increased stability was obtained by overcoating with 
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albumin or Tween. A further increase in stability was seen with PEG-PGA coated 
nanoparticles. 
The cellular uptake of the RBITC labelled nanoparticle formulations was studied on 
the C6 medulloblastoma cell line using monolayer and 3-D aggregate cultures using 
fluorescence microscopy, confocal microscopy, transmission electron microscopy 
(TEM) and flow cytometry. The results indicated that these particles were readily 
internalised in C6 cells, but with an unusual subcellular distribution. Uptake was 
dependent on both nanoparticle concentration and incubation time. The incubation of 
cells with internalised particles demonstrated that particles were metabolised and 
fluorescence was lost from cells over a period of 4±12 hours. TEM studies showed 
that, after 1 hour, nanoparticles were found in all subcellular compartments, but that 
the route of entry into cells could not be readily determined. Experiments using 3-D 
cell cultures demonstrated that nanoparticles were readily taken up into aggregates, 
with nanoparticles penetrating deep into the aggregates. 
Overall, these studies demonstrated novel formulations of iron oxide nanoparticles 
coated with well-defined biodegradable PGA polymer layers, which were stable 
against aggregation under physiological conditions. These formulations show 
promise for use in a variety of medical applications. 
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CHAPTER 1 
1. INTRODUCTION 
1.1 A Brief Overview of Iron Oxide Nanoparticles  
Iron oxide nanoparticles (IONP) have been studied extensively over the past few 
decades to fabricate various novel contrast agents. Considerable research has been 
directed towards developing particles with an appropriate size and stability and 
modifying their properties by coating them with biodegradable polymers, to enhance 
their application in providing high resolution in magnetic resonance imaging (MRI) 
and as a good diagnostic agent.  
Over 50 years ago the application of small IONPs was investigated for in vitro 
diagnostic tests (Gilchrist et al., 1957). Since then, studies on different types of iron 
oxides have been carried out in the field of magnetic particles  with a small size of 
about 5±20 nm in diameter. Studies reported to date have dealt with magKHPLWHȖ-
Fe2O3, or magnetite, Fe3O4. Of these two, magnetite is a very promising candidate 
and subsequently its biocompatibility has already been tested (Schwertmann and 
Cornell, 1991) 
1.2 Review of Iron Oxide Nanoparticles 
A basic requirement for the use of nanoparticles in different areas in medical 
applications is a controlled particle size distribution. Superparamagnetic iron oxide 
nanoparticles (SPIONs) with suitable surface modification can be used for 
applications such as MRI contrast agents, drug delivery, tissue repair, hyperthermia, 
detoxification of biological fluids and immunoassay. For all these applications, the 
particle size must be smaller than 100 nm with a narrow distribution and have high 
magnetisation values (Gupta and Gupta, 2005).  
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The control of particle size is most important because the properties of the 
nanocrystals rely greatly on the dimension of the nanoparticles. Many studies have 
investigated the behaviour of the nanoparticles, and others have focussed on 
improving their applications, the stability of the particles and the control of 
surfactants (Laurent et al., 2008). 
The type of method used for producing nanoparticles is very important. Additionally, 
the stability of the uncoated nanoparticles should be addressed as the aggregation 
process due to Van der Waals forces is the principal disadvantage of IONPs. 
To prevent aggregation the nanoparticle must be coated by degradable nontoxic and 
biocompatible polymer. There are many polymers which have been used to coat iron 
oxide particles, such as dextran, poly(ethylene glycol) (PEG), poly(lactide-co-
glycolide) (PLGA), and poly(vinylalchohol) (PVA). The nature of surface coatings 
and their subsequent geometric arrangement on nanoparticles determines not only the 
overall size of the colloid but also plays a significant role in the biokinetics and 
biodistribution of nanoparticles in the body. Some authors have reviewed the 
different factors related to the clearance of the IONPs from blood: particle size, dose, 
surface charge, coating material, and stability in physiological environment. The 
IONPs could also bind enzymes, nucleotides and drugs. Moreover, it has been 
proposed that, by using an external magnetic field, nanoparticles can be directed to a 
tumour, organ or tissue.  (Gupta and Gupta, 2005).  
Various methods have been developed for the preparation of IONPs (Mornet et al., 
2006). The co-precipitation technique is a very cheap and simple method (Qu et al., 
1999). Hydrothermal synthesis techniques are an alternative method for the 
preparation of highly crystalline IONPs (Wang et al., 2005). But there is no direct 
way to control the size and the shape of the final particles (Figuerola et al., 2010).  
Over the last ten years, significant advances have been made on the colloidal 
synthesis of nanocrystals in high-boiling point organic solvents (Park et al., 2004). 
There are others, such as sol-gel reactions, thermal decomposition method, etc.   
Chapter 1  Introduction 
3 
Characterisation of the nanoparticles, including their physicochemical properties and 
structure, can be done using techniques such as direct light scattering (DLS), 
Transmission electron microscopy (TEM), X-ray diffraction and photon correlation 
spectroscopy. There are many factors affecting the properties of nanoparticles such 
as the chemical and physical size, surface coating and the thickness of surface 
coating. The nanoparticles have a large surface area. Furthermore, the attractive 
forces between the particles make them aggregate. To overcome all these problems, 
nanoparticles can be coated by polymers. There are two kinds of polymer: natural, 
like dextran, and synthetic like PVA. The coating must be hydrophilic and 
biocompatible so that the particles can disperse in biological fluids. Also the surface 
coating has an effect on the magnetic behaviour of nanoparticles. Agglomeration will 
occur when the particles have a strong magnetic attraction or the polymers have a 
short length. On the other hand particles with sufficiently low ferromagnetic effects 
and polymers with long length can produce sufficient repulsive forces to prevent the 
agglomeration (Huber, 2005). 
The copolymers typically have a hydrophobic part that acts as an anchor and a 
hydrophilic part which forms tails to prevent bridge flocculation between one particle 
and another particle. Polymers must cover the entire surface of particles in order to 
overcome this aggregation problem (Storm et al., 1995). The iron oxide core can be 
coated with polymers during the synthesis process and it must be a long chain. 
However, the pH and temperature have an effect on the surface bound polymers 
(Enochs et al., 1993). Covering particles by a dense brush of polymers, e.g. dextran, 
prevents the particles reacting with blood proteins and receptors (Weissleder et al., 
1995a). 
1.3 Properties of Iron Oxide Nanoparticles  
The size of particles usually refers to the total diameter of the particles including the 
iron oxide and coating.  Because the smallest capillaries are 4 µm in diameter, 
particles or aggregates larger than this size will be captured and precipitated and   
this could cause emboli within the capillary bed of the lungs (Kreuter, 1983).  
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Particles tend to aggregate based on their magnetic energy, thus reducing their 
surface charge. As a result, this could lead to precipitation that may cause a very high 
risk if the particles are injected. The surface charge and aggregation behaviour of the 
particles in the blood must be known (Storm et al., 1995). Nanoparticles were 
eliminated immediately via macrophages of the mononuclear phagocytic system 
(MPS) because the defence system in the body recognised them as being alien to the 
body (Muller et al., 1997). 
 Particle sizes smaller than 4 µm are taken up by the cells of the reticuloendothelial 
system, mainly in the liver (60±90%) and spleen (3±10%) (Neuberger et al., 2005). 
While it is more likely that small particles up to 100 nm will be phagocytosed 
through liver cells, there is a tendency for particles larger than 200 nm to be filtered 
by the venous sinuses of the spleen (Moghimi et al., 2001). When particles with sizes 
in the range between 30 and 100 nm are injected intravenously, the larger particles 
will be eliminated by the liver from the blood faster than the small particles. 
Therefore, the larger particles are, the shorter is their plasma half-life-period (Chouly 
et al., 1996b). The uptake can be classified according the particle size, as 
phagocytosis of all size, or pinocytosis (particles <150 nm) (Muller et al., 1997). 
Phagocytes recognise and remove the larger particles, while smaller particles can be 
removed by all types of cell through pinocytosis. An increase in particles size leads 
to an increase in the phagocytotic activity (Maaßen et al., 1993).  
For particles smaller than about 15 nm the cooperative phenomenon of 
ferromagnetism cannot be seen for longer periods and temporary magnetisation does 
not remain after the particles have been subject to a temporary external magnetic 
field (Sorensen, 2002). 
Ferromagnetic particles occur when unpaired electron spins align themselves 
spontaneously. Then the material is able to exhibit magnetisation without being in a 
magnetic field. Single atoms cannot exhibit ferromagnetism, but when a number of 
atoms unite in solid form, ferromagnetic properties arise and particles exhibit 
permanent magnetisation once the ferromagnetic particles are removed from the 
field. The ferromagnetic material will initially oppose the field change soon after 
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field reversal, but finally the majority of domains will have turned their 
magnetisation vectors and the same inverse magnetisation is achieved. However, 
when the dimensions of ferromagnetic materials is reduced to particle dimensions 
smaller than a particular domain, the particles are no longer ferromagnetic but exhibit 
superparamagnetism (Elliott, 1998).  
In the case of paramagnetic particles, a magnetic field is altered by the magnetic 
materials present in it. If a particle contains magnetic moments that can be aligned in 
an external magnetic field, this will amplify the field. Such substances exhibit the 
property of paramagnetism. In contrast to ferromagnetic materials (ferromagnetism), 
no permanent magnetization remains in paramagnetic materials when they are 
removed from the magnetic field.  Paramagnetism can be understood by postulating 
permanent atomic magnetic moments, which can be reoriented in an external field. 
These moments can be either due to orbiting electrons or due to atomic nuclei. The 
torque applied by an external magnetic field on these moments will tend to orientate 
them parallel to the field (Chen, 1986). 
1.4 Synthesis of Iron Oxide Nanoparticles  
Numerous methods can be used to synthesise IONPs for medical applications and 
especially for medical imaging applications. These methods include thermal 
hydrolysis, sol-gel syntheses, hydrothermal reactions, microemulsions, sonochemical 
reactions, flow injection synthesis, electrospray syntheses, hydrolysis and 
thermolysis of precursors, and the common method co-precipitation, which is widely 
used for preparation of IONPs.  
1.4.1 Co-precipitation Method 
The wet chemical method has many advantages for producing IONPs.  It is simple 
and efficient and has the capability of control over the size, composition and even the 
shape of the nanoparticles (Gupta and Curtis, 2004a, Gupta and Wells, 2004 and 
Reimers and Khalafalla, 1972). Iron oxide, either Fe3O4 or Ȗ Fe2O3, can be produced 
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using  the co-precipitation of Fe2+ and Fe3+ aqueous salt solutions by addition of a 
base (Reimers and Khalafalla, 1972). The size, shape and composition of 
nanoparticles can be controlled according on the type of salts used (sulphates, 
nitrates, chlorides,  etc.), ionic strength of the media, Fe2+ and Fe3+ ratio, and pH 
(Hadjipanayis and Siegel, 1993 and Sjoegren et al., 1994).  
In the traditional way, magnetite is prepared by adding a base to an aqueous mixture 
of Fe2+ and Fe3+ chloride at a 1:2 molar ratio. The precipitated magnetite is black in 
colour. (Schwertmann and Cornell, 1991 and Cotton, 1988) 
Aqueous co-precipitation of Fe3+ and Fe2+ at a ratio of 2:1 to prepare the magnetite 
nanoparticle is usually carried out in the presence of a base at pH 8±14 under 
anaerobic conditions. Magnetite is sensitive to oxidation and not stable in the air. 
This could critically affect the physical and chemical properties of the IONPs. Often 
the particles are coated with organic or inorganic molecules during the precipitation 
process to prevent the oxidation caused by air and also the formation of aggregates. 
To overcome the oxidation of Fe3O4 nanoparticles as which depends on oxidation 
speed and species, the reaction must be under a N2 atmosphere to protect the particles 
and to reduce the size, when compared with methods without removing the oxygen 
(Gupta and Curtis, 2004a and Kim et al., 2001). The influence of different wet-
chemical synthesis parameters such as iron (II) iron (III) ratio or varying pH and 
ionic strength on the resulting iron oxide structure have been described by (Jolivet et 
al., 1992 and Tronc et al., 1992). 
Electronic or ion transfers are dependent upon the pH of the suspension. In basic 
medium, the oxidation of magnetite involves the oxidation±reduction of the surface 
of magnetite. Under anaerobic and acidic conditions, surface Fe2+ ions are desorbed 
as hexa-aquo complexes in solution (electron and ion transfer) according to: 
[Fe3+]A [Fe22.5+]BO4 + 2 H+ ĺ>)H3+]A [Fe3+  5/3 L1/3 ]B O4 + Fe2+  + H2O 
Where A and B stand for tetrahedral and octahedral sites, respectively, and L 
represents a vacancy. Maghemite nanoparticles, bearing a high positive charge 
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density (ı §  & P±2 at pH 2, and low ionic strength, 10±2/5.10±2 mol l±1), carry 
high positive charge density and can easily be dispersed in acidic water, forming 
cationic sols practically free from aggregation. Maghemite particles could easily be  
concentrated aqueous dispersions when resulting from oxidation of magnetite 
(Jolivet and Massart, 1983, Jolivet et al., 1997 and Prene et al., 1993). 
There is no migration of iron ions towards the interior of particles. Electrons and 
presumably protons are injected into the particle from the ferrous hydroxide adsorbed 
layer. This layer crystallises as spinel and the reaction stops when equal populations 
of Fe3+
 
and Fe2+ in the octahedral sub-lattice are reached. Similar electron transfers 
occur during adsorption of ferric ions on magnetite (Belleville et al., 1992). 
Several parameters can influence the properties of the particles produced. These 
parameters include: 
x Nature of salt  
x Concentration of salts  
x Volume ratio of the salt phase  
x Temperature  
x Ionic strength  
This method has many advantages. It can easily produce a large number of 
nanoparticles (Laurent et al., 2008). 
(Babes et al., 1999) have investigated the basics of the co-precipitation process, the 
influence of different parameters (media composition, iron ,, / iron ,,, ratio, injection 
fluxes, iron, temperature, and oxygen) on magnetic properties, size and morphology.  
Results by (Gnanaprakash et al., 2007) showed that the initial pH and temperature of 
the ferrous and ferric salt solution before initiation of the precipitation reaction and 
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the final pH are critical parameters controlling the formation of magnetite and 
nanoparticles. 
1.4.2 Gas phase Methods 
Gas phase methods for preparing nanomaterials is based on thermal decomposition 
(pyrolysis), reduction and disproportionation, oxidation, or other reactions to 
precipitate solid products from the gas phase (Pierson, 1999). In the chemical vapour 
deposition (CVD) process, a carrier gas stream with precursors is delivered 
continuously by a gas delivery system to a reaction chamber maintained under 
vacuum at high temperature (> 900 qC) (Tavakoli et al. and 2007, Chang et al., 
1994a). The products stick together and form aggregates or nanoparticles after the 
CVD reactions take place in the heated reaction chamber. Growth and agglomeration 
of the particles are minimised via rapid expansion of the two-phase gas stream at the 
outlet of the reaction chamber. Then heat treatment of the nano powders in various 
high-purity gas streams allows all the properties, such as compositional and 
structural modifications, particle purification and crystallisation, as well as 
transformation to a desirable size, composition, and morphology, to take place 
(Tavakoli et al., 2007 and Pierson, 1999). Important factors influencing the 
production of the nanoparticles are low concentrations of precursor in the carrier gas, 
as well as rapid expansion and quenching of the nucleated clusters or nanoparticles 
as they exit from the reactor (Tavakoli et al., 2007 and Chang et al., 1994b). 
Laser pyrolysis of organometallic precursors is dependent on the resonant interaction 
between laser photons and one or more gaseous species, reactants or sensitisers. A 
sensitiser is an energy transfer agent that is excited by absorption of CO2 laser 
radiation and transfers the absorbed energy to the reactants by collision (Dumitrache 
et al., 2005). The technique includes heating a flowing mixture of gases with an 
uninterrupted wave CO2 laser to initiate and sustain chemical reaction until a critical 
concentration of nuclei is reached  in the reaction zone, and homogeneous nucleation 
of particles occurs (Tartaj et al., 2005). The nucleated particles formed during the 
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reaction are entrained by the gas stream and are collected at the exit (Tartaj et al., 
2003a).  
1.4.3 Aerosol / vapour Methods  
Spray and laser pyrolysis are good direct techniques for producing small particles 
based on chemical processes to provide a high level of production; by spraying a 
solution into a series of reactors where the aerosol droplets undergo evaporation of 
the solvent and solute condensation within the droplet, followed by drying and 
thermolysis of the precipitated particle at higher temperature (Pecharromán et al., 
1995). Very small IONPs with a size about 5 nm are obtained by this method 
(Veintemillas-Verdaguer et al., 1998). 
1.4.4 Thermal Decomposition Method 
This method depends on two main routes to form the ferrites through hydrothermal 
conditions by oxidation or neutralisation of mixed metal hydroxides through the 
reaction of different ferrous salts as in the first method (Willard et al., 2004). Small 
particle sizes between 4±20 nm have been obtained using this method in the presence 
of alcohol, oleylamine and oleic acid. Particles can be transformed into a hydrophilic 
form by adding a bipolar solvent  (Sun et al., 2004a). A modification of this method 
was done by Maity et al., (2009) who used solvent±free thermal decomposition just 
in the presence of the stabilising surfactant and produced small nanoparticles around 
5 nm in diameter. Different parameters of the thermal decomposition procedure can 
be used to obtain high crystallinity and narrow size distribution and particle sizes 
between 4.9 to 14.1 nm in diameter.   
Further modification of this method by Ahniyaz et al., (2008) using thermal 
decomposition of an iron 2-methoxy-ethoxide with surfactant-free conditions 
together with oleic acid yielded relatively monodisperse iron oxide nanocrystals and 
resulted in an average size of  about 5.6 nm.  
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1.4.5 Polyols Method  
The polyol process is a chemical method which refers to the use of polyols such as 
ethylene glycol and diethylene glycol to reduce metal salts to metal particles. 
Preparation of a variety of inorganic compound with non-aggregated particles has 
been successful. The polyols in this method often work as high boiling solvents and 
reducing agents, and also as stabilisers to control the growth of particles and prevent 
the aggregation of the particles. One of the important advantages of this method is 
that it can control experimental conditions. Moreover, it is easy to scale up (Fievet et 
al., 1989b and Claus and Hans-Otto, 2001).  
In a similar reaction procedure with a variety of liquid polyols, including ethylene 
glycol, diethylene glycol, triethylene glycol and tetraethylene glycol Fe(acac)3 (acac  
acetyl cetonate) have  been reduced  to magnetite. The size obtained by this method 
was 20 nm in diameter and required only a single iron rich precursor and further 
reducing agent and surfactants (Cai and Wan, 2007).  
By using hybrid (organo-inorganic) aerosols and the temperature of pyrolysis, the 
method depended on utilising ethanol/water solutions containing iron inorganic salts 
and mono- or polysaccharides and produced nanoparticles with sizes from 50 to 400 
nm in diameter (Tartaj et al., 2007). 
1.4.6 Microemulsion Method  
The aqueous phase, containing Fe3+ (1M) and Fe2+ (0.5 M) in 0.1 M HCL, prevents 
oxidation with different ratios of microemulsion containing a volume ratio of 
cyclohexane. The method is based on stirring the mixture under a N2 atmosphere at 
room temperature for 10 min then stirring again at 50qC. Base microemulsion was 
injected to precipitate the particles and the change of colour to black was evidence of 
the formation of magnetite particles and their aggregation. Particles were subjected 
to washing with 0.5% tetramethylammoniun hydroxide and a large amount of 
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acetone to remove the surfactants and flocculate the particles. Particles were dried at 
65qC for at least 24h (Vidal-Vidal et al., 2006). 
Chin and Yaacob, (2007) have adopted this method to prepare IONPs at room 
temperature via water in oil microemulsion, resulting in IONPs which were spherical 
in shape and less than 10 nm.  
In the opposite way, Capek, (2004) used one microemulsion. IONPs were obtained in 
bis(2-ethylhexyl) sulfosuccinate AOT microemulsions with a stopped-flow 
technique. The processes of nucleation and growth can be observed in the production 
of nanoparticles that after precipitation and drying showed no aggregates in TEM 
images with a size less than 4 nm.  
1.4.7  Flow Injection Method 
This method is a modified version of manufacturing zinc oxide nanoparticles (Wang 
and Muhammed, 1999). The idea of this technique is that it consists of continuous 
injection of reagents into a carrier stream. One reagent injected might be sufficient. 
The reaction mixture transfers into the capillary reactor at the same time as the 
reaction takes place.  
By the ratio between the length of the manifold and the pumping rate, the residence 
time of the particles in the reaction mixture can easily be controlled. Mechanically, a 
propulsion unit, injection manifold, capillary reactor, and product collector are 
connected to the flow injection system. The most important part of the system is the 
injection manifold, which could be T- or X-shaped, where the reagents mix head-on 
with high accuracy in time and amount. The manifold function can be provided by an 
injection valve with segmentation capabilities. The function of the propulsion unit is 
the transportation of solutions through the system.  
The time of the reacting mixture residence can be defined by the pumping rate and 
dimensions of the capillary reactor. The additional features, such as inert atmosphere 
and temperature control, that could be provided by the injection system have led to 
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the development of this method and nanoparticles have been obtained with a narrow 
size distribution in the range 2±7 nm in diameter (Salazar-Alvarez et al., 2006). 
1.4.8 Electrochemical Method  
This method consists of an electrolytic cell with anode and cathode, using an iron 
plate and stainless steel thin sheet as anode and cathode respectively where the space 
between them was 5 mm. The pH was maintained at 10 with concentrated sodium 
hydroxide solution and the electrolyte was Na2S2O3 with a concentration of 
0.02 mol/L. The applied current density was defined at the start by adjusting the 
voltage, until the change of the colour of the mixture to black occurred during the 
first 20 min. The electrolysis reaction was directly controlled by imposing the 
temperature, current density and intense agitation for a specific time. The final 
product was centrifuged and the residue was removed by deionised water at constant 
temperature in a hydrogen stream into the reactor for reduction at constant flow rate 
(2 L/h) for 3 h. The particles were then cooled to room temperature under a hydrogen 
atmosphere. To modulate the magnetic properties of the composites the reduction 
temperature was varied between 300 and 400qC.  
IONPs have been synthesised within the pores of mesoporous silica (MS) 
microspheres by an electrochemical method to produce IONPs with a diameter of 20 
nm inside the pore of MS spheres (Wang et al., 2007). Sizes varying from 20 to 30 
nm of IONPs have been obtained using electrochemical method (Cabrera et al., 
2008).  
IONPs having an average size of 6.2 nm with a quite narrow distribution were 
synthesised with new parameters based on electro-precipitation in ethanol medium. 
The reaction precipitated the Fe(OH)3. The next step was reduction of iron hydroxide 
to magnetite in presence of hydroxyl ions which are generated at the cathode 
(Ibrahim et al., 2009).  
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1.5  Surface Coating 
A variety of biodegradable polymers have been used to coat the IONPs. Polymers 
can be manipulated by modifying with different functional groups to increase the 
stability of the nanoparticles. These coatings can also protect the nanoparticles 
in vitro and in vivo. This review will cover both natural organic polymers and 
synthetic polymers. 
1.5.1  Dextran  
Dextran is a polysaccharide (C6H10O5)n, composed exclusively of alpha-D(1-6) 
linkages with some unusual 1,3 glucosidic linkages at branching points. Dextrans are 
used to coat IONPs in aqueous solution, resulting in particles with overall sizes 
between 20±50 nm  (Tueng et al., 1993). 
The first report of the formation of magnetite in the presence of dextran was by 
Molday and MacKenzie, (1982). Co-precipitation is the most common method to 
obtain polysaccharide-coated iron oxide particles (Goetze et al., 2002). An average 
magnetite core size of 7.1 nm was found by X-ray diffraction and that of 8 nm was 
found by transmission electron microscopy. An average diameter of 25 nm was 
observed for dextran coated IONPs by scanning electron microscopy and a 
hydrodynamic diameter of 25±300 nm was obtained by photon correlation 
spectroscopy. The coated particles showed a weak negative charge in the buffer 
solutions at pH between 5.5 and 9.5 (Xu et al.,2005). 
By using the Molday co-precipitation method, ferumoxtran-10 and ferumoxides have 
been produced (Lee et al., 2002).  The effects of the molecular weight of dextran 
upon the formation and the stability, on size, morphology, coating efficiency and 
magnetic property have all been investigated. Dextrans with molecular weights of 
3000, 10,000, 20,000 and 40,000 have been used. The low molecular weight dextran 
gave the smaller desired particle size of 77.80 nm, while increasing the molecular 
weight resulted in a particle size increase to 121.4 nm, 156.2 nm and 192.1 nm 
respectively (Hong et al., 2009).  
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A comparison has been made between the laser pyrolysis technique and co-
precipitation method for preparation of dextran coated IONPs to explore the 
mechanism of adsorption of the dextran on the surface of IONPs. At 25±500 °C, the 
mechanism of adsorption is probably hydrogen bonding between dextran hydroxyl 
groups and the iron oxide particle surface (Carmen Bautista et al., 2005).  
Dextran provides hydroxyl functional groups that can be substituted, carboxymethyl 
dextran (CMD) being very common. IONPs coated by CMD using a co-precipitation 
method with diameters of about 90 nm and 120 nm were produced. The stability of 
particles against aggregation was investigated over a period of more than one week. 
A strong agglomeration and increase of particle size was observed after one day 
(Dutz et al., 2007). 
1.5.2  Polyethylene Glycol (PEG) 
Poly(ethylene glycol) (PEG) is non-toxic and non-immunogenic, and provides high 
steric stabilisation. Its uncharged hydrophilic residues and high surface mobility keep 
the particles apart and stable in aqueous solution and prevent protein adsorption to 
the particles and adhesion to cells (Yasugi et al., 1999 and Zhou et al., 2003). 
Therefore, the presence of covalently immobilised PEG on the surface of IONPs is 
most likely to enhance the biocompatibility and stabilisation of the nanoparticles. 
PEG has chains with some terminal functionality and can be coupled with 
biopolymers to create biodegradable copolymers such as SRO\İ-caprolactone)-
poly(ethylene glycol)-pol\İ-caprolactone) (PCL-PEG-PCL, PCEC) copolymers  
(Gou et al., 2008).  
PEG polymers with molecular weights below 100,000 Da are amphiphilic and 
soluble in water. They are also soluble in many organic solvents, such as methylene 
chloride, toluene, acetone, chloroform, and ethanol. This allows PEG to be reacted 
with IONP surfaces using different chemistries that require the use of either aqueous 
or organic solvents (Veiseh et al., 2010). Various methods of coating were developed 
to prepare small (60±100 nm) and ultrasmall (20±35 nm) particles without size 
separation processes (Acar et al., 2005). 
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Iron nanoparticles were coated with PEG diacid via the grafting of 
aminopropylsilane groups and the coupling of oxidised PEG through the formation 
of a covalent bond. PEG diacid is covalently coated on the surface of the 
nanoparticles via at least one of their carboxylic groups, leaving the other COOH 
group available for further chemical reaction. PEG diacid coated IONPs were 
investigated by TEM and found to have an approximately spherical shape and an 
average diameter of 20 nm (Feng et al., 2008).  
Kumagai et al., (2009) have reported a method to synthesise block copolymer-coated 
IONPs by chelation between the carboxylic acid groups in poly(ethylene glycol)±
poly(aspartic acid) block copolymer (PEG±PAsp) and Fe on the surface of the 
IONPs. The TEM image showed PEG±PAsp-coated nanoparticles forming clusters 
with a size range of 100 nm, the hydrodynamic diameter with DLS and shown to be 
in the range of 100 to 120 nm with a unimodal distribution, for Asp/Fe ratios ranging 
from 0.02±0.5. 
In a one-step procedure, IONPs were coated with silanated monomethoxy 
poly(ethylene glycol) (m-PEG) in aqueous medium. The mean particle sizes of the 
nanoparticles determined by X-ray diffraction and TEM gave an average size of 
20 nm in diameter (Hu et al., 2008). 
1.5.3 Poly(D, L-lactic-co-glycolic acid) (PLGA) 
Poly(dl-lactic-co-glycolic acid) is a biocompatible, biodegradable and non-toxic 
material used for preparing nanoparticles and microparticles. PLGA is a copolymer 
of lactic and glycolic acid (Zimmer and Kreuter, 1995 and Bala et al., 2004). 
 Lee et al., (2004) have prepared magnetic nanoparticles of Fe3O4 encapsulated 
within PLGA for MRI contrast agents by using an emulsification diffusion method. 
The size was reduced to 120 nm by increasing the homogeniser speed up to 22,000 
rpm.  
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Zhao et al., (2009) have produced poly(lactic acid) (PLA)-coated magnetic 
nanoparticles using uncapped PLA with free carboxylate groups. Magnetic 
microspheres (MMS) with the matrix material PLGA or PLA were then formed by 
the emulsion solvent evaporation method. The physical properties of these particles 
were compared to those of oleate-coated or oleate/sulphonate bilayer coated 
magnetic particles. PLA coated IONPs using w/o emulsion resulted in particle sizes 
of 180 ± 50 nm diameter. The polymer shell showed high protection of particles in 
pH 5.5 to 10.8 sensitivity with respect to the stability of magnetite particles (Gómez-
Lopera et al., 2006). 
1.5.4 Polyvinyl alcohol 
PVA is a water-soluble polymer and has isolated hydroxyl functional groups, which 
can adsorb and complex with metal ions (Jiu et al., 2002). 
Xu and Teja, (2008) have modified the surface of IONPs with PVA by continuous 
hydrothermal synthesis. The final polymer coated particles produced at different 
concentrations of PVA showed different sizes from 7 to 27 nm. The average particle 
size was shown to increase with temperature and residence time, and is accompanied 
by morphology changes in some cases. (Mahmoudi et al., 2010)  have  reported  
synthesis  of IONPs  with PVA  by precipitation of  iron  oxide  salts  in PVA 
aqueous solution  at various temperatures and at different concentrations. The results 
suggest that the PVA binds to the surface of the nanoparticles due to the presence of 
OH groups on the polymer chains and the nanoparticles. Also, using the same 
method, PVA coated super-paramagnetic iron oxide nanoparticles (SPION) of 
6-10 nm core and 30 nm hydrodynamic sizes were obtained. The IONPs were first 
obtained by classical co-precipitation in water. A thermochemical treatment and 
centrifugation was then applied to obtain well-dispersed primary nanoparticles. PVA 
of molecular weight 12,000 was used to coat the particles (Schöpf et al., 2005).   
Lee et al., (1996) found that crystallinity of the core decreased with increasing 
concentration of PVA present during the synthesis of iron oxide particles in the range 
of 4±10 nm through a precipitation reaction to form a stable dispersion. Binding 
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between the surface of nanoparticles and the polymer was found using FTIR 
absorbance shifts. 
1.5.5 Alginate    
$OJLQDWH LVD OLQHDUSRO\PHUFRPSRVHGRIĮ-d-PDQQXURQDWH 0DQGĮ-l-guluronate 
*XQLWVOLQNHGE\Į-DQGĮ-1,4 glycosidic bonds. M and G units are organised in 
MM, GG and MG blocks (Rocher et al., 2010). 
Alginate-coated IONPs showed good biocompatibility and some magnetic targeting 
under a magnetic field. The high stability provided by alginate coated IONPs may be 
attributed to the binding of the carboxyl group of alginate to iron oxide (Ma et al., 
2007).  
Morales et al., (2008) and Finotelli et al., (2004) have prepared alginate-coated 
particles by dropping commercial sodium alginate solution (3%) into aqueous ferric 
chloride solution.  
Two samples were prepared, sample A with 0.01 M and sample B with 0.5 M ferric 
chloride solution, which produced preformed IONPs encapsulated in Ca-alginate 
beads. IONPs coated with alginate were Fe3O4 with a core diameter of 5±10 nm and 
had a hydrodynamic diameter of 193.8 nm.  ȟ-potential was -65.0 mV with good 
stability (Ma et al., 2008). 
1.5.6 Chitosan  
Chitosan is a hydrophilic, biocompatible,  biodegradable,  alkaline, non-toxic natural 
polymer (Chung et al., 2005). Chitosan-coated IONPs varied from 10 to 80 nm with 
the different molecular weight of the chitosan  (Zhi et al., 2006). 
Tsai et al., (2010) have reported a simple method to coat IONPs in situ precipitation 
of ferrous hydroxide by the alkaline treatment of chitosan. Ammonium hydroxide 
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solution was rapidly added to the brown solution under sonication at 50 qC. The 
results revealed that the IONPs coated with chitosan had a hydrodynamic diameter of 
87.2 nm.  
Zhang et al., (2010b) have prepared chitosan coated IONPs via a novel 
photochemical method in an emulsifier-free aqueous system at room temperature. 
The results, using scanning electron microscopy (SEM) and TEM showed that the 
chitosan-coated nanoparticles were a regular shape with a mean diameter of 41 nm. 
However, the average size was 64 nm when measured by photon correlation 
spectroscopy. 
Microspheres composed of SPION with spherical particle size about 15nm were 
synthesised and embedded in the presence of polyglucosamine (chitosan) by a 
sonochemical method. The ferrofluid, a solution of SPION-embedded chitosan, was 
sprayed on the surface of an alkali solution with a nozzle to produce IONPs in 
chitosan microspheres of 100±150 µm. The SPION-chitosan microspheres showed a 
strong enhancement of MR image contrast similar to the ferrofluid in vitro (Kim et 
al., 2007) 
In another study, IONPs were synthesised by a classic method, co-precipitation 
resulting in a mean particle size of 14.1 nm. These particles were then dispersed well 
in two polymers, chitosan or o-carboxymethylchitosan OCMCS. The results revealed 
the mean particle radius as measured by DLS of 42 nm for chitosan/Fe3O4 
nanoparticles, and 38 nm with OCMCS/Fe3O4. Fe3O4 nanoparticles have net positive 
charge and OCMCS stabilised magnetic Fe3O4 nanoparticles have functional 
carboxyl groups (Zhu et al., 2008). 
Chitosan coated IONPs have also been prepared by a crosslinking method. Oleic acid 
modified IONPs were firstly prepared by co-precipitation, chitosan was then added 
to coat the surface of the nanoparticles by physical absorption. The average size of 
such chitosan coated IONPs was approximately 10.5 nm. The chitosan coated IONPs 
had a remarkable heating effect which has great potential in hyperthermia therapy 
(Qu et al., 2010). 
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1.5.7 Silica  
Coating of IONPs with a silica layer provides a chemically inert surface in biological 
systems for the core of IONPs (Deng et al., 2005).  
The two main methods for coating IONP with silica, the Stöber method and the 
reverse micelle method, have both been used for the preparation of different 
inorganic nanoparticles. The Stöber method is an easy method for coating 
nanoparticles with a layer of silica simply by mixing the nanoparticles, aqueous 
solution and alkoxysilane in alcohol. With the sol±gel method, the reaction ends in a 
short time or at a maximum will take several hours. The parameters which are very 
important to control the coating thickness are the optimisation of solvent components 
and volume of alkoxysilane (Narita et al., 2009).   
The uncoated IONPs with a particle size of 30 nm were prepared by a co-
precipitation method which was followed by coating with silica using the Stöber 
method. The size of the coated nanoparticles was 50 nm using TEM (Khosroshahi 
and Ghazanfari, 2010). 
Using another method by Lien and Wu, (2008) to coat IONPs,  thermosensitive 
polymers were grafted onto the surfaces of 6 nm monodisperse IONPs coated with 
silica. The nanoparticles were synthesised using reverse microemulsions and free 
radical polymerisation. The nanoparticles produced contained a layer of silica coated 
onto the surface of nanoparticles in the range from 20 to 30 nm. The poly(N-
isopropylacrylamide) (PNIPAM) grafted silica-coated IONPs were produced with 
different ratios of PNIPAM. The particle sizes of three samples increased by around 
3±5 nm compared to that of pure silica coated IONPs as determined by TEM. 
PNIPAM grafted onto SiO2/Fe3O4 nanoparticles were confirmed by FT-IR spectra. 
Amine modified silica coated IONPs were prepared using a water-in-oil 
microemulsion technique, which employed amine-modified silica as the shell and 
iron oxide as the core of the magnetic nanoparticles. The particle size of the core was 
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8 nm while the coating increased the particle size up to 40 ±5 nm (Ashtari et al., 
2005). 
Deng et al., (2005) used the sol±gel method for the preparation of silica-coated 
IONPs. The particle size of coated nanoparticles was 40 nm using TEM. 
Silica coated IONPs with about 10 nm diameter IONP cores and about 2 nm thick 
silica shells were prepared using a co-precipitation method, and then the 
nanoparticles were covalently bonded with amine and carboxyl groups. The presence 
of the functional groups was proved by FTIR spectra (Jang and Lim, 2010).  
1.5.8 Gold  
Gold is another inorganic coating that has been used to coat nanoparticles and act 
like a coating polymer to enhance the stability. These properties give gold a 
particularly attractive surface chemistry for IONPs. However, one limitation is that 
gold-coating can weaken the magnetic properties of IONPs (Dale 2005). 
The formation of a gold shell on the IONPs was achieved by an iterative reduction 
method using hydroxylamine as a reductant. The surface of the gold coated IONPs 
was further functionalised with mercapto-hexadecanoic acid (MHA) to bind the 
positively charged Arg6-esterase effectively. The gold-coated IONPs had a size 
distribution of 50±100 nm in diameter with an average size of about 70 nm, while the 
core IONPs had a size of 8±10 nm (Jeong et al., 2006). 
Gold was coated onto IONPs using a facile reverse micelle procedure and the effect 
of water to surfactant molar ratio on the size was investigated. The particles were 
coated by polyglycerol through capping with thiol followed by polymerisation of 
glycidol. It was shown that ultrafine nanoparticles 9±16 nm could be synthesised 
with a thin gold layer of about 2 nm thicknesses (Jafari et al., 2010). 
Lu et al., (2006) have prepared well dispersed nanoparticles comprised of a citrate 
stabilized gold shell and Fe oxide core. Results from (TEM) and energy dispersive 
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spectroscopy (EDS) indicated that the particle coated was with gold and had a size 
larger than 10 nm in diameter.  
Monosized core/shell, IONPs/gold with magnetic±optic multifunctional properties 
were synthesised using a modified nanoemulsion method in the presence of 
poly(vinylpyrrolidone) (PVP) as the surfactant. The iron oxide /gold core±shell were 
prepared by seeding the iron nanoparticles core and then coating with a gold shell. 
The particle size of coated IONPs using TEM, was 8.7 nm, while the uncoated 
IONPs had a size of  3±6 nm diameter, FTIR confirmed that the PVP was bound to 
the surface of the nanoparticles (Liu et al., 2010). 
1.5.9 Other Polymer coated iron oxide nanoparticles  
IONPs have been coated with many other polymers to improve their stability and 
protect them in the biological environment. For example, superparamagnetic IONPs 
were coated with polyethylenimine and then conjugated with DNA. IONPs were 
prepared by the co-precipitation method. PEI coating of IONPs followed this 
procedure: the iron oxide suspension was mixed at various ratios with 25 kDa 
polyethylenimine PEI. An average size was 27±12 nm as obtained by TEM. The 
complexes were added to cells and exposed to permanent and pulsating magnetic 
fields. The presence of these magnetic fields significantly increased the transfection 
efficiency (Steitz et al., 2007). 
IONPs could be stabilised during the synthesis by oleic acid using the co 
precipitation method, and then further stabilised by coating them with PEI and co-
polymer using direct ligand-exchange reactions. The first layer coating the IONPs 
was PEI.  The second was formed by poly(ethylene oxide) PEI. The hydrodynamic 
diameter of IONPs was 10 nm and 30 nm with a core size of 10 nm. The 
nanoparticles coated with PEG-g-PEI showed an average hydrodynamic diameter of 
25 nm, however, the nanoparticles coated with PEI had smaller hydrodynamic sizes 
of 14±15 nm (Duan et al., 2008). 
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Magnetic polymer nanospheres were also prepared using new procedures based on 
miniemulsion polymerisation. A stable water-based dispersion of sodium dodecyl 
sulfate and oleic acid coated magnetite aggregates was first synthesised as a bilayer 
and mixed with monomer styrene miniemulsion. The second step was another 
encapsulation of magnetite into monomer droplets using miniemulsification. The 
particle size of the latex-3 particles showed a diameter of 8 nm of superparamagnetic 
magnetite particles and after encapsulating within the polymer nanosphere the size 
increased to an average diameter of 80 nm (Zheng et al., 2005). 
Another study showed that superparamagnetic particles could be stabilised with 
polyaniline.  The polyaniline and IONPs composite was formed by polymerisation in 
the presence of the ferrofluid. IR spectra confirmed the composition on the surface of 
the oxide particles (Kryszewski and Jeszka, 1998).  
Hu et al., (2006) have prepared a magnetite/poly(L-lactic acid) composite using  a 
solvent evaporation/extraction technique in an oil/water emulsion. The average size 
of the composite was about 200 nm. However, the size of the core was 6.2 ± 0.7 nm 
in diameter. The composite was then loaded with an anti-cancer drug. 
A method based on the so-called anionic polymerisation procedure to coat IONPs 
resulted in a shell of poly(ethyl-2-cyanoacrylate). The particle size of coated IONPs 
was determined by TEM to be 144 ±15 nm. The images showed the layer coating the 
nanoparticles, and the thickness of the polymer shell was about 30 nm (Arias et al., 
2007).  
Ma et al., (2009) have also described the coating of IONPs with polyacrylic acid 
(PAA) to prevent the aggregation of the IONPs using chemical co-precipitation. 
PAA oligomer of low molecular weight was used as a dispersing agent and coating. 
The TEM result revealed that the average diameter of uncoated particles was 
9.2 ± 2.6 nm while coated nanoparticles size using dynamic light scattering 
measurement indicated a hydrodynamic diameter of 246 ±11 nm. 
In drug delivery using ethylcellulose, coated IONPs were synthesised by an emulsion 
solvent evaporation process. The particles were then used as a drug carrier loaded 
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with diclofenac sodium for arthritis treatment. The particle size was measured using 
TEM showing an average diameter of 430 ± 40 nm and a spherical shape. The 
nanoparticles showed good loading, and a slow drug release profile (Arias et al., 
2009). 
1.6 Applications of Iron Oxide Nanoparticles  
IONPs have been used a research tool for a variety of applications over the last 
decade. IONPs have been applied in various medical fields, and numerous reports 
have emerged using IONPs as a powerful tool to perform different functions. 
Currently, IONPs are commercially available and approved. In addition to being a 
research tool, IONPs hold great promise in MRI, drug delivery, cellular labelling/cell 
separation, tissue repair, hyperthermia treatment, etc. 
1.6.1 Magnetic Resonance Imaging (MRI) 
Diagnostic medical imaging has been the subject of enormous improvements over 
the last 35 years with the development of techniques such as MRI. This is one of the 
most useful non-invasive methods in the application of diagnostic imaging and is 
characterised by its high resolution of soft-tissues and by its absence of exposure to 
radiation. MRI, both in preclinical and clinical settings, has many advantages: high 
speed, clear image and high resolution with relative accessibility and low cost better 
than other techniques such as positron emission tomography (Wang et al., 2006). 
To recognise the difference between healthy and pathological tissues, MR imaging 
uses contrast agents that can be localised to a particular tissue or cellular epitope 
which will permit the visualisation and characterisation of different disease states 
(Morawski et al., 2005). Today the main contrast agents are, firstly, paramagnetic 
gadolinium based contrast agents which shorten the longitudinal relaxation time (T1) 
and increase the contrast of the image (positive enhancement) (Hanns-Joachim et al., 
2003). Secondly, IONPs, which shorten the transverse relaxation time (T2) and 
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provide many advantages as contrast agents, such as improved contrast, carrying 
high payloads and  long circulation times (Cormode et al., 2010).  
Magnetic resonance imaging relies on the nuclear magnetic resonance of protons in a 
molecule, and for medical imaging, specifically follows water. It can act in different 
tissues to give a picture of anatomical structure. The characteristic measure in MRI is 
the proton relaxation rate (R) or its inverse, the relaxation time (T). 
There are two types of proton relaxation times, the longitudinal relaxation time, T1, 
(spin±lattice relaxation) and the transverse relaxation time, T1 (spin±spin relaxation). 
Moreover, there are two types of contrast agents, positive and negative; positive acts 
on T1 to give a positive enhancement of the signal appearing bright on the MRI scan. 
The negative agents provide negative enhancement, appearing as dark spots in the 
scan (Kubaska et al., 2001). Comparing gadolinium-based contrast agents and 
superparamagnatic iron oxide nanoparticles in terms of rates, SPION can produce 
enhanced relaxation in certain organs at lower doses than paramagnetic ions (Corot 
et al., 2006, Wang et al., 2001). Gadolinium contrast agents are commonly used in 
MRI but are non-specific with rapid accumulation in the liver, so they only permit a 
short time-imaging window (Fahlvik et al., 1990). 
Overall, the transverse relaxation (T1and T2) effect of SPION is mainly used in 
detection of liver lesions by MR imaging. The shortening of T2 relaxation times in 
the transverse relaxation occurs when SPION are distributed in reticuloendothelial 
cells, such as Kupffer cells (KCs), according to phagocytic activity, and because of 
local field inhomogeneities that produce rapid dephasing of neighbouring proton 
spins. However, because of the lack of reticuloendothelial cells, liver tumours such 
as metastatic liver cancer cannot absorb these agents. Therefore, the contrast between 
tumour tissue and surrounding normal liver tissue is improved because of signal loss 
in the liver tissue (Saini et al., 1987). 
Currently, only two SPION preparations have been approved for clinical use 
especially for liver MR imaging, such as Ferumoxides (i.e. Endorem® in Europe, 
Feridex® in the USA and Japan, Advanced Magnetics, USA) coated with dextran 
(Weissleder et al., 1989).  
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Ma et al., (2008) have used MRI to provide information on liver tumour by using 
IONPs coated with alginate. The nanoparticles were rapidly cleared from serum and 
accumulated mainly in the liver and spleen with a total percentage of more than 90% 
after intravenous injection and could have the capability to enhance detection of a 
liver tumour as contrast agents in MRI. IONPs prepared by laser-induced pyrolysis 
have been coated with dextran to give a hydrodynamic diameter of 50 nm, their 1H 
NMR relaxation times and the magnetic properties of these particles showed they are 
suitable for use as contrast agents for MRI. Two important factors affect the 
relaxation properties, in particular particle and crystal size for the transverse 
relaxation rate, R2 (Morales et al., 2003). 
Patel et al., (2008) have developed contrast agents comprising of PLGA encapsulated 
SPION, which were applied as a MRI contrast agent in the liver of a rabbit. The 
change in spin relaxation time occurred because the nanoparticles in the liver interact 
with the hydrogen nuclei around the nanoparticles. Comparing the images before and 
after the injection showed the image with high resolution. For this reason, PLGA 
encapsulated SPIONs (II) might be used as an MRI contrast agent.  
Tanaka et al., (2008)  modified SPIOs with biotin, hemin, and 5-phosphorylated 
DNA via the ligand exchange method. From the DLS measurements the particle size 
was 51.2 ± 22.4 nm and these nanoparticles could be expected to be potential 
applications both as a contrast agent and for cell cycle monitoring.  
Microbubbles with a polyvinyl alcohol (PVA) outer layer and a poly(DL-lactide) 
(PLA) inner layer were prepared using a double emulsion solvent evaporation 
interfacial deposition (water-in-oil-in-water emulsion) process. The PLA and PVA 
double-layered polymer shell of 50±70 nm thicknesses can let the 12 nm SIONPs be 
loaded heterogeneously in their shell to significantly enhance magnetic susceptibility 
(Yang et al., 2009). 
IONPs coated with non-magnetic precursor microgel, which is made up of 
polymerised methacrylic acid (MAA) and ethyl acrylate (EA) crosslinked with 
di- allyl phthalate (DAP), have been used for in vivo tracking of stem cells after 
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transplantation by labelling primary endothelial progenitor  stem cells with magnetic 
particles. They can be tracked by magnetic resonance. The nanoparticles showed 
hydrodynamic diameters of 87±766 nm. Micro-gel iron oxide particles might be a 
useful tool for the study of relaxation induced by magnetic particles and cellular 
tracking by MRI (Lee et al., 2010). 
C2-coated superparamagnetic IONPs can induce a significant increase in image 
contrast where the regions have a large number of apoptotic cells. The C2 is a 
domain of synaptotagmin I which binds to anionic phospholipids in cell membranes. 
The protein bound with the SPION can be detected by using MRI. The detection of 
apoptotic cells using this candidate diagnostic agent was illustrated in vitro with 
isolated apoptotic tumour cells and in vivo in a tumour treated with chemotherapeutic 
drugs (Blankenberg et al., 1997). 
 IONPs give diagnostic opportunities to detect diseases and understand their 
mechanisms. Nanoparticles are used widely to give more information on diseases, 
such as location. Medical imaging has been traditionally based on the use of X- rays 
and radioactive substances. The newer diagnostic imaging modalities, such as 
ultrasound and magnetic resonance, are now well-established techniques in patient 
management. Details of four major diagnostic imaging modalities in routine clinical 
settings with the physical basis of the techniques are illustrated in (Table 1.1).  
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Table 1-1: Diagnostic imaging modalities and contrast media. 
Modality Physical basis Equipment Image contrast 
media 
X-ray imaging Attenuation  X-rays X-ray generator, 
Radiographic film 
Absorption of X- rays 
by high atomic weight 
X-ray CT 
 
Attenuation  X-rays Scanning X-ray 
generator,  Detector 
array and Computer 
Compounds mainly 
containing Iodine 
Ultrasound Doppler 
ultrasound 
Reflection of sound Piezoelectric, Scan 
converter frequency 
Encapsulated gas       
bubbles 
MRI Magnetic  moment 
of moment of ¹H 
Magnetic RF  
transmitter 
Reduced T1and T2 
Nuclear imaging Gamma emitting  
radiopharmaceutical 
Scintillation camera, 
Image  workstation 
tissue concentration 
of radiopharmaceutical 
suitable ligand and  
radiolabel  e.g. 99 
mTcm, 123I and   111 In 
 
 
Diagnostics such as MRI and ultrasound are starting to develop clearer imaging and 
more accuracy (Perkins, 1998). Organic and inorganic polymers are used as 
nanoparticles or contrast agents, evenly coating the metal nanoparticles to reduce 
systemic toxicity and increase drug bioavailability. Here, in Table 1.2, are examples 
of the polymers used as imaging and contrast agents (Perkins, 2002). 
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Table 1-2: Examples of polymers that have been used as imaging agents. 
Polymer Reference 
Radiopharmaceuticals  
 
99m Tc-DTPA-BCP Pimm et al (1995) 
99m Tc-DTPA-MPEG Bogdanov et al (1994) 
X-ray contrast    
Polymer based on iodine complex Bogdanov et al (1995) 
Ultrasound contrast   
Polymeric micro balloons Schneider et al ( 1992 and 1994) 
MRI contrast   
Gd-DTPA-cascade polymer Schwickert et al  (1995) 
CMDGd-DTPA Siauve  et al   (1996) 
Carboxymethyl dextran Wiener et al  (1994) and Schmitt  and 
Willich (1997) 
Dendrimer Gd chelates Berthezene et al (1992) 
Polylysine Gd-DTPA Harika et al (1995) 
Gd-DTPA-PG.polyglucose 
macrocomplex 
However, there are other methods of diagnostic imaging, such as X-ray where 
contrast agents are non-specific materials dependent on the use of dense materials to 
attenuate the X-ray photons, for example barium orally or iodine by the intravenous 
route. Polymer based contrast agents are attractive for use as vascular contrast agents 
in X-ray because they are polymers having a long clearance time in circulation, such 
as methoxy-polyethylene glycol (MPEG) and incorporate iodine for CT imaging 
(Perkins, 2002).  Contrast agents for X-ray photons such as barium and iodine  for 
the site specific targeting of X-ray contrast agents has not proven to be of any clinical 
value, mainly because the reporter moieties (barium and iodine) have to be delivered 
in such large amounts that it is not considered to be a viable possibility (Perkins, 
2002). 
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Another important diagnostic imaging modality is nuclear medicine imaging, which 
relies on physiological processes and on the administration of radiolabelled tracers. 
This technique is for tissue imaging. There are many materials used for specific 
organs such as TC-99 m-bone scanning, lipophilic materials for cardiac and brain 
and biological materials such as pooled human serum albumin and monoclonal 
antibodies. Viral contamination is the main problem caused by human blood 
products. As a result, some radiopharmaceuticals cannot be supplied, e.g. serum 
albumin used for the measurement of plasma volume and macro-aggregates of serum 
albumin and for lung perfusion imaging (Hindle and Perkins, 1995). Ultrasound 
contrast agents work based on  the production of a backscattered echo within the 
frequency range between 1 and 20 MHz. Contrast agents for ultrasound rely on an 
injectable formulation of constant gas-filled microbubbles which produce a strong 
reflection of the incident sound beam (Schneider et al., 1992). Polymers like 
polybutyl-2 cyanoacrylate with a wall thickness of 100 nm are enough to protect the 
enclosed gas bubble from dissolution in the blood stream and sufficiently elastic to 
oscillate in the ultra-sound field (Perkins, 2002). 
1.6.2 Drug Delivery  
Classic pharmaceuticals have many problems with systemic drug administration, 
including biodistribution throughout the body. There is also the lack of drug 
specificity for the pathological site and the need for a large dose to give a high 
concentration in the site, which could lead to side effects. Drug targeting could 
overcome some of these problems (Torchilin, 2000b). For example, through the 
targeting of the drug immobilised on magnetic materials under the action of an 
external magnetic field (Berry and Curtis, 2003), or to improve the target of drug 
binding with another molecule which recognises the target site, such as protein, 
hormones, antibodies, lectins, charged molecules and some low molecular weight 
ligands such as folate (Sudimack and Lee, 2000). 
In drug delivery, the charge and surface chemistry of magnetic particles and the size 
have strong effects on blood circulation and the bioavailability of the particles within 
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the body (Chouly et al., 1996a). The first clinical trial in humans with magnetic 
targeting were reported by Lubbe et al., (1996). These trials used IONPs coated with 
starch and anionic phosphate, then the cationic binding to the positively charged 
amino sugars of epirubicin was possible. Successful preliminary animal trials led to 
human trials, the treatment consisting of intravenous infusion of the chemically 
bound drug and a course of conventional chemotherapy. During the infusion and for 
45 min after, a magnetic field was built up as close to the unsuccessfully pre-treated 
tumour as possible (Bonadonna et al., 1993). 
The physiological parameters of the patient, such as body weight, blood volume, 
cardiac output, peripheral resistance of the circulation system and organ function, all 
affect the external magnetic field in addition to the problem of placing the magnetic 
field close to the target location (Lubbe et al., 2001). The size of the nanoparticles 
plays a very important role in drug delivery which affects the adsorption of the drug 
and reaching the defective tissue with maximum dose and minimum side effect. This 
as a result changes the response of the organ to the drug.  
After injection, large particles with diameters larger than 200 nm are easily removed 
by the spleen and ultimately eliminated by the cells of the phagocytic system, 
causing decreased blood circulation times. However, particles with diameters of less 
than 10 nm are rapidly removed through extravasation and renal clearance. Particles 
with sizes from 10 to 100 nm in diameter are optimal for intravenous injection and 
demonstrate the most prolonged blood circulation times. These particles are small 
enough both to evade RES of the body as well as to penetrate the small capillaries of 
the body tissues and so could offer the most effective distribution in certain tissues 
(Pratsinis and Vemury, 1996). 
After offering all these advantages with the clear route of the nanoparticles in the 
body, the nanoparticles provide encouragement to use as tools for studies in this 
field. (Kayal and Ramanujan, 2010) have shown that, after administration of iron 
oxide nanoparticles coated with PVA containing doxorubicin, up to 45% of the 
adsorbed drug was released in 80 h, indicating the success of drug delivery via 
magnetic particles. IONPs were covered by glycerol mono-oleate and used as a drug 
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carrier. The anticancer chemotherapy agents paclitaxel and rapamycin anticancer 
showed high entrapment efficiency of about 95% and sustained release of 
encapsulated drug for more weeks under in vitro conditions. These results offer the 
possibility of improved therapeutic treatments of cancer cells (Dilnawaz et al., 2010). 
Aminodextran-coated IONPs were synthesised as drug carriers detectable by MRI. 
Agents were based on a macromolecular backbone with a high density of sites for 
MRI reporters. This radiopharmaceutical is the first specifically designed anticancer 
drug carrier. The aim of these nanoparticles is to increase the pharmaceutical 
potential of the MRI technique (Saboktakin et al., 2010). 
Gaihre et al., (2009) have reported the coating of IONPs with gelatine containing 
doxorubicin DXR and evaluated their potential as a carrier system for magnetic drug 
targeting. To understand their role, doxorubicin in coated iron oxide particles was 
prepared using adsorption and desolvation/cross-linking methods. Drug loading was 
carried out in various conditions of pH. The particles showed pH responsive drug 
release leading to progressive release of the drug at pH 4 compared to pH 7.4. The 
increase in the surface charge of coated particles after loading led to adsorption of 
positive doxorubicin to negative coated iron oxide particles, which indicated the 
loading had occurred. The increase or decrease in encapsulation efficiency was 
dependent on the surface charge of the coated particles and also confirmed the 
involvement of drug-to-particle interaction in the drug-loading. 
Sun et al., (2008) have reported the development of a chlorotoxin (CTX) loaded 
IONP drug carrier that may potentially be used as an MRI contrast enhancement 
agent. The CTX immobilised on the surface of nanoparticles via PEG functional 
groups offers a platform to allow for conjugation of other diagnostic and therapeutic 
agents to develop further platforms for both improved visualisation and targeting. 
Drug delivery was demonstrated in vitro in 9L cells and in vivo in mouse tumour 
models and compared to studies with control nanoprobes. Cellular uptake 
experiments showed that the uptake of IONPs coated with PEG and CTX conjugates 
by glioma cells was considerably higher than that of control nanoparticles. MRI 
contrast in 9L cells cultured with IONPs coated with PEG±&7;DWȝJ)HP/IRU
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1 h at 37 °C were visualised with TEM, which shows that PEG±CTX nanoparticles 
were internalised into the 9L cells cytoplasm. Then they examined the efficacy of 
CTX-conjugated nanoprobes in targeting glioma cells and providing contrast 
enhancement for MRI also under the same conditions. 
Oleic acid coated IONPs in the presence of pluronic F-127 as stabiliser were used in 
both drug delivery and magnetic resonance imaging MRI in vivo. The drugs, 
doxorubicin and paclitaxel were incorporated into nanoparticles, either individually 
or together. This incorporation of drugs affected the physical size and zeta potential 
and magnetisation properties of the nanoparticles. Both of these drug nanoparticles 
showed high efficiency, either alone or in combination, for real time monitoring of 
drug distribution (Jain et al., 2008b). 
1.6.3 Hyperthermia  
Hyperthermia is being introduced as a new modality for cancer therapy. This is based 
on the principle that under an alternating magnetic field (AMF), a magnetic particle 
can create heat via hysteresis losses (Baker et al., 2006 and Hergt et al., 2004). The 
applications of IONPs for hyperthermia treatment were envisaged in the similar work 
of (Jordan et al., 1993). This experiment provided evidence of the capability of 
superparamagnetic particles to absorb the energy of an oscillating magnetic field and 
convert it into heat. This can be used in vivo to increase the temperature of the 
tumour and to damage the cell by hyperthermia (Jordan et al., 1999 and Moroz et al., 
2002).  
IONPs, prepared using the microemulsion method and then coated with a thin 
hexamethyldisilazane layer used to protect the iron core, replaced the cetyl trimethyl 
ammonium bromide (CTAB) coating on the particles. In the next step, 
phosphatidylcholine was coated on the nanoparticles¶ surface. These particles 
showed high magnetisation and increased hysteresis losses, improving its use for 
hyperthermia when compared with uncoated IONPs (Zhang et al., 2010a). 
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The effect of the particle size on this application was studied by Gonzales-Weimuller 
et al., (2009) who showed for the first time that, at a given frequency, the heating 
rates of superparamagnetic particles are dependent on particle size. The results 
showed that higher heating rates are possible by increasing the size of the particles 
from 4.6nm to about 12.5 nm. IONPs were coated with oleic acid by a co-
precipitation method then coated with chitosan by crosslinking. The saturation 
magnetisation of the nanoparticles was 30.7 emu/g measured by magnetic 
measurement, and showed superparamagnetic properties at room temperature. The 
results indicated that the heating effect was significant and the heating could be 
adjusted by changing the concentration of nanoparticles (Qu et al., 2010).   
IONPs were embedded in silica microparticles for treatment of cancer lesions by 
magnetically induced local hyperthermia. The injectable formulations form gels 
entrapping magnetic particles into a tumour. The nanoparticles provided the 
possibility of administration by syringe with a high proportion of IONPs to permit 
large heating capacities. Hydrogel (poloxamer, chitosan and organogel) were 
incorporated with nanoparticles and injected into human cancers in mice. 
Organogel 8% poly(ethylene-vinyl alcohol) in Dimethyl sulfoxide DMSO containing 
40% w/v of magnetic nanoparticles showed magnetically induced local hyperthermia 
of the tumour where hydrogel alone did not show adequate magnetic response to 
induce hyperthermia (Le Renard et al., 2010). 
1.6.4 Tissue Repair 
Tissue repair using IONPs is accomplished either through separating two apposing 
tissue surfaces then heating the tissues sufficiently to join them, or through welding, 
where protein or synthetic polymer-coated nanoparticles are acting as a bridge 
between two tissue surfaces to improve joining of the tissues. Temperature at  55.5ºC  
is the best to induce tissue union (Lobel et al., 2000).  
StHP FHOOV DUH WKH ERG\¶V PDVWHU FHOOV DQG KDYH D XQLTXH DELOLW\ WR UHQHZ
themselvesand give rise to other specialised cell types. These cells, therefore, have 
the potential to be used for transplantation purposes, for example, to replace 
Chapter 1  Introduction 
34 
degenerated cells or in the repair of destroyed tissue, providing signals so that the 
stem cells can yield suitable cell types for the development of a tissue (Kiessling-
Cooper and Anderson, 2003). 
Using thrombin, which has been used for topical haemostasis and wound 
management for more than six decades, IONPs were bound to thrombin to show the 
efficiency of treatment for wounds and were compared with unbound thrombin using 
wounded rat skin. The investigation revealed that thrombin bound to IONPs 
increased the healing of the wound  better than the free thrombin with reduced side 
effects compared to normal surgery (Ziv-Polat et al., 2010).  
IONPs have also been used in transplant monitoring. For example, IONPs modified 
with the near-infrared fluorescent CY5.5 dye (MN-NIRF) and covered with dextran. 
Preliminary MRI on an islet phantom showed the possibility of detecting a signal 
drop in the analysis. After implantation under kidney capsules, many MRI 
examinations were implemented over half a year, with no significant change in the 
T2 relaxation time in the labelled graft. Both implantation under kidney capsules and 
administration by intraportal infusion into diabetic mice models resulted in 
restoration of normoglycemia. The ability of the transplanted islets to secrete insulin 
was confirmed by ex vivo microscopy studies (Evgenov et al., 2006). 
In comparison between IONPs coated with poly(vinyl pyrrolidone) (PVP) and 
commercial IONPs (Feridex formulation) for monitoring of pancreatic islets, the 
PVP coated nanoparticle labelled cells showed no changes in morphology and 
viability and showed  higher iron accumulation because of the small nanoparticle 
size, which was 5±8 nm in diameter, and because of the biocompatibility of the PVP 
coating (Huang et al., 2009).  
1.7 Colloidal Stabilisation  
IONPs dispersed in a medium show Brownian motion and a natural tendency to 
adhere with each other and form aggregates due to the magnetic attractive forces 
between the particles. One of the main interactions is the Van der Waals long range 
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attractive forces between the particles. These interactions can be counteracted by 
electrical repulsive force between the particles created by the electric double layer at 
the particle surface, or by coating the particles with long chain polymers, performing 
a steric hindrance between the particles (Vennapusa et al., 2008 and Van Oss, 1994). 
1.7.1 Fundamental Methods to Stabilise Colloidal Particles 
There are two important methods to maintain the stability of nanoparticles which 
prevent the aggregation of the particles and provide long range repulsive force 
between the particles. This repulsive force should be as strong as the attractive force 
or equal to the range of the attractive interaction. To maintain stability a comparable 
number of counterions with opposite charge need to cover the particles. As a result, 
the charge becomes a neutral double layer of ions (Napper, 1989). 
Steric stabilisation is achieved by the stabilising moiety chains extending into the 
continuous phase beyond the particle surface and isolating the ions and counterions 
of the ionic surfactant (Sung and Piirma, 1994). Steric stabilisation has been used 
widely because it has many advantages over electrostatic stabilisation, which are (1) 
independence of the presence of electrolytes, (2) effective also at high particle 
concentrations, (3) commonly, redispersion of flocculated particles can be readily 
achieved, (4) good freeze-thaw and dry-rehydrate stability, and (5) equal 
effectiveness in polar and nonpolar media (Storm et al., 1995).  
Steric stabilisation is achieved by a layer of polymer chains attached to the surface of 
the particles and protects the particle from flocculation. The polymer chains in the 
thick steric layer repulse one another and are stretched from their free coil 
conformation, thus providing repulsion between particles. If the thickness of the 
coating is sufficient, this will prevent flocculation due to London-van der Waals 
attractions. Once sterically-stabilised particles are suspended in a polymer solution, 
the interactions are complicated by the repulsion between anchored and free chains 
(Gast and Leibler, 1986).  
Chapter 1  Introduction 
36 
If the distance between two particles with adsorbed polymer layers become less than 
twice the thickness of the adsorbed layer then interaction between the two particles 
will occur. The steric repulsion has been evaluated in terms of difference in free 
energy ǻ* over the interaction of the adsorbed layers. The Gibbs free energy change 
of the overlap interaction of the adsorbed layers can be calculated using the Gibbs 
equation ǻ*   ǻ+ - 7ǻ6 flocculation or coagulation occurs when ǻ* is negative. 
However, stabilisation will take place when ǻ* is positive. Many of the theoretical 
aspects of steric repulsion have been developed (Robert et al., 1972). 
The other possibility of stabilisation is the generally accepted entropic stabilisation 
theory.  The entropy term opposes flocculation whereas the enthalpy term favours it. 
The main role of the entropic contribution to the free energy of close approach could 
be titled entropic stabilisation (Napper, 1977).  
The idea of this theory supposes that the second approaching adsorbed layer is not 
penetrable. Hence, the adsorbed layer is compressed and the polymer segments 
present in the interaction zone lose configurational energy in the compressed form 
but not in the uncompressed state. This causes a decrease in entropy and increase in 
ǻ*. As a result, the net effect of repulsion between the particles results in avoiding 
the flocculation of the particles (Napper, 1989). 
1.8 Uptake of Nanoparticles by Cells  
1.8.1 Mononuclear Phagocyte System (MPS) 
The efficient removal of foreign particulate material introduced into the bloodstream 
by the MPS has been known for a long time. About 3 decades ago it was shown that 
interfacial physicochemical events mediate the uptake of circulating foreign particles 
by MPS macrophages. The mononuclear phagocyte system is a group of cells 
comprising bone marrow progenitors, blood monocytes and tissue macrophages 
(Hume, 2006). These cells are widely distributed and occur strategically in several 
tissues of the body to recognise and clear altered and senescent cells, invading 
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particulates, as well as macromolecular ligands via a multitude of specialised plasma 
membrane receptors (Moghimi et al., 2001). 
The rapid uptake of uncoated nanoparticles from the bloodstream by the 
macrophages of the MPS within seconds after intravenous administration make such 
particles ineffective as site-specific drug delivery devices. The cells involved, 
typically Kupffer cells or macrophages of the liver, cannot directly identify the 
nanoparticles themselves, but rather recognise specific opsonin proteins bound to the 
surface of the particles (Gref et al., 1994b and Frank and Fries, 1991). 
1.8.2 Mechanism of Intracellular Uptake 
Endocytosis is a complex mechanism which generally includes the processes of 
pinocytosis, nonspecific endocytosis, receptor-mediated endocytosis and 
phagocytosis, which is typically defined as endocytosis of large particles. Among the 
various types of receptors involved in endocytosis, the family of macrophage 
scavenger receptors are able to endocytose a wide array of polyanionic ligands and 
nanoparticles. In vitro, ferumoxide endocytosis by mouse peritoneal macrophages 
was dose-dependently inhibited by polyinosinic acid and fucoidan, suggesting that a 
scavenger receptor A (SR-A) mediated endocytosis is involved for this contrast agent 
(Raynal et al., 2004).  
In general, phagocytosis is typically restricted to specialised mammalian cells, 
including macrophages, monocytes and neutrophils. Pinocytosis, which occurs in all 
cells, most commonly refers to the constitutive formation of smaller vesicles carrying 
extracellular fluid and macromolecules non-specifically bound to the plasma 
membrane. Receptor±mediated endocytosis includes clathrin-mediated endocytosis 
and caveolin-mediated endocytosis (Conner and Schmid, 2003). 
Biologically, the main requirement for MRI is that the cells efficiently capture the 
IONPs they are exposed to by endocytosis pathways (Berry and Curtis, 2003). 
Particles taken and stored in coronary artery cells were described by (Panyam and 
Labhasetwar, 2003). The nanoparticles internalisation is in part through fluid phase 
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pinocytosis and in part through clathrin-coated pits. Caveoli and phagocytosis were 
not involved in nanoparticle uptake in this cell line. Following their uptake, 
nanoparticles were transported to primary endosomes and then probably to sorting 
endosomes. From sorting endosomes, a fraction of nanoparticles is sorted back to the 
cell exterior through recycling endosomes, while the remaining fraction is 
transported to secondary endosomes, which then fuse with lysosomes. Then the 
nanoparticles can escape the endo-lysosomes and enter the cytosolic compartment.  
The acidic pH of endo-lysosomes is schemed as the mechanism responsible for the 
endo-lysosomal escape of the nanoparticles. The early endosomes have an acidic pH 
(pH 5.5), while the later lysosomes have a lower pH (pH 4.5) and return to pH 7.4 in 
cytoplasm. The change of surface charge is from negative in early endosomes to 
positive in later endosomes and then back to positive in cytoplasm, therefore 
involving the transfer of protons / hydronium ions from the bulk solution to the 
nanoparticle surface under acidic conditions.  
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Figure 1-1: Intracellular pathways of nanoparticles and sorting. 
After entering into the cell, nanoparticles taken up by phagocytosis or receptor-
mediated endocytosis transfer to early endosomes and are then transported to the late 
endo-lysosome where they are degraded by high and low acidic compartments. A 
fraction of nanoparticles recycles back to the cell exterior while another fraction is 
transported to secondary endosomes/lysosomes from where nanoparticles may 
escape into the cytoplasm. Nanoparticles that escape into the cytoplasm could act as 
intracellular reservoirs for sustained release of an encapsulated therapeutic agent. 
1.9 Effect of Particles and Surface Coating  
The factors affecting biodistribution are particle size, surface charge, and surface 
coating and the type of coating and concentration, i.e. these are used to enhance the 
function of nanoparticles in all biomedical applications. Large particles with a 
diameter more than 200 nm are adsorbed by spleen phagocytic cells. However, small 
particles with a diameter less than 10 nm are quickly removed through extravasation 
and renal clearance. ParWLFOHV ZKLFK KDYH VL]HV IURP í100 nm are suitable for 
injection and illustrate the most prolonged blood circulation times, their size being 
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very suitable to evade the RES of the body, and can enter the very small capillaries 
within the body tissues (Stolnik et al., 1995). 
They are distributed in tissues according to their size and have two types of targeting. 
PASSIVE TARGETING, where SPIONs have a size more than 40 nm and thus 
accumulate in mononuclear phagocyte organs and are quickly cleared in less than 10 
min by the reticuloendothelial system (Mornet et al., 2004). Ultrasmall paramagnetic 
iron oxide (USPIO) nanoparticles, on the other hand, are called monocrystalline iron 
oxide nanoparticles (MION)s and will have a size less than 40 nm with a polymer 
coating and a half-life of more than two hours. The second type of targeting is 
ACTIVE TARGETING, which is the surface coating by different biocompatible 
materials such as antibodies, proteins and DNA fragments and polysaccharides. 
These agents are specific for certain tissues because of specific biological 
interactions (Mikhaylova et al., 2004, Perez et al., 2003 and Illum et al., 2001). In 
ferrofluid, distribution parameters were found to depend on the sizes and coating 
materials of iron oxide particles in the fluid. The biodistribution of iron oxide with 
large size > 30 nm lead to accumulation in the lung and spleen. However, small size 
particles < 30 nm lead to accumulation in the liver, lymph nodes and bone marrow 
(Weissleder et al., 1995b). IONPs coated with N(CH3)4OH showed a good 
distribution and superparamagnetic behaviour on MRI (Cheng et al., 2005). 
IONPs were made with different hydrodynamic diameter of 10, 20, 33, 46 and 65 nm 
and then coated with carboxydextran. When injected intravenously  they gave a good 
distribution with prolonged signal enhancement up to 25 minutes when compared to 
gadopentate dimeglumine (Allkemper et al., 2002). Superparamagnetic particles of 
14 nm coated with poly(ethylene glycol) and phosphate micelle coating have good 
delivery into primary human dermal fibroblast cells. Particles showed good 
advantage for MRI intracellular molecular imaging (Nitin et al., 2004).  
In another case, when  iron oxide particles were coated with starch (starch-coated 
SPION) with size of 42 nm, which was smaller than commercially available 
magnetic nanoparticles, and injected into brain parenchyma they exhibited a 
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biocompatibility and a possibility of being transported in the extracellular space and 
being  internalised in nerve cells to give good imaging (Kim et al., 2003a). 
Many authors found that when iron oxide particles were coated with a thick layer of 
dextran, the particles accumulated in the lymph nodes (Papisov et al., 1993). The 
mechanism of particle uptake is that they infiltrate all the cells then into the bone 
marrow and reticulo-endothelial structures (liver, spleen and lymph). Iron oxide 
particles with diameter 30±150 nm coated with polymers such as albumin, silicones 
and starch can also be used as  MRI contrast agents (Babes et al., 1999). 
Bulte et al., (1999) have prepared magnetoliposomes with poly(ethylene glycol) 
coating as contrast agent and tried to increase the rapid uptake of the 
magnetoliposomes by the reticulo-endothelial cells. It can be seen from all these 
studies that the size, surface charge, kind of coating, the organ of the body and the 
concentration of iron all affect the biodistribution. 
1.10 Poly(Glycerol Adipate) Polymer 
Substituted poly(glycerol adipate) (PGA) was designed as a novel biodegradable 
polymer by Dr Martin Garnett and Dr Christopher St Pourçain and prepared by Dr 
Gillian Hutcheon. It has been synthesised from glycerol and divinyladipate using the 
enzyme Novozyme 435 as a catalyst. 
PGA has been developed in response to the need for relatively higher drug loading 
and sustained release of encapsulated therapeutic agent. Moreover, PGA with 
hydrolysable ester bonds and side chains with hydroxyl groups offer flexibility to 
substitution by an aliphatic group such as C8 and C18 with a variety of proportions: 
40%, 80% and 100%. Recently, PGA has been used in nanoparticles production for 
drug delivery by loading with anticancer drugs such as cytosine arabinoside and 
dexamethasone phosphate. It showed high loading and sustained release after side 
chain modifications. The best methods to prepare these nanoparticles and the use of 
overcoatings like Tween 80 have been investigated. In the cell work, PGA has been 
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used in investigating the cell uptake and metabolism and penetration in different cell 
types and models (Meng et al., 2006 and Puri et al., 2008).  
PGA has also been used in microparticles to incorporate model protein with surface 
bound ligand to encourage cellular aggregation. In this study, PGA was coupled with 
different polymers through the hydroxyl groups. Coupling PGA to PEG has also 
been described by James Rimmer in his thesis (2009). Polymer PGA backbone and 
backbone acylated by aliphatic groups of aliphatic groups of hydroxyl group with 
proportions of 20%, 40%,60%, 80% and 100%  will be used as coatings through the 
thesis. 
1.11 Aims of this Project  
This project¶s aim was to establish a system for manufacturing polymer coated 
IONPs with small size suitable for use as contrast agents in MRI. The project 
emphasis will be on the polymer coatings and drug delivery aspects of the system 
The project will go through the stages, which are necessary to build a strong basic 
system that could be used in a number of applications 
The first aim is to develop a method with right parameters to produce model IONPs 
which are a suitable size to be candidate diagnostic agents in MRI. I will investigate 
the factors governing the particle size and produce particles with a suitable size for 
this work.  
The second goal is using dextran and carboxymethyl dextran to coat these particles 
as reference. Dextran coated particles have been extensively investigated and are 
used clinically. This will give a starting point and help to identify and overcome 
some problems of coating iron oxide with those and other polymers. 
The third objective is preparation of novel small size coated nanoparticles with novel 
polymer PGA and show in detail the influence of factors affecting the polymer 
coating of nanoparticles by using different methods adjusting the parameters effect 
Chapter 1  Introduction 
43 
on the particles size, like the amount of polymer and solvent. The objective is to 
produce IONPs coated with biodegradable polymers in a simple process resulting in 
nanoparticles comparable in size with the best currently available formulations (i.e. a 
size range of 20±60 nm diameter)  
The fourth aim is to improve the stability of nanoparticles and the chance for more 
modifications, by modifying PGA polymer and to assess the efficacy of the system. 
Also synthesis of PEGylated PGA 40%C18   will be carried out and this material used 
in coating nanoparticles.  
The fifth aim is to assess the stability of the nanoparticles for use in physiological 
conditions. 
The final project objective is investigation of uptake, metabolism and penetration of 
polymer coated nanoparticles by incorporating fluorescent dyes and using cell 
monolayers and aggregates in tissue culture model system.
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 CHAPTER 2 
2. MATERIALS AND METHODS 
2.1 Materials 
All chemicals used in this project were purchased from Sigma-Aldrich (Poole, UK) 
unless specifically stated. The water was obtained from an ELGA purification system 
(resistivity 12-0ȍFP-3, Maxima USF ELGA, Wycombe, UK). Water used in cell 
culture was of tissue culture grade.  
The reagents used for cell work were obtained from Invitrogen Life Technologies 
Ltd. (Paisley, UK). Fluorescent dyes were purchased from Molecular Probes 
(Invitrogen, UK). All reagents used in TEM were from Agar Scientific Ltd. (Essex, 
UK).  
2.1.1 Reagents and Buffers  
HEPES (0.01M buffer N-(2-hydroxyethyl) piperazine-N¶-(2-ethanesulphonic acid) 
was adjusted to pH 7.4 with sodium hydroxide. 
Phosphate buffered saline (PBS, 0.01M, pH 7.4) was prepared by dissolving the 
tablets in 200ml in purified water. 
Paraformaldehyde (8 g) was dissolved in 100 ml water including 3±4 drops of 5M 
6RGLXP K\GUR[LGHKHDWHG WRÛ& LQD IXPH KRRG, then the solution became clear 
and was allowed to cool and was filtered. 
Fixative 4% was prepared by mixing 80 ml of 10% paraformaldehyde and 100 ml 
0.2M phosphate buffer pH 7.4. Water (20 ml) was added to the mixture and the pH 
was adjusted to between 7.2±DQGILQDOO\VWRUHGDWÛ& 
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4,6-diamidino-2-phenylindol dilactate (DAPI) was dissolved in water to prepare a 
5mg/ml solution which was aliquoted to the final required concentration then stored 
DWÛ&Poly(D-Lysine) (PDL) for biological study was prepared to the required 
strength with water.  
Newborn calf serum (NCS) was heated inactivated for 30 min in a water bath at 
Û&Minimum essential medium (MEM) was purchased from Gibco (Paisley, UK).  
Trypsin/ethylene diamine tetra-acetic acid (EDTA) was composed of 0.25 % (w/v) 
trypsin and 0.01 % (w/v) EDTA in sterile PBS. $OOPDWHULDOVZHUHVWRUHGDW Û&
for long term and 2±Û&IRU short time storage. 
2.2 Methods  
2.2.1    Synthesis of Iron Oxide Nanoparticles 
2.2.1.1 The effect of pH on the size  
To establish a method to produce the right size of IONPs, four preparations were 
prepared using the co- precipitation method at different pH (7, 4, 2 and 0.5) 
2.2.1.2 Preparation of iron oxide nanoparticles (IONPs)  
IONPs were prepared by alkaline co-precipitation. Ferrous chloride 
tetrahydrate (0.49 g) was suspended in ferric chloride hexahydrate (1M, 5.06 ml). 
Pure water (6 ml) was added under nitrogen with rapid stirring then heated to 80 °C 
for 1hr. The mixture was cooled to room temperature then precipitated by adding 
NaOH (6 M, 6.5 ml) rapidly. After adding 4 M HCL to the mixture to neutralise to 
pH 0.5, it was refluxed for 1 hr under nitrogen gas. In this step, the black colour 
turned brown. The reaction was allowed to cool to room temperature; the mixture 
was dialyzed using a MWCO 1000 dialysis tubing overnight against deoxygenated 
water to remove any salts. This modified method was based on that by (Kresse M, 
1998). 
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2.2.2 Stability of Uncoated Iron Oxide Nanoparticles  
To compare two samples of uncoated IONPs to identify the stability of the 
nanoparticles over a seven day period. 
IONPs were prepared as above, except that at the neutralisation step, particles were 
adjusted to pH 0.5 and pH 1.0 before reflux and dialysis. Each nanoparticle sample 
was stored in a glass beaker covered with parafilm in the refrigerator at 4°C. The 
particles size of each sample was assessed daily for seven days using DLS.  
2.2.3 Synthesis of Carboxymethyl Dextran 
Different functionalised dextrans using chemical groups like carboxymethyl, 
benzylamide and sulphonate have been widely studied for more than fifteen years, 
particularly for biological heparin-like activities. The reaction to produce 
carboxymethyl dextrans (CMD) involves the carboxymethylation of hydroxyl group 
on D-glucose unit of carboxylic group (Mauzac. M., 1984 and Chaubet.F., 1995).  
2.0 g of dextran (Mw 40,000)   was dissolved in 42.5 ml distilled water and 20 ml of 
chloroacetate acid added. The carboxymethylation reaction was initiated by the 
addition slowly of 7.5 ml of 3.8 M NaOH. The system is subjected to contentious 
stirring during 1 h at room temperature. The reaction mixture was then diluted to 50 
ml total volume with water. Carboxymethylation was allowed to proceed for 90 min 
at 60 ºC with stirring. The reaction was then terminated by lowering the solution pH 
to 7 with 6 M HCl. The product was precipitated with 50 ml absolute methanol and 
allowed to stand overnight. The precipitate was dissolved in water, then was dialyzed 
by using a M WCO 100 dialysis tubing over night. The dialysed solution was rapidly 
frozen using liquid nitrogen and dried in freeze dried two days, giving a white 
powder. The  method was based on (Rémi.H., 1998). 
(CMD) with a degree of substitution (DS) of Carboxymethyl groups DS > 0.9 are 
precursors for the synthesis of derivatised dextrans termed CMD which present 
heparin-like biological properties  (Rémi.H., 1998). 
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Figure 2-1: Synthesis of Carboxymethyl Dextran.   
2.2.3.1 Determination of degree substitution of carboxy methyl dextran.  
The substitution of carboxylic group on modified dextran was determined by 
dissolving 2 mg of the product in 3 ml of acetic acid and titrating with NaOH 0.1 M.  
2.2.4    Preparation of Iron Oxide Nanoparticles Coated with 
Carboxymethyl dextran in the absence or presence of CMD 
2.2.4.1   In the absence of CMD 
An aqueous solution containing ferrous chloride tetrahydrate (0.49 g) and ferric 
chloride hexahydrate (6 M, 5.06 ml) was heated to 80°C with stirring under a 
nitrogen stream for 30 min. The product was then precipitated by rapid addition of 
NaOH (4 M, 3.4 ml) within 30 sec. After neutralisation with 6 M HCL, the mixture 
was refluxed for 1h. The mixture was dialysed using a MWCO 1000 dialysis tubing 
overnight. The CMD-coated nanoparticles were prepared by dissolving the CMD 
(1.9 g) into a minimum amount (2 ml) of pure water. The CMD solution was added 
slowly dropwise to the nanoparticles at 70°C under a nitrogen stream.  
60ºC for 90 mins 
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2.2.4.2   In the presence of CMD 
In a typical procedure, CMD (1.9 g) was dissolved in pure water (6.3 ml) and then 
added dropwise to an aqueous solution containing ferrous chloride (0.49 g) in ferric 
chloride (6 M, 5.06 ml). The mixture was heated to 80°C with stirring under N2 
atmosphere for 1 h. After cooling to room temperature, the mixture was dialyzed 
with a membrane MWCO 1000 against water overnight to remove unincorporated 
inorganic material. These modified methods were based on (Kresse et al., 1998). 
2.2.5   Dextran Coated Iron Oxide Nanoparticles. 
The preparation of dextran (MW 1000 Da) coated IONPs was prepared as above in 
the presence of unmodified dextran. 
2.2.6   Poly (glycerol adipate) PGA Coated Iron Oxide 
Nanoparticles  
Poly (glycerol-adipate) (PGA) was provided by Dr G.A. Hutcheon and Dr S. Higgins 
of Liverpool John Moores University, U.K. The method of synthesis and structure of 
PGA are shown in Figs. 2.2 and 2.3 and were described by (Kallinteri. P., 2005). 
O
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Figure 2-2: Structure of poly (glycerol adipate) backbone. 
IONPs were coated with PGA by using the modified interfacial deposition method. 
Briefly, PGA (20 mg) was dissolved in acetone (2 ml) then the solution was added 
dropwise to an aqueous solution containing IONPs (2 ml) suspended in pure water 
(3 ml) under gentle stirring. The product was stirred overnight in a fume hood to 
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allow evaporation of the organic solvent. This modified method was based on that of 
Fessi et al. (1989) for polymer nanoparticle production. 
 
                
 
 
 
 
 
 
 
 
 
Figure 2-3: Synthesis of poly(glycerol adipate) PGA. 
 
2.2.7 Optimisation of Nanoparticle Coating Produced with PGA 
The important goal of this experiment was synthesise PGA coated nanoparticles with 
small size and thin coatings. Briefly, the amount of PGA was reduced (1 mg, 0.5 mg, 
2 mg and 0.1 mg) and the amount of solvent (acetone) was increased using the 
interfacial deposition method. PGA samples (2 ml) were added to IONPs (5 ml) 
under stirring. The nanoparticles were then left stirring overnight in a fume hood to 
allow evaporation of the acetone. 
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2.2.8  Purification of PGA-Coated Iron Oxide Nanoparticles  
A very low concentration of NaCl (200 µL, 3 mM) was added to 1 ml of PGA coated 
IONPs. The mixture was left for 5 min then centrifuged for 2 min (MSE 
microcentaur microcentrifuge, 13,500 rpm) to remove large and uncoated aggregates. 
The supernatant was then used as purified polymer coated IONP. 
2.2.9  Modification of PGA Polymers 
2.2.9.1 Synthesis of PGA 40%C18 by acylation of backbone PGA 
Dry THF (20 ml) was added to PGA (2 g, 0.16 mmol) in a round bottomed flask and 
refluxed under a nitrogen atmosphere at 80 °C to dissolve the polymer. Stearoyl 
chloride (656 mg, 43 mmol) was warmed to 25 °C in a small flask and dried THF 
(0.5 ml) added. The stearoyl chloride was then added to a flask containing the PGA. 
The flask containing stearoyl chloride was washed three times with dried THF and 
washings added to the mixture. Pyridine (0.5 ml) was also added to the mixture. The 
system was refluxed for two hours. The reaction was cooled to room temperature and 
(30 ml) of DCM added and then poured into a mixture of  pure water (20 ml) and of 
1 M HCl (0.5 ml) and washed twice  in a separating funnel. The polymer was then 
washed using a further aliquot of acidified water as above. The initial reaction vessel 
was rinsed with DCM (10 ml), and the organic fraction then combined with the 
collected fraction. The organic fraction was washed twice with pure water (40 ml) 
following which the polymer was dried using MgSO4. The product was filtered 
through a filter paper with DCM to remove flocculated MgSO4. Product was obtained 
by removal of DCM using a rotary evaporator. 
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Figure 2-4: Structure of poly(glycerol adipate) 40%C18. 
 
Figure 2-5: Synthesis of poly(glycerol adipate) 40%. 
 
2.2.10 Poly(glycerol adipate) 40%C18 Coated IONPs 
IONPs were coated with PGA 40%C18 using the interfacial deposition method with 
changes in the amount of polymer and solvent.  
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2.2.11 0.1% Tween80±coated PGA-coated IONPs and PGA 40%C18 
coated IONPs 
After coating the IONPs with the polymer, 0.1% Tween 80 (2 ml) was added to the 
0.2 mg of polymers (PGA and PGA 40%C18) coated IONPs and the stirred for 5 min. 
2.2.12  0.1% Albumin±coated PGA-coated IONPs and PGA 
40%C18-coated IONPs 
NPs were coated with 1% albumin in a method similar to that used for the 0.1% 
Tween 80 as above.  
2.2.13 PEGylated PGA 40%C18 
PEGylated PGA substituted with 40% C18 acyl groups. Briefly, PEG-NH2 with Mn of 
2000 was dried by MgSO4 in DCM and precipitated with cold ether, then filtered and 
dried under vacuum. Carbonyl di-imidazole (CDI) was prepared by dissolving CDI 
(40 mg, 0.25 mmol) in DCM (5 ml). The PEGylation reaction was carried out by 
dissolving PEG-NH2 (110 mg, 0.05 mmol) in chloroform (3 ml) in a double-necked 
round±bottomed flask and then CDI (1 ml) solution was transferred to the CH3-O-
PEG-NH2. The polymer PGA 40%C18 (600 mg, 0.05 mmol) was then dissolved in 
DCM (10 ml) under stirring. The CH3-O-PEG-NH2 solution was added to the 
PGA40%C18 solution. The resulting product was stirred for 7 days under a nitrogen 
atmosphere. After this time, the product was obtained by removal of the solvent by 
vacuum. Excess unreacted polymers PEG or PGA were also removed by washing the 
product by diethyl ether (1.5 ml) three times. The product was then allowed to dry 
for 30 min. 
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Figure 2-6: Structure of  PEGylated poly(glycerol adipate)  backbone 
substituted with acyl group 40%C18. 
 
2.2.14 PEGylated PGA 40%C18 Coated IONPs  
Different amounts of PEG-PGA 40% C18 (0.2 mg, 0.1 mg and 0.05 mg copolymer in 
2 ml acetone) were added dropwise to an aqueous solution containing IONPs (2 ml) 
suspended in pure water (3 ml) under gentle stirring. The product was stirred 
overnight in a fume hood to allow evaporation of the organic solvent. (This modified 
method was based on that of Fessi et al. 1994 for polymer nanoparticle production.) 
2.2.15 Stability of Iron Oxide Nanoparticles Coated with polymer 
The IONPs uncoated and coated were investigated by turbidity measurements 
following salting out with a range of NaCl concentrations (1 mM to 600 mM. After 
rapid homogenisation the samples were left for 5 min and then the turbidity was 
measured by light absorption at a wavelength of 500 nm. 
2.2.16   RBITC Labelled PGA-Coated Iron Oxide Nanoparticles 
RBITC labelled nanoparticles were prepared as follows.  RBITC in acetone (125 ȝO
2 mg/ml) was added to PGA-coated IONPs (7 ml) under stirring for 5 min as the 
organic phase. The mixture was diluted into HEPES (0.01M, pH 7.4, and 7 ml) under 
magnetic stirring. The mixture was left stirring with an aluminium foil cover 
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overnight in fume hood to allow the acetone to evaporate. The product was dialyzed 
against pure water using a MWCO 1000 dialysis tubing to remove excess rhodamine.  
2.2.17   Determination of Fluorescent Dye Loading   
The amount of fluorescent dye encapsulated was determined by a direct method. 
Freeze-dried Rhodamine B Isothiocyanate (RBITC) labelled PGA-coated IONPs 
were dissolved in an acetone/methanol (2:1 ratio) organic solvent mixture. The 
IOXRUHVFHQW VROXWLRQ ZDV PHDVXUHG DW Ȝ([  QP Ȝ(P  nm, slit width=5.0 
(Hitachi F-4500 fluorescence spectrophotometer, Hitachi Scientific Instruments, 
Finchampstead, UK). The amount of fluorescent dye was calculated by using a 
standard curve of RBITC fluorescence in HEPES buffer (0.01 M, pH 7.4). The 
experiment was repeated with RBITC at concentrations ranging from 1.25 µg/ml to 
5 µg/ml. 
2.2.18 Cell Culture Studies  
2.2.18.1  Preparation of the nanoparticles for cell work 
To avoid hypotonicity, nanoparticles in water (5 ml) were added to a 2x concentrated 
medium to give a stock particle solution. Particles were then used undiluted (1.0ml 
nanoparticles) or diluted 1:2, 1:5 and 1:10 in a normal cell culture medium to give 
various concentrations of the nanoparticles added to the cells, described as 0.5, 0.2 or 
0.1 ml of nanoparticles. .  
IONPs were calculated to be at a concentration of 0.34 M (19 mg/ml) with respect to 
iron. The concentration of coated IONPs was 0.07 M (3.92 mg/ml) diluted into 
medium to give amounts of 1.96, 0.98, 0.39 or 0.2 mg of nanoparticles added to 
cells. 
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2.2.18.2 C6 cell 
The C6 cell line was obtained from the American tissue culture collection.and is a 
brain derived rat glioma line which has fibroblast morphology and adherent growth 
properties. 
2.2.18.3   Preparation of media for C6 cell line 
These require full culture media supplemented with 10% foetal calf serum, sodium 
bicarbonate and 2 mM L-glutamine. 100 ml, 10x Minimum Essential Medium 
(MEM) (10 ml) was added to new-born calf serum (10 ml) and then sodium 
bicarbonate (5 ml) was added to the mixture followed by the addition of glutamine 
(one aliquot of 1 ml 200 mM glutamine). The medium was then made up to 100 ml 
with super ultra-pure water (SUPW) and filtered through a 0.2 µm sterile filter. 
2.2.18.4   Routine cell culture 
The C6 glioma tumour cells were cultured as monolayer in 75-cm2 culture flask in 
medium composed of 10% foetal calf serum, 7.5% sodium bicarbonate, L-glutamine, 
MEM and SUPW&HOOVZHUH LQFXEDWHGDWÛ&ZLWK&22 and 100% humidity 
and passaged every 5±7 days at about 80%±90% subconfluency. 
2.2.18.5   Washing coverslips 
Coverslips were handled by wearing gloves to to avoid deposition of fingerprints etc. 
SUPW (100 ml) was added to the coverslips in a 250 ml glass beaker then sonicated 
for 20±30 minutes and rinsed with running SUPW from the water tank for a 30 
minute slow rinse. HCl (1M, 50 ml) was added after removing the water and 
sonicated for 20±30 minutes. The HCl was removed and the coverslips rinsed 6 times 
with water. The covers were then placed on a filter paper in a large petri dish using 
forceps, sealed, dried and heat-sterilised in an autoclave overnight. 
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2.2.18.6   Coating coverslips with poly-D-Lysine (PDL) 
PDL was stored in aliquots (10 ml) in the freezer at 1 mg/ml. PDL (100 Pg/ml) was 
prepared to coat coverslips. The coverslips were placed in 24 well plates and then 
enough PDL was pipetted until the surface was covered (approximately 1 ml) and 
then the coverslips were allowed to stand in a laminar flow hood overnight. The 
coverslips were washed three times with SUPW and after the last rinse were left to 
stand in a laminar flow hood overnight. The water was then removed and the 
coverslips left to dry in a laminar flow hood. 
2.2.18.7   Cell staining for fluorescence microscopy 
Medium was removed and then cells were washed and fixed then mounted with a 
drop of DAPI.  
2.2.18.8 Cell staining for confocal microscopy 
A stock solution of DAPI (20 µl) was diluted into PBS (10 ml). The stain (0.5 ml) 
was added to the cells and then left for 10 min, before the solution was removed. 
2.2.18.9 Qualitative nanoparticle uptake by cells study 
Cellular uptake studies were carried out with 0.1% Tween-PGA 40%C18-coated 
IONPs and PEG-PGA 40%C18 coated IONPs. The subcellular localisation of 
nanoparticles following uptake was investigated using fluorescence microscopy and 
confocal fluorescence microscopy. C6 cells growing in monolayers on PDL-coated 
coverslips in 24 well plates were incubated with a quantity of RBITC labelled 
polymer coated IONPs for 2 h and then washed twice with PBS and fixed with 4% 
paraformaldehyde. The cells were washed again with PBS and left in PBS for 
microscopy. The uptake was evaluated either with or without serum present with 
different doses of particles (1 ml, 0.5 ml, 0.2 ml and 0.1 ml). 
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2.2.18.10 Qualitative uptake of nanoparticles in C6 cells 
Uptake was determined in the continuous presence of particles. C6 cells growing in 
monolayers on PDL-coated coverslips in 24 well plates were incubated with 
polymer-coated IONPs for varying periods of time (1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 18 h 
and 24 h) then washed. Cells were then mounted with a drop of DAPI, and visualised 
under fluorescence or confocal microscopy.  
2.2.18.11 Qualitative uptake and metabolism of nanoparticles in C6 
cell   
C6 cells growing in monolayers on PDL coated coverslips in 24 well plates were 
incubated with polymer coated IONPs for 1 h then washed off and incubated for 
varying periods of time (1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 18 h and 24 h).  The cells were 
then mounted with a drop of DAPI, and visualised under fluorescence or confocal 
microscopy. 
2.2.18.12 Evaluation of time±dependent uptake of NPs by cells 
growing in monolayer culture using TEM 
To demonstrate subcellular localisation of NPs in the cells for different time periods, 
cells were seeded on an insert membrane in a 12 well plate and incubated overnight. 
NP suspension (1 ml) was added to the cells and incubated with media and serum at 
37 ºC for increasing time intervals from 1 h, 4 h, 12 h and 24 h before dehydration 
and embedding.  
2.2.18.13 Dehydration and embedding of cells 
C6 cells were incubated with NPs for (1 h, 4 h, 12 h, and 24 h and rinsed with PBS 
three times. The cells were fixed in 4 % PFA and 3% glutaraldehyde in cacodylate 
(0.1 M) buffer for 1 hr and then postfixed in 1% osmium tetroxide for 1h. The cells 
were dehydrated in a graded series of ethanol solutions (60 %, 80 % and 100 %) then 
they were soaked in a mixture of 100 % 1, 2-epoxypropane and agar embedding resin 
Chapter 2                                                                                    Materials and methods  
58 
DW UDWLRRYHUQLJKWDWÛ&. After that they were soaked three times in fresh neat 
agar resin for 2 K DQG WKHQ SODFHG LQ D YDFXXP RYHQ DW Û& IRU  GD\V IRU
polymerisation of resin. The polymerised blocks were then cut into sections (80±100 
nm thick). Then sections were placed on formvar-coated copper grids, stained with 
an aqueous solution of 2% uranyl acetate for 10 min and washed by soaking them in 
water about 10 times, then stained with Reynolds lead citrate for 5 min and washed 
again with water before visualisation. Samples were imaged under TEM with 
magnifications from 10,000 to 20,000x. 
2.2.18.14 Quantitative NP uptake study dependent on dose and time 
To demonstrate the amount of uptake of the NPs by the C6 cancer cells, C6 cells 
(1ml, 1×106 cells) were put into Flow cytometry (FACS) tubes and NP suspensions 
were added in different doses 1 ml, 0.5 ml, 0.2 ml and 0.1 ml. The suspension was 
incubated for 2 h, and then centrifuged at 800 rpm for 5 min in an MSE centaur 
centrifuge (FISONS UK). The supernatant was removed, cells were washed once 
with PBS and centrifuged again. The supernatant was removed, cells were fixed with 
4% PFA and kept until uptake was quantitated using FACS over time periods up to 
24 h. 
2.2.18.15 Quantitative determination of loss of nanoparticles from 
cells 
C6 cells suspension at (1 ml, 1u106 cells) was put into flow cytometery tubes and 
NPs were added. The suspension was incubated for 1 h and the cells then centrifuged 
at 800 for 5 min. The supernatant was removed, and cells were washed once with 
PBS and were centrifuged again. The supernatant was removed and a medium with 
serum was added to the cells and the cells were incubated again for different time 
periods (1 h, 4 h, and 24 h), then cells were washed with PBS and fixed with 4% 
PFA and kept until flow cytometry measurement.  
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2.2.18.16 Aggregate cultures 
C6 cells were grown in monolayers and detached from the substratum by using 
trypsin-EDTA. The C6 cell aggregates were formed using the rotation method. C6 
cells (2 ml, 1u106 cells/ml) were cultured in C6 culture media in 10 ml screw top 
culture flasks (Scientific Laboratory Supplies, UK) and maintained at a constant 
rotation of 70 rev/min on an orbital shaker (Cole-Palmer, USA) at 37 Û&RYHUQLJKW                        
Cultures were then observed and the medium was changed and the rotation decreased 
to 50 rev/min. 
2.2.18.17 Cell aggregate uptake of RBITC NPs 
After C6 cell aggregates were prepared (see 2.2.18.16) the growth medium was 
replaced with a new culture medium, then the aggregate suspension (50 µl) and fresh 
media (0.5 ml) were transferred to a well plate with a PDL-coated coverslip in 24-
well plates. NPs were then added to the cells and incubated for a range of times (1 h, 
4 h and 24 h) and at different doses (1 ml, 5 ml, 0.2 ml and 0.1 ml). At the end of the 
incubation period, aggregates were washed three times with PBS and fixed with 40% 
PFA paraformaldehyde for microscopic study. 
2.2.19 Instrumental Methods 
2.2.19.1 Measurement of particle size 
Measurement of particle size was carried out using dynamic light scattering on a 
Viscotek 802 instrument. All measurements were performed at a temperature of 
22 ºC at a measuring angle of 90 ºC to the incident beam. The analysis mode was 
CONTIN and 10 readings were taken for each sample. Data output is produced for a 
number of different parameters.  Rh is the hydrated radius of the particles. The 
standard deviation (Std Dev) is the absolute value of the coefficient of variation. 
Percentage relative standard deviation (% RSD) is a normalized measure of 
dispersion obtained from the ratio of size and standard deviation. 
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2.2.19.2 Surface charge measurement 
7KH ȗ-potential of the nanoparticles was determined by laser Doppler anemometry 
(LDA). The principle of measurement of zeta potential is that an electric field is 
applied across the dispersion. Particles within the dispersion with a zeta potential will 
migrate toward the electrode of opposite charge with a velocity proportional to the 
magnitude of the zeta potential. This velocity was measured using the technique of 
laser Doppler anemometry. The frequency shift or phase shift of an incident laser 
beam caused by these moving particles is measured as the particle mobility, and this 
mobility is converted to the zeta potential by inputting the dispersant viscosity, then 
the velocity is analysed by a computer. 
2.2.19.3 Transmission electron microscopy 
The morphology of the particles was examined using TEM (Jeol Jem 1010 electron 
microscope, Japan). One uncoated IONP sample was examined using TEM without 
staining. One drop of the sample was placed for 1 minute on the copper grid with a 
formvar carbon film. The excess of the sample was whisked away with the aid of 
filter paper. The sample was then ready for analysis by TEM 
A staining procedure was used for all other TEM analyses. A sample of particle 
suspension was diluted with 3% w/v phosphotungstic acid and adjusted to pH 7.5 
with potassium hydroxide corresponding to a 1:1 ratio before examination. One drop 
of the sample was placed for 1 minute on a copper grid coated with a formvar carbon 
film. The excess of the sample was whisked away with the aid of filter paper. The 
sample was then ready for analysis by TEM.  
2.2.19.4 Nuclear magnetic resonance spectroscopy (NMR) 
Polymer samples (2 mg) were dissolved in 0.86 ml deuterated acetone, while pure 
amino acids (2 mg) were dissolved in deuterated methanol (1 ml) and subjected to 
NMR analysis. The NMR spectra were recorded on a Bruker 400 MHz spectrometer. 
The data was processed using the Omnispin software. 
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2.2.19.5 Fourier transformed infrared spectroscopy (FTIR) 
Fourier transformed infrared (FT-IR) spectra were obtained on a Nicolet AVATAR 
360 FT-IR spectrometer. Samples of polymers were prepared in KBr discs 
(2 mg sample in 200 mg KBr). The scanning range was 450±4000 cm-1 and the 
resolution was 1 cm-1. Sample analyses were carried out using the E2 OMNIC 
software. 
2.2.19.6 Flow cytometry 
Flow cytometry (Fig 2.7) uses the principle of hydrodynamic focusing for presenting 
cells to a laser. The sample is injected into the centre of a sheath flow. The combined 
flow is reduced in diameter, forcing the cells into the centre of the stream and the 
sensing area of the flow chamber. One unusual feature of flow cytometry is that it 
measures fluorescence per cell or particle.  This contrasts with spectrophotometry in 
which the percentage of absorption and transmission of specific wavelengths of light 
is measured for a bulk volume of sample. Cells or particles of interest intercept the 
light source. They scatter light and fluorochromes are excited to a higher energy 
state. This energy is released as a photon of light with specific spectral properties 
unique to different fluorochromes. Finally, scattered and emitted light from cells and 
particles is converted to electrical pulses by optical detectors. Collimated (parallel 
light waveforms) light is picked up by confocal lenses focused at the intersection 
point of cells and the light source. Light is sent to different detectors by using optical 
filters. The most common type of detector used in flow cytometry is the 
photomultiplier tube.  
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Figure 2-7: Principle of Flow Cytometry (website image).    
(http://biology.berkeley.edu/crl/flow_cytometry_basic.html) 
 
2.2.19.7  Method of measuring cell uptake NPs by flow cytometry 
Cells were kept in 4% PFA tubes until quantitation by flow cytometry. The 
intracellular fluorescence intensity was determined on a Beckman coulter EPICS 
XL-MCL flow cytometer (BECKMAN Coulter, Buckinghamshire, UK) using 
XLSYSTEM ,,TM
.  
The numbers of cells were measured by forward scatter while side 
scatter determined the amount of NP labelled with dye taken by cells.   
2.2.19.8 Fluorescence microscopy 
The principle of the fluorescence microscope is to let excitation light radiate the 
specimen and then sort out the much weaker emitted light to make up the image.  
The microscope has a filter that only permits passage of radiation with the desired 
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wavelength that matches your fluorescing material. The radiation collides with the 
atoms in the specimen and electrons are excited to a higher energy level. When they 
relax to a lower level, they emit light. To become visible, the emitted light is 
separated from the much brighter excitation light in a second filter. Here, the fact that 
the emitted light is of lower energy and has a longer wavelength is used. The 
fluorescing areas can be observed in the microscope and shine out against a dark 
background with high contrast. 
2.2.19.9  Confocal laser scanning microscopy 
The key working principle of the confocal laser scanning microscope (CLSM) is to 
restrict the illumination area by using an illumination point source. Hence, at a given 
time, merely local information from a very small sample area can be obtained. An 
image of the entire specimen surface is produced by a scanning mechanism. In 
addition to the small aperture used for illumination, a second small aperture is used 
in front of the detector. The intermediate image of the specimen in the back-focal 
plane of the objective lens is simultaneously placed in the focal plane of the collector 
lens (Fig. 2.8) which gives rise to the name "confocal". This leads automatically to a 
further important characteristic of the CLSM. Light rays with an origin off the 
optical axis and off the focal plane are focused in a different plane, and thus are 
excluded from image formation by the pinhole aperture. Because the CLSM is able 
to focus in the third dimension by moving step by step through the specimen, a laser, 
which has a small beam diameter and small beam divergence with high intensity, is 
generally used as a light source for CLSMs.  
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Figure 2-8: Principle of confocal laser scanning microscopy (website image). 
(http://www.fz-juelich.de/ibn/Light_microscopy/conf). 
 
2.2.19.10   Method of fluorescence studies 
The cells were carefully washed three times with PBS then fixed with 4% PFA, again 
washed three times with PBS, stained with DAPI and viewed using fluorescence 
microscopy (Leica DMRB, Leica Microsystem Wetzlar GmbH). Cell monolayers 
were imaged and visualised by adjusting the filters, which were DAPI for the nuclei 
and red plate for the rhodamine, using a high resolution camera and Openlab 
software. For confocal laser scanning fluorescence microscopy (Leica SP2 MP, 
Microsystem Ltd., UK) cells were  pictured and viewed  using UV laser (DAPI), 543 
nm filter (RBITC), 488 nm filter (fluorescein) and 476 nm filter (Lyso Tracker).
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CHAPTER 3 
3. SYNTHESIS OF IRON OXIDE 
NANOPARTICLES AND NANOPARTICLES 
COATED WITH CARBOXYMETHYL 
DEXTRAN AND DEXTRAN 
3.1 INTRODUCTION 
Biodegradable polymers, synthetic and natural such as polysaccharides and 
proteins have been widely used and investigated for biomedical applications 
(Jeong et al., 1997and Yamamoto et al., 1996). Dextran is a polysaccharide 
mainly composed of 1,6-linked D-glucopyranose residues. According to its 
biocompatibility and biodegradability, dextran and its derivatives have been 
used as blood substitutes and drug carriers (Hoste et al., 1994). Much work has 
been carried out to impart useful properties to dextran by different chemical 
modifications for various applications as drug carriers. (van Dijk-Wolthuis et 
al., 1997) developed non-degradable and degradable hydrogels using 
methacrylated dextrans and studied the degradation and drug release behaviour 
of the hydrogels. The degradation rate of the hydrogels was dependent on the 
amount of the encapsulated dextranase and the degree of substitution or 
crosslinking (Franssen et al., 1997). Carboxylated dextran is negatively 
charged because of the carboxyl group. Their function is to bind to cationic 
IONPs. The approach used in this work was to introduce carboxylic acid 
functionality in the form of a high acid value by acetic acid. The result showed 
a degree of substitution of carboxymethylated polysaccharide with dextran 
molecular weight of 10,000. Carboxylated polysaccharides with value of 
degree of substitution between 0.4 and 0.9 and a range of polymer molecular 
weights from 20,000 to 100,000 g/mol have been reported (Wotschadlo et al., 
Chapter 3                                     Iron oxide nanoparticles coated with Dextrans 
66 
2009a). Commercially available dextran-coated IONPs are currently in clinical 
use or in clinical trials as MRI contrast agents (Harisinghani et al., 1997).  
IONPs have great potential as magnetic resonance (MRI) contrast agents due to 
their strong magnetic susceptibility and superparamagnetic properties (Koenig 
and Kellar, 1995 and  Bulte and Kraitchman, 2004). The main problem with 
IONPs is the aggregation at biological pH, therefore the nanoparticles must be 
coated with biocompatible materials for medical applications. IONPs have 
been coated with many materials, including polyethylene glycol (PEG), starch 
and dextran, resulting in a size range from 200  to 1000 nm. Today the most 
common are dextran coated IONPs and these are the only clinically approved 
iron nanoparticle MRI contrast agents (Thorek et al., 2006). Various physical 
and chemical synthesis methods can produce small nanoparticles with an 
average size under 10 nm (Schutt et al., 1997 and Olsvik et al., 1994). Many 
studies have demonstrated different parameters to control size and shape. By 
changing the oxidising agents, spherical particles with mean diameter from 30 
to 100 nm can be produced (Sugimoto and Matijevic, 1980).  Ferrous and ferric 
hydroxides in aqueous media were mixed stoichiometrically producing 
spherical particles homogeneous in size (Massart and Cabuil, 1987).  
Use of water-in-oil microemulsions resulted in a small size of IONP in the 
range 4±12 nm (Lopezquintela and Rivas, 1993). There are many methods 
producing different sizes of IONP, such as sonochemical, electrochemical, 
spray pyrolysis and laser pyrolysis. All these have advantages in obtaining a 
small size but are not suitable for lab work and are expensive to produce. The 
method and the synthetic parameters used have a great effect on the size. The 
IONPs in this study were prepared using the common method, which is co-
precipitation where nanoparticles of small size can be obtained reproducibly, 
easily and at low cost. This will provide a suitable model nanoparticle of the 
correct size. Particles prepared by precipitation have saturation magnetisation 
higher than the particles prepared by the pyrolysis method (Tartaj et al., 
2003b).   
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In this study, I present the preparation of IONPs and their characterisation by 
size, zeta potential and coating the particle with CMD and dextran using a co-
precipitation method. The presence of free pendant hydroxyl groups on dextran 
allows the ready functionalisation of dextran to convert the nanoparticles to 
have a negative charge. Dextran and CMD were chosen as a coating for initial 
studies in order to compare results with established IONPs used as contrast 
agents. In this project, small IONPs were prepared to establish the method to 
obtain them and for coating with polymers based on reported methodology.  
3.2 Aim of the chapter 
x Synthesis of iron oxide nanoparticles.  
x Production of IONPs with particle size less than 20 nm.  
x Narrow particle size distribution of iron oxide nanoparticles.  
x Synthesis of carboxymethyl dextran. 
x Coating of IONPs with dextran and carboxymethyl dextran. 
3.3 Methods 
Preparation of iron oxide nanoparticles (see 2.2.1.2). 
 The effect of pH on the size of iron oxide nanoparticles (see 2.2.1.1). 
Stability of iron oxide nanoparticles; nanoparticles were prepared using method 
described in (see 2.2.2).  
Synthesis of carboxymethyl dextran (see 2.2.3). 
Determination of degree substitution of carboxymethyl dextran (see 2.2.3.1). 
Preparation of iron oxide nanoparticles coated with carboxymethyl dextran 
either during or after synthesis (see 2.2.4.1 and 2.2.4.2). 
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Preparation of dextran-coated iron oxide nanoparticles (see 2.2.5). 
Measurement of particle size and zeta potential (see 2.2.19.1 and 2.2.19.2). 
Transmission electron microscopy (TEM) (see 2.2.19.3). 
3.4 RESULTS  
3.4.1 Iron Oxide Nanoparticle Preparation and 
Characterisation  
The synthesis of IONPs using the co-precipitation method has been described 
in chapter 2. The co-precipitation method is more favoured for medical 
applications because it is possible to obtain  uniform particles which are not 
soluble in water, only in certain solvents (Bumb et al., 2008). The first goal of 
this work was the synthesis of iron oxide nanoparticles with small size. The 
reaction pathway chosen for the preparation of iron oxide nanoparticles used a 
mixture of ferrous and ferric salts in alkaline medium, under a nitrogen 
atmosphere to prevent oxidation. The particles are protected from oxidation 
and this results in a reduced size in the absence of oxygen when compared with 
methods preparing them in the presence of oxygen (Kim et al., 2001). 
Deoxygenated water was also used in the mixture to prevent oxidation. 
Adjusting the pH by HCl in the synthetic process may reduce the size while 
maintaining the ratio of Fe3+  : Fe2+  at 1: 1.   
 
3.4.2 Particle Size  
IONP prepared using the co-precipitation method were measured using DLS, 
and the results are shown in Table 3.2 and Figure (3.1). It is immediately 
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obvious that these uncoated nanoparticles are mainly of a very small size with 
very little aggregation. The particle sizes ranged between 6±13 nm when 
measured both by light scattering and electron microscopy. This indicates that, 
under the simple conditions of the preparative procedure, the resulting 
dispersions exhibited high homogeneity.  
 
 
 
 
 
 
Figure 3-1: The particle size distribution of IONPs by DLS. Shows sample 
prepared by the co-precipitation method at pH 0.5. 
 
3.4.3 Zeta Potential   
The surface charge of the iron oxide nanoparticles is an important parameter 
for medical applications in vivo and vitro. Uncoated nanoparticles have been 
measured in pure water; IONP showed a positive charge of 21.2 ±7.3 mV, 
(Table 3.2).         
 Area % Rh  (nm) Std  Dev % RSD 
1 87.4 6.74 1.07 15.9 
2 12.6 336.48 142.76 42.4 
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3.4.4 TEM Images 
A transmission electronic microscopy (TEM) study was carried out to analyse 
the morphology of iron oxide nanoparticles. Different batches showed the same 
mean particle size calculated by TEM when synthesised under the same 
conditions. Thus, samples were estimated to be 13.9 ± 3 nm in diameter when 
stained and 13.1 ± 9 nm unstained (Fig. 3.2). Samples showed that the particles 
are a spherical shape and smooth with a narrow size distribution. The image 
shows a few large particles or aggregates, but indicates that the majority of 
nanoparticles are single as also shown in the DLS results in figure 3.1. The 
particles measured by DLS are a very similar size to those viewed by TEM. In 
the absence of a coating, the IONP hydrodynamic value would be expected to 
be a similar size to the dehydrated value seen under vacuum. 
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Figure 3-2: TEM images for uncoated IONPs. NPs were prepared under 
the same conditions (A Scale bar 200 nm and B 500 nm). Nanoparticles were 
prepared by co-precipitation and placed on copper grids, sample (A) was 
stained with 3% phosphotungstic acid for 2 minutes, and dried  (Average size 
13.9 ± 3 nm), while sample (B) was unstained (Average size 13.1 ± 9 nm). 
Images were taken at 100 k and 200 k magnification.  
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3.4.5 The Effect of pH on the Stability of IONPs  
The pH of the IONP during synthesis and storage was studied. Three different 
preparations were made under the same conditions using the co-precipitation 
method to produce suspensions with a final pH of 0.5, 2.0, 4.0 and 7.0. were 
measured by DLS (Fig. 3.3). It was clearly shown that decreasing the pH was 
accompanied by a decrease in IONP size. At pH 0.5, the nanoparticles ended 
up with a small size below 20 nm. At pH 7.0, the IONPs showed a size above 
70 nm, which was almost 3 times that at pH 2.0 or at pH 4.0. 
 
Figure 3-3: The effect of pH on the stability of IONPs.  
 
3.4.6 Stability of IONPs 
The colloidal stability of IONP suspension prepared in the experiment of Fig. 
3.2 was checked by DLS analysis and compared with another preparation using 
the same method but acidified to pH 1.0.  Where peaks reflect the population of 
the particles size. (Figs. 3.4, 3.5 and 3.6) and show the size distribution of 
IONP during storage. For particles at pH 0.5, no significant change was 
observed after this period with size constant at below 20 nm in diameter and 
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also the area showed one main, small nanoparticle population. (Fig. 3.4). 
Particles prepared at pH 1 are shown in figures 3.5 and 3.6. Two main 
nanoparticle peaks were observed in the pH 1 preparation. The first peak 
showed a small population of IONP with smaller size (20 nm in diameter) than 
the large peak (120 nm in diameter) but which was larger than IONP produced 
by acidification to pH 0.5. During the first day of incubation there was a small 
increase in particle size for both peaks, with no significant change in particle 
size on longer storage.  The results show only the particles synthesised at pH 
0.5 are stable enough to be used in further work.  
 
Figure 3-4 :  Preparation pH 0.5 (Peak 1): IONP stability over 7 days. 
Peak 1 was the principle particle size in this preparation.  IONP were prepared 
using the co-SUHFLSLWDWLRQPHWKRGRQ'D\DFLGLILHGWRS+VWRUHGDWÛ&
and measured daily by DLS up to days 7.  
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Figure 3-5 : Preparation pH 1 (peak 1): IONP stability over 7 days.  IONP 
were prepared using the co-precipitation method on day 1, acidified to pH 1.0, 
VWRUHGDWÛ&DQGPHDVXUHGGDLO\E\'/6XS WRGD\7KLVSHDNZDVD VPDOO
proportion of the particles formed and showed particles smaller than pH1 
preparation peak 2 but still bigger than the preparation at 0.5 pH. 
 
Figure 3-6 : Preparation pH 1 (peak 2): IONP stability over 7 days.  
IONP were prepared using the co-precipitation method on day 1, acidified to 
pH 1, stored DWÛ&DQGPHDVXUHGGDLO\E\'/6IRUGD\V7KHSHDNFRQWDLQHG
most of the particles formed at this pH, and were large particles. 
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Preparation DSs
1 0.34
2 0.32
3 0.35
4 0.47
5 0.49
6 0.49
3.4.7 Carboxylated Dextran  
The synthesis of CMD involved the methylation of dextran. The carboxyl 
group of the monomer can readily react with the hydroxyl group on the dextran 
to form ester linkages as shown in Figure 2.1. The successful incorporation of 
the COOH into dextran was demonstrated by calculation of the degree of 
substitution. The CMD had degree of substitution values in the range 0.32 to 
0.49 (Table 3.1). The number of COOH group in the CMDs preparations were 
calculated from acid-base titration.  
Table 3-1: IONP Coated Degree of substitution of COOH on dextran. 
 
 
 
 
 
3.4.8  IONP Coated with CMD and Dextran 
IONPs tend to aggregate and to be recognised by the reticuloendothelial system 
following surface adsorption of plasma protein. Coating the IONP is necessary 
to prevent both to prevent aggregation and in future work to reduce protein 
adsorption.  
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3.4.8.1    CMD±IONPs 
Uncoated particles were prepared by the co-precipitation method and the 
reaction was carried out under standard conditions both in the absence of CMD 
and the presence of CMD. The resulting particle size distribution is shown in 
Table. 3.1. The uncoated IONP had a particle size 13 nm in diameter. Their 
zeta potential of 21.2 ±7.3 mV was positive as expected from the literature.  
When CMD was added to IONP the diameter of CMD coated IONP (CMD±
 IONP) was increased to 41± 9 nm as measured by TEM (Fig. 3.9) and 44 and 
163 nm when measured by DLS, the majority being the small size (Fig.3.7). 
These CMD±IONP had a zeta potential of - 91.9 ± 53 mV (Table 3.2) 
CMD±IONP prepared in the presence of carboxymethyl dextran showed an 
increase in size to 46 ±10 nm measured by TEM (Table 3.2 and Fig. 3.10) 
similar to the CMD±IONP prepared by adding CMD to IONP. The final 
nanoparticles then displayed a negative zeta potential of -39.8 ± 0.5 mV, 
somewhat less than the nanoparticles coated with CMD after IONP 
preparation. We interpret the increase in the size and the high negative zeta 
potential to be a result of coating the iron oxide with negatively charged 
polymer. IONP coated in these two ways have a hydrodynamic diameter 
measured by DLS of 44 nm with IONP coated with polymer (Fig 3.7) and 
46 nm when prepared in the presence of polymer (Fig 3.8) which is well in 
agreement with TEM measurements. 
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% Area Rh (nm) Std Dev % RSD
1 60.6 22.19 7.78 35.1
2 37.1 81.91 31.12 38
3 2.3 1881.23 426.41 22.7
 
 
 
Figure 3-7 :    The particle size distribution of CMD ±IONP by DLS. 
IONP were synthesised using the co-precipitation method and then coated with 
CMD. 
 
  
 
 
 
 
 
 
 
Figure 3-8 : The particle size distribution of CMD±IONP by DLS.  IONP 
synthesised in the presence of CMD in the suspension using co-precipitation 
method. 
 
 
 % Area Rh (nm) Std Dev % RSD 
1 0.5 1.90 0.09 4.9 
2 66.6 22.94 6.71 29.2 
3 33.0 128.53 41.30 32.1 
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Figure 3-9: TEM image for CMD±IONP. The IONP were synthesised using 
the co-precipitation method and then coated with CMD (Average size 41± 9 
nm). (Scale bar 500 nm). 
 
Figure 3-10: TEM image for CMD±IONP.  Synthesised in the presence of 
CMD in the suspension (Average size 46 ± 10 nm). (Scale bar 200 nm). 
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3.4.8.2 Dextran±coated iron oxide nanoparticles  
IONPs were coated with dextran using co-precipitation in the presence of the 
polymer. Comparison of the hydrodynamic diameter of CMD±IONPs and 
dextran-coated±IONPs (Fig 3.8 and 3.11 respectively) revealed a similar 
hydrodynamic diameter and size distribution for the dextran±IONPs, 46 nm 
compared to 50 nm. The average diameter for dextran coated IONP was 40 ±12 
nm measured by TEM (Fig 3.12). There was a significant effect of coating 
increasing the nanoparticle size from 13± 9 nm to 40 nm or 50 nm. The zeta 
potential values of dextran and CMD coated IONP were more negative than the 
IONPs (Table3.2), decreasing from +21.2 ±7.3 mV to -35.8 ± 0.5 mV with 
dextran.  The dextran coated IONP was less negative than the CMD±IONP.  
 
 
 
 
 
 
 
 
 
 
Figure 3-11: The particle size distribution of dextran coated IONPs by 
DLS.  IONP were made using the co-precipitation method in the presence of 
dextran. 
 
  % Area Rh (nm) Std Dev % RSD 
1 2.6 1.72 0.16 9.6 
2 66 24.96 10.61 42.5 
3 4.3 408.37 55.12 13.5 
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Figure 3-12:  TEM image of dextran coated IONPs. IONP were made 
using the co-precipitation method in the presence of dextran (Average size 
40± 12 nm) (Scale bar 200 nm). 
The specifications for the CMD and Dextran coated IONP are summarised 
below in (Table 3.2) showing size determined by both DLS and TEM and also 
the zeta potential. 
Table 3-2: The zeta potential and sizes of uncoated nanoparticles and 
CMD and dextran-coated iron oxide nanoparticles. The negative ȗ-
potential of the particles arose from the free terminal carboxyl groups of the 
polymer. 
Nanoparticles  DLS NP diameter 
(nm) 
TEM NP diameter 
(nm) 
ȗ-potential  mV 
 ± S.D 
IONP 13.48 13 21.2 ±7.3 
CMD±IONPcoated 
after IONP preparation 
44 and 163 41± 9 -91.9 ±53.1 
CMD±IONP made in 
the presence of polymer 
46 and 257 46 ± 10 -39.8 ±0.7 
Dextran±IONP made in 
the presence of polymer 
50 40 ± 12 -30.8 ±0.5 
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3.5 Discussion  
3.5.1 IONP Preparation and Characterisation  
The initial work concentrated on producing NPs in a range consistent with 
SPION reported in the literature and with a narrow particle size distribution. It 
was clear that this could be achieved by understanding the mechanism of NP 
formation and choosing the right procedure. The iron oxide nanoparticles 
produced in this project were produced by a co-precipitation method and 
determined to be in the size range 13 nm in a diameter by both DLS and TEM.  
This is a size range comprising most of the reported IONP and well within the 
required specification. Co-precipitation is the simplest, cheapest method which 
involves the simultaneous precipitation of Fe2+ and Fe3+ ions in basic aqueous 
media (Kang et al., 1996) was used. 
 
IONP are very suitable for medical applications. IONP can be prepared with 
control of the size by a number of methods. By homogeneous precipitation 
reaction, including the separation of the nucleation and growth of nuclei, 
uniform particles can be obtained (Sugimoto, 2000). SPION of magnetite with 
a mean diameter of 10 nm and narrow size distribution were synthesized by the 
co-precipitation method using a homogenizer at a stirring velocity of 10,000 
rpm (Valenzuela et al., 2009). 
Small size particles have also been obtained using the precipitation method by 
reaction of iron (,,,) acetylacetonate in phenyl ether in the presence of 
oleylamine, alcohol and oleic acid under a high temperature (Sun and Zeng, 
2002). Aqueous FeCl3 and FeCl2 solutions are mixed at a concentration ratio of 
Fe (III)/Fe (II) = 2/1 in an aqueous ammonia solution, yielding Fe3O4 NPs with 
diameters from 3 to 15 nm using the co-precipitation method. In order to 
prepare SPION with a narrow size distribution, several parameters should be 
Chapter 3                                     Iron oxide nanoparticles coated with Dextrans 
82 
controlled including pH, temperature, and mixing method, as well as the nature 
and concentration of anions (Oh and Park, 2011). 
3.5.1.1 Particle size  
Nanoparticles with iron oxide core sizes of 13 nm can be used in a variety of 
medical applications and biological fields, SPION of 10 nm size used as MRI 
contrast agents are also used for many other purposes, such as non-viral gene 
delivery (Berry et al., 2003). Many investigations have reported a size of 
uncoated IONP of a similar size to the uncoated IONP produced in the present 
work. LaConte et al., (2005) reported that particles with diameters of 10±40 
nm, including ultra-small SPIOs (USPIOs), are ideal for prolonged blood 
circulation, can pass through capillary walls, and are often phagocytosed by 
macrophages which carry them to bone marrow and lymph nodes. The method 
selected and modified resulted in smooth nanoparticles with no aggregation 
(Fig. 3.2). Types of uncoated IONP have been produced with different sizes. 
This was done by varying the methods used to prepare the NP core. Uncoated 
NPs with spherical shape and narrow size distribution with a mean diameter 
from 30 to100 nm can be prepared from Fe (,,) salt, a base and mild oxidant, 
nitrate ions (Sugimoto and Matijevic, 1980). IONP of 20±100 nm were 
obtained by controlling the temperature of reaction velocity at 5±Û&DQGWKH
concentration of iron salts (Bergemann et al., 1999).  IONP in a range of 4 nm 
to 12 nm were prepared using microemulsion method (Feltin and Pileni, 1997). 
Also IONP with size around 100 nm can be prepared by a disproportionation of 
ferrous ions in the organic media method (Fievet et al., 1989a). In the most 
common commercial method, spray pyrolysis, IONP were obtained with a 
mean diameter UDQJLQJ IURPí60 nm according to the nature of the iron salt 
(González-Carreño et al., 1993).   
Gupta and Curtis, (2004b) have prepared IONP by using the chemical 
precipitation method and these were found to be small in size, around 13.6 nm 
measured by TEM.  
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 IONPs which are very uniform in size and shape have been prepared by the 
co-precipitation method in the present work. Particle diameters average size 
13 nm were determined from TEM measurement (Fig.3.2). The particles were 
very smooth and with a good shape and there were no aggregates. The size of 
the IONPs measured by DLS was 13 nm in hydrodynamic diameter, while in 
TEM size was measured in a dried state.  
3.5.1.2 Zeta potential 
The IONPs suspension in water produced in the present work were 
characterised by a high positive zeta potential of 21.2 ± 7.3 mV (Table 3.2) at 
pH 0.5. It is generally agreed that iron oxide nanoparticles have a strong 
positive charge. A high value of zeta potential was found of 14 mV at pH 1 
which may be explained due to the formation of Fe-OH2+  in acid medium (Yu 
and Chow, 2004).   
3.5.1.3 Stability of uncoated iron oxide nanoparticles 
During the synthesis of IONPs, the mixture was acidified to pH 0.5 to produce 
a small size. The particle was stored after synthesis in the IULGJH DW Û&
(Figs.3.4, 3.5 and 3.6). To further investigate the stability during storage we 
synthesised the uncoated NP acidified to pH 1.0 for comparison.  The IONPs 
which we routinely prepared at pH 0.5 showed high stability and had nearly the 
same size over the7 day period while the IONP with higher pH 1, 4 and 7 had 
DQDYHUDJHVL]HRIí200 nm.  
Different hydrodynamic sizes of IONP about, 250 and 320 nm, indicating as 
aggregates after storage in water  for 5 days (Chen et al., 2008).  
Indeed, for this work, it was important that the IONPs produced could be 
maintained at their original size without aggregation, making them suitable for 
our work on coating particles for possible use as a contrast agent. Not much 
work has been done with IONP in order to investigate how long they can 
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maintained in an unaggregated form in storage.  Although the IONPs in this 
study were uncoated, no obvious change of the size was detectable during the 7 
days of the experiment. In addition, the IONPs were stored for more than a 
year and we found that particle sizes did not change over this longer period.   
3.5.1.4 The effect of pH on the size of IONPs 
The chemical stability and properties of nanoparticles is dependent on many 
parameters. One of the most important factors is pH during the process of 
synthesis of IONPs (Fig. 3.3). Variation of the co-precipitation method has 
been used to prepare nanoparticles. Generally, a basic aqueous solution of 
ferric and ferrous are precipitated as magnetite. At the same time some 
parameters can be changed, such as the ratio and nature of ferric and ferrous or 
reaction conditions, e.g. pH, temperature to control the size (Thunemann et al., 
2006 and Schulze et al., 2006). The IONPs produced in this project were 
optimised by varying the pH during the synthesis, and the smallest size was 
observed at pH 0.5. It has been found that in the aqueous dispersion of 
nanoparticles pH has a major effect on the particle size. The pH and the ionic 
strength of the co-precipitation can be adjusted to control the size of 
nanoparticles over an order of magnitude 2±15 nm (Jolivet et al., 2000).   
IONPs are often stabilised using fatty acyl moieties. In terms of particle size, 
the concentration of sodium oleate in reaction has an effect on the size of IONP 
together with an increase of solution pH. A pH lower than 11 resulted in a 
reduction in the size while at pH higher than 11 the particle size was increased 
(Sun et al., 2007). In IONPs that were prepared at different pH  and then 
treated with trypsin, the size was between 8.5 to 25 nm (Kim et al., 2005a). 
IONP obtained at pH 9 gave a size of 30 nm while the mean diameter of the 
IONP was estimated to be 10 nm at pH 10 when measured by TEM (Lin et al., 
2005).  
The change of pH has a strong effect on the size, and it is useful to take this 
into account during synthesis. The ratio and type of salt, ionic strength of the 
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media and pH have an important role in controlling the size and shape of 
nanoparticles (Siegel, 1993 and Carl et al., 1994).   
In conclusion, the results from this study show that it is possible to store 
uncoated nanoparticles that can be used subsequently at any time for up to a 
year without any change in the size.  
3.5.2 Carboxylated Dextran   
Dextran with Mw 40,000 was carboxylated by monochloracetic acid. The 
effect of parameters such as reaction time, temperature, catalyst and the 
amount of reactants of  DS of carboxylated dextran were examined and showed 
different values from 0.36 to 1.53 (Kim et al., 1999). The degree of substitution 
of carboxyl groups was found to be 4.6 mmol (Hildebrandt et al., 2007). It 
would be expected that COOH groups on CMD would be very attractive to 
Fe2+ ions, which is an advantage. The successful incorporation of the COOH 
group into dextran was demonstrated by titration and calculation of the 
carboxylic groups (Table 3.1). 
3.5.3 Coated Iron Oxide with CMD and Dextra 
In this project CMD and dextran have been both coated onto IONPs using a 
common method which is a co-precipitation. This led to a highly homogenous 
suspension with little aggregation of particles. The particles have a large 
surface area and have been coated and conjugated with biomolecules 
(enzymes, antibodies, DNA, etc.) and sugars (dextran, starch, albumin, 
poly(ethylene glycol) for a variety of uses (Luckarift et al., 2004, Kneuer et al., 
2000,  Santarelli et al., 1988 and Lesot et al., 1998). 
Jarrett et al., (2007) have reported that dextran has been used for coating IONP 
because many investigators reported that it is non-toxic and is approved for 
clinical use. The most common method for coating IONP is co-precipitation 
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(Weissleder et al., 1990 and Kawaguchi et al., 2001). Polysaccharides are 
common as coatings for IONP (Weissleder et al., 1995c).  
Coated  IONPs  made either in the presence of CMD or by subsequent addition 
of polymer and with dextran by subsequent addition of polymer showed no 
significant difference in size between these two methods, as shown in 
(Figs.3.9, 3.10 and 3.12) and (Table 3.1) DLS measurements showed similar 
sizes between the three formulations (Figs. 3.7,3.8 and 3.11).  It has been 
reported that IONP have been coated with dextran by using two methods, laser 
pyrolysis and co precipitation (Carmen Bautista et al., 2005).  
Different forms of dextran polymers, including carboxydextran and 
carboxymethyl dextran, have been used to produce SPIONs, Ferumoxtran-10 
and ferumoxytol, using the co precipitation method (Laurent et al., 2008).  
In a majority of studies on nanoparticle formulations, particle sizes have been 
correlated to the amount of polymer or the methods, including the parameters 
such as temperature and ratio of the iron salts, but not their combined effect. 
The co-precipitation method can be used for the preparation of CMD and 
dextran-coated IONP, and it is an easy, low cost and reproducible method. 
3.5.3.1 Particle size  
All the coated particles formed with polymers were larger in size than the 
uncoated particles (Fig. 3.2) and this proves the presence of the polymer on the 
IONP surface (Figs. 3.9, 3.10 and 3.12) and also the effect of hydration due to 
the coating layer on the size. Jarrett et al., (2007) have reported the effect of 
reaction time, pH, iron ratio and polysaccharide content on coating iron oxide 
with dextran sulphate produced in a range of sizes.   Nanoparticles produced in 
the present work were shown to be spherical, well-dispersed and, in the larger 
particles, the denser IONP were seen within a the lighter matrix of the dextran 
coating. The nanoparticles are slightly larger in DLS because TEM 
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measurement corresponds to particles in a dried state, whereas the DLS 
measurement is of hydrated polymer coating (Figs. 3.7, 3.8 and 3.11). 
Comparing other work where iron oxide nanoparticles were prepared with 
dextran and CMD coatings using the co precipitation method. CMD±IONP 
sizes of 75 nm mean particle diameter and 88 nm with dextran were reported 
by (Horák et al., 2007). CMD±IONP made in the presence of the polymer 
using the co-precipitation method were produced with a size around 20 nm as 
measured by TEM (Hildebrandt et al. 2007). SPION in commercial products 
Resovist and SHU555C, used as magnetic resonance imaging contrast agents, 
are polydisperse and covered with a thick layer of CMD producing average 
particle sizes between 3 and 62 nm (Chen et al., 2009). On the other hand, 
CMD±IONP measured using photon correlation spectroscopy and atomic force 
microscopy, the particle size core was from 6±40 nm and hydrodynamic 
particles size of coated nanoparticles was between 13±80 nm (Büscher et al., 
2004). 
Iron oxide nanoparticles coated in the presence of dextran under alkaline 
conditions  were produced with a diameter from 40 nm to 60 nm (Duan et al., 
2005). Commercial nanoparticles called ferumoxides are dextran-coated magnetite 
nanoparticles with a mean hydrodynamic size of approximately 141 nm (Jain et 
al., 2008a). By using the co-precipitation method to coat IONP with  dextran 
mean aggregate sizes are 57 ± 17 nm were measured by TEM and 
hydrodynamic size around 214 ± 8 nm (Carmen Bautista et al., 2005).  
CM±polysaccharide±coated IONPs were measured in dry state with sizes 
found from 140 nm to 200 nm in diameter (Wotschadlo et al., 2009b). IONPs 
coated with dextran prepared by laser pyrolysis were shown to produce sizes 
about 50 nm in diameter (Veintemillas-Verdaguer et al., 2004). The NP 
preparation procedure studied in this work investigated coating methods both 
in the presence and in the absence of the polymer, showing both can be used to 
prepare coated iron oxide nanoparticles.  
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The sizes of dextran and CMD coated IONPs prepared in the present work 
were very similar to those reported in the literature and for the commercially 
available IONP contrast agents. 
3.5.3.2 Zeta potential  
IONPs show a positive charge, but when they were coated with CMD there 
was a negative charge, most likely due to the presence of an ionised carboxyl 
group of the polymer present on the nanoparticle¶s surface. Dextran was 
carboxymethylated to introduce COOH to produce a negatively charged 
polymer. SPION was coated with carboxymethyldextran by a co-precipitation 
method, providing COOH on iron oxide surface (Lee et al., 2009). To improve 
the interaction  IONPs coated with CMD showed good interactions with  
tumour cells (Schwalbe et al., 2006). The results in Table 3.2 showed that the 
CMD±IONPs and dextran prepared in this work were highly negative. This 
means the particles were well coated with dextran and CMD.  
The CMD±IONP prepared in the presence of polymer had a very similar zeta 
potential to the dextran±IONP prepared in the presence of polymer, whereas 
CMD±IONP prepared in the absence of polymer had a much more negative 
zeta potential.  This suggests that when the polymer is present during IONP 
production, the carboxyl groups on CMD interact much more with the IONP 
but that when added afterwards, many more carboxyl groups are present on the 
CMD±IONP surface. 
3.6  CONCLUSIONS 
We have presented a controlled co-precipitation method which produced iron 
oxide nanoparticles. The pH was a crucial factor to control the IONP size.  
IONP with a 13 nm narrow size distribution was determined by TEM and DLS.  
The optimized conditions for producing small particle size can be achieved by 
changing the pH to 0.5 during synthesis. The IONPs showed high stability 
during a 7 day experiment but even longer operationally; from our records up 
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to 1 year without any change of the particle size. Carboxymethyl dextran was 
SUHSDUHG VWDUWLQJ IURP GH[WUDQ Įĺ OLQNHG EDFNERQH with a degree of 
substitution value in the range between 0.32í0.49.  We have prepared CMD 
and dextran coated IONPs about 41 ± 9 nm, 46 ±10 nm and 40 ±12 nm in 
size respectively using the co-precipitation method, and these appear to be of a 
similar size specification to dextran and CMD±IONP described in the 
literature. 
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CHAPTER 4 
4. POLY (GLYCEROL ADIPATE) AND PGA 
40%C18 COATED IRON OXIDE 
NANOPARTICLES 
4.1 INTRODUCTION 
Major phagocytic cells macrophages and neutrophils typically take up large 
particles >200nm but will also take up small hydrophobic particles. Small 
particles can also be taken by a variety of cell types including endothelial cells. 
Most coated contrast agents are mainly taken up by macrophages (Moghimi et 
al., 2005) 
If the particles could be coated to both avoid macrophages and remain in 
circulation or be taken up by different cell types this could result in many 
different applications for these contrast agents. If we could use these PGA 
polymers as a delivery system by coating IONPs instead of incorporating 
drugs, we could perhaps develop better delivery for contrast agents. PGA 
nanoparticles coated with Tween have a good stability and selective uptake 
into tumour cells (Meng et al., 2006). 
In fact, all biological compartments act as barriers to the passage of nanosized 
materials, with many other barriers to consider such as epithelium, which plays 
a role as a general barrier to prevent the materials entering into the body. The 
particles will therefore be injected into the blood and circulation where the 
body has a number of defences against pathogenic organisms such as protozoa, 
bacteria and viruses. Serum proteins act as opsonins and when the particles are 
hydrophobic they be easily coated by the proteins. The opsonins are mainly 
antibodies and complement factors which promote the binding of nanoparticles 
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to the phagocytic cells, especially macrophages and neutrophils in the 
mononuclear phagocyte system, which rapidly remove the particles from the 
bloodstream (Stolnik et al., 1995). The mechanism of protein adsorption 
leading to the elimination of the nanoparticles is based on different 
interactions, but specifically those between the hydrophobic part of the proteins 
with the hydrophobic surface on the nanoparticles (Rieger et al., 2007). Organs 
with high concentrations of mononuclear phagocytic cells are the liver, spleen 
and lymph nodes. Opsonised particles can be cleared from the circulation to the 
liver and spleen in less than 5 min (Illum et al., 1982). The ideal IONPs for 
biomedical applications should have a narrow size distribution and their 
surface should be coated with biocompatible hydrophilic materials to form a 
stable aqueous dispersion at the physiological pH of 7.4. Commonly, 
stabilisation of a ferrofluid is achieved by optimising the electrostatic repulsion 
of similarly charged surfaces, but stable IONPs coated with biocompatible 
polymer is necessary for biological applications. Recently, biocompatible and 
biodegradable polymers such as poly(D,L,lactide-co-glycolide) (PLGA), 
poly(D,L-lactide) (PLA), and poly(glycolide) (PGA) have been used (Kim et 
al., 2003b, Herrmann and Bodmeier, 1998 and Lin et al., 1985).  
In order to prevent particle aggregation, because of attractive van der Waals or 
magnetic dipole-dipole interactions, a steric or electrostatic repulsion can be 
produced by coating the particles with polymers. Stability can be achieved by 
one or two fundamental mechanisms: either the presence of an electrical 
double layer on the particles or the presence of a polymer providing steric 
stabilisation (Majewski and Thierry, 2007).  
IONPs have been coated using different methods and with different polymers. 
Different coatings have effects on both the nanoparticle size and also on their 
stability. Several methods have been used for coating, such as emulsion 
polymerisation, double emulsion, water-in-oil-in-water, evaporation, inverse 
microemulsion polymerisation, miniemulsion polymerisation and the 
emulsification±diffusion method or two-step emulsion polymerisation (Arias et 
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al., 2001, Gomez-Lopera et al., 2001, Deng et al., 2003, Zheng et al., 2005 and)  
Lee et al., 2005).  
Poly(ethylene imine) and  poly(ethylene oxide)±block-poly(glutamic acid) 
coated IONP that were stored in sodium chloride 0.15 M for 30 days and 6 
months showed no change of the particle size (Thunemann et al., 2006). 
Lyophilized solid lipid nanoparticles were stored for 6 and 9 months at 
Û&UHODWLve humidity and the size increased to 400 nm with just a few 
small sized particles about 40 nm (del Pozo-Rodriguez et al., 2009).   
Recently, a novel polymer poly(glycerol-adipate) has also been used to create 
nanoparticles. It met with success in encapsulating a variety of different drugs 
and is a biodegradable polymer made from non-toxic monomers. These 
characteristics suggest that PGA polymers are useful for preparing 
nanoparticles for drug delivery. They have the capability to self ±assemble into 
small particles and have showed the ability to entrap an anticancer drug with a 
high efficiency (Kallinteri et al., 2005). The presence of free pendant hydroxyl 
groups on the backbone introduces synthetic flexibility in the backbone as they 
are available for substitution with different functional groups and different 
chemistries and showed excellent drug incorporation. They also showed a good 
uptake into different cells, a long sustained drug release in physiological 
conditions and rapid drug release when taken up into cells. 
In this study, a co-precipitation method was used to synthesise iron oxide 
nanoparticles for potential use as MRI contrast enhancement agents in the 
diagnosis of cancer and other diseases. The synthetic method described in 
chapter 3 was based on a solution of Fe2+ and Fe3+ salts in an alkaline medium. 
In this chapter, iron oxide nanoparticle will be coated with PGA backbone and 
PGA 40%C18 polymers using a modified interfacial deposition (IDP) method. 
Either unmodified PGA (PGA 0%) or PGA with different acyl substitutions 
(different acyl chain lengths and different degrees of substitution) will be used 
to coat IONPs by using the interfacial deposition method (Fessi et al., 1989). 
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 This method was previously used by our team and showed a good result in 
producing nanoparticles for drug delivery systems. The effect of the method 
and different PGAs on the particle size has been studied extensively (Meng et 
al., 2007b and  Puri et al., 2008).  
 In this chapter various characterisation techniques have been applied to obtain 
information about the size, structure and coating of the nanoparticles. The 
nanoparticles were manufactured using various amounts of solvent and 
polymers under various conditions and were characterised using transmission 
electron microscopy (TEM) for morphological properties, DLS and zeta-
potential for particle site surface charge. In this chapter, work establishing a 
new method based on the above technique to produce small polymer coated 
nanoparticles will be described. Also the further coating of the nanoparticles 
with Tween or albumin and their stability to aggregation will be determined. 
The nanoparticle properties of these systems will be assessed in terms of their 
colloidal stability in physiological media and their ability to interact with cells. 
4.2 Aims of the Chapter 
x To evaluate the methods of preparation of PGAs±IONPs and select the 
best method for coating nanoparticles.  
x To determine the optimum method of PGA±IONPs to obtain small 
nanoparticles. 
x To study the influence of polymer functionalisation and degree of 
acylation on coating IONPs. 
4.3 Methods 
Poly(glycerol adipate) PGA and different PGA±IONPs  (see 2.2.6).  
Optimisation of IONPs coating produced with PGA (see 2.2.7). 
Modification of PGA polymers (see 2.2.9). 
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Synthesis of PGA 40%C18 by acylation of backbone PGA (see 2.2.9.1). 
PGA 40%C18 coated IONPs (see 2.2.10). 
0.1% Tween 80 coated±PGA 40%C18±IONPs and PGA 40%C18±IONPs (see 
2.2.11). 
0.1% Albumin±coated PGA 40%C18±IONPs and PGA 40%C18±IONPs (see 
2.2.12). 
Stability of IONPs coated with polymers (see 2.2.15). 
Purification of PGA±IONPs (see 2.2.8).  
4.4 Results  
4.4.1 Coated IONPs Using Different PGAs and two Different 
Methods. 
The effects of the method of coating and different polymer PGAs on 
nanoparticle size were investigated.  PGA substituted with different acyl chain 
lengths at 20%, 60%, 80% and 100% substitution were studied to produce 
coated IONPs.  There were two aims in these experiments: to determine 
whether the polymer specification influenced polymer coating of IONPs with 
the PGA polymer and to determine the best method to coat the IONPs with 
PGA. The two different methods were (1) a modified interfacial deposition 
method and (2) a sonication method were polymers added dropwise to 5 ml of 
IONPs. The product was sonicated at 30 W for 30 min. These were used to 
prepare PGA-coated IONPs by using a number of PGAs with different 
substitutions, The same amount of IONPs (5 ml) and polymers was used in 
both methods and all the polymers were used at 20 mg/ml dissolved in 1 ml of 
acetone, then all particles size of samples were measured using DLS 
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Figure 4-1:   IONPs coated with different polymers using the IDP method. 
Fig. 4.1 shows that the particle sizes produced by IDP method measured using 
DLS where PGA 0%±IONPs 126 nm in diameter and PGA 60%C8±IONPs 129 
nm in diameter, were the smallest size, compared with other polymers where 
PGA 20%C8 ±IONPs, PGA 80%C8±IONPs and PGA 100%C6±IONPs were 163 
nm in diameter, 173 nm in diameter and 210 nm in diameter, respectively. 
 
  Figure 4-2: IONPs coated with different PGA by sonication method. 
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Fig. 4.2 shows the different PGAs±IONPs prepared using sonication. Sizes 
given are of diameter. Significant differences in trends could be observed 
between two methods. Comparing the particles obtained by IDP and particles 
prepared by sonication, mean hydrodynamic diameters between 120 nm to 160 
nm were found for PGAs±IONPs prepared by IDP, while particles obtained by 
sonication method resulted in a range from 176 nm to 240 nm in diameter. 
Looking at some specific examples, PGA 60%C8±IONPS were coated using 
two different methods. The hydrodynamic diameter of those prepared by 
sonication were measured with DLS and shown to be 176 nm in diameter, 
while the same polymer used for coating IONPs using the IDP method was 
smaller at 137 nm in diameter. Also the difference between the PGA 80%C8 ±
 IONPs gave 173 nm in diameter by IDP and 186 nm in diameter by sonication. 
With the sonication method the smallest IONPs was 176 nm in diameter, while 
with the IDP method the smallest size observed was 126 nm.  
The polymer specification did affect the size of the coated particle, but there 
was no obvious correlation between the substitution and the size of coated 
nanoaparticles. It was interesting to observe that the PGA 0% prepared using 
IDP were smaller than all the other preparations; however, it may be that the 
conditions used were still not optimal for our nanoparticles. Figs. 4.1 and 4.2 
show the influence of the method of preparation on PGA±IONPs.  
Fig. 4.3 shows the. PGA 60%C8±IONP prepared by IDP which appeared to be 
spherical with a rounded surface where many small PGA 60%C8±IONPs with 
different sizes can be seen. This result indicates the feasibility of coating of 
PGA 60%C8±IONPs. The TEM image (Fig. 4.3) showed high populations of 
small particles in the background. In general, there are lots of small particles 
with around 84 ± 27.15 nm. 
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Mean  105.2
StDev 44.54
N            210
 
Figure 4-3: TEM image of PGA 60%C8±IONPs by using IDP method. 
Showing mostly small particles with different sizes of large particles (Average 
size 84 ± 27 nm) (Scale bar 500 nm). 
Figure 4-4: TEM image of PGA 100%C8±IONPs by using sonication 
method. Showing mostly small particles with different sizes of large particles 
(Average size 105 ± 44 nm) (Scale bar 500). 
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Fig. 4.4 shows coated particles using the sonication method. The image showed 
that the NPs are almost spherical in shape. PGA 100%C8 coated IONPs 
appeared similar in size and also had a low polydispersity. There are a lot of 
small coated particles and also large particles, the average size was around 
105 ± 44 nm. Although the IDP method produced particles with a slightly 
smaller and narrower particle distribution, we would like to obtain still smaller 
and more monodisperse particles. 
4.4.1.1 Zeta potential  
Table 4.1 shows the zeta potential for IONPs coated with a number of PGAs 
with different substitutions either using the IDP method or by the sonication 
method. It shows that the zeta potential of all the particles is positive.  
The zeta potential for the particles prepared by the sonication was around 25 ± 
2.2 mV with 100% C6, C10 25 ± 2.2 mV and C8 27 ± 5.1 mV which was very 
near to the uncoated and very near to the neutral. For the PGA0%±IONPs 
particles zeta potential became less positive: 5.3 ± 2.2 mV. Acylation of 
60%C8 and 20%C8 increased positive zeta potential values to 31 ± 2.5 mV and 
28.2 ± 3.9 mV. In the case of PGA 0%±IONPs and PGA 100%C8±IONPs, 
using a different method for nanoparticles synthesis resulted in similar value. 
The zeta potential probably arose from the type of the acyl group attached on 
the polymers coated IONPs. The PGAs±IONPs were prepared using two 
methods leading to no significant difference between the preparations with 
regard to zeta potential.  In the following experiments, we investigated a range 
of conditions for coating particles using PGA backbone.   
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Table 4-1: Shows H[DPSOHVRIȟSRWHQWLDORI3*$V±IONPs. 
 
 
4.4.2 Optimisation of IONPs Coating Produced with PGA 0% 
Modified 
The aim of this work was to determine how various formulation parameters 
affect the particle size. The amounts of polymers and acetone volume used in 
the IDP method and observed from the results were found to be critical for 
PGA coatings on IONPs. An experiment was designed to investigate effect on 
coating  particles size the amounts of PGA with a constant a volume of acetone 
and different volumes of acetone with constant amounts of PGA to coat 
IONPs. The effect of organic solvent volume and amount of polymer was 
studied using the IDP method. Firstly, decreasing amounts of polymer were 
used in the presence of 1 ml acetone with different amount of polymers 1, 0.5, 
0.2 and 0.1 mg.   Figures 4.5a indicate that using 1ml acetone with 1 mg PGA 
0% to coat IONPs led to very large nanoparticles. The mean PGA 0%±IONPs 
size in diameter was approximately 176 nm in diameter. So, a range of 
Nanoparticles Zeta potential mV ± S.D  Method 
IONPs 21.2 ±7.3 Co-precipitation 
PGA  0%±IONPs 5.3 ± 2.2 IDP 
PGA  20% C8±IONPs 28.2 ± 3.9 IDP 
PGA  60% C8±IONPs 31.2 ± 2.5 IDP 
PGA  100% C6±IONPs 22.8 ± 4.1 Sonication 
PGA  100% C8±IONPs 27 ± 5.1 Sonication 
PGA  100% C10±IONPs 25 ± 2.2 Sonication 
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amounts of acetone was used with a constant amount of polymer (1 mg). 
Acetone (1 ml) with different amounts of polymer led to very large particles.  
The results are shown in Fig. 4.5. In the range 1.0 mg and 0.5 mg of PGA 0% 
coat IONPs, a increase in the size from 176 nm and 227 nm in diameter 
respectively were observed (Fig. 4.5a and 4.5 b), while with 0.2 mg PGA 0% 
coated IONPs the mean diameter was 200 nm (Fig. 4.5c). Nanoparticles with a 
large mean diameter of 201 nm in diameter were obtained with 1 ml of acetone 
and 0.1 mg of PGA 0% to coat IONPs (Fig. 4.5d). 
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Figure 4-5: Different amounts of polymer with constant volume of 
acetone.  
 
 
 
Figure 4.5a: The particle size distribution of 1 mg PGA 0%±IONPs by 
DLS (1 ml of acetone). 
 
 
 
Figure 4.5b:  The particle size distribution of 0.5 mg PGA 0%±IONPs by 
DLS (1 ml of acetone). 
 Area % Rh  (nm) Std  Dev % RSD 
1 1.7 11.67 0.82 7.0 
2 98.3 88.27 22.58 25.6 
 Area % Rh  (nm) Std  Dev % RSD 
1 10.5 22.18 2.18 9.8 
2 89.5 113.73 25.00 22.0 
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 Area % Rh  (nm) Std  Dev % RSD 
1 7.0 18.01 1.64 9.1 
2 93.0 100.46 21.76 21.7 
Figure 4.5c: The particle size distribution of 0.2 mg PGA 0%±IONPs by 
DLS (1 ml acetone). 
 
 
 Area % Rh  (nm) Std  Dev % RSD 
1 2.6 17.04 1.96 11.5 
2 97.4 100.54 28.92 28.8 
Figure 4.5d: The particle size distribution of 0.1 mg PGA 0%±IONPs by 
DLS (1 ml of acetone). 
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% Area Rh (nm) Std Dev % RSD
1 0.7 13.88 1.03 7.4
2 93.1 109.15 34.65 31.7
Increasing the amount of acetone (1.5, 2, 2.5 and 3 ml) with a constant amount 
of PGA 0% (1.0 mg)  resulted in an optimum small size of polymers using 2 ml 
of acetone, with a subsequent increase again to bigger particles with larger 
volumes of acetone (Figs. 4.6 a-d, and 4.6 c). Nanoparticles made using 1mg of 
PGA 0% with 3 ml of acetone (Fig 4.6a) shows mono modal size distribution 
with peak at 218 nm in diameter, a very large particle. DLS analysis of 
nanoparticles made from 2.5 ml of acetone with 1 mg of PGA 0% (Fig. 4.6b) 
show a bimodal distribution with peaks at 46 nm in diameter and large particles 
about 240 nm in diameter with aggregates. . For the batch with 2 ml acetone 
(Fig 4.6c), mono modal particle size distribution was shown, with the majority 
of particles averaging 130 nm in diameter. A DLS graph showing the size 
distribution of particles made from 1.5 ml of acetone with 1 mg of PGA 0% 
(Fig 4.6d) gave a multi modal distribution, with main peak of 64 nm in 
diameter and some populations with nearly 2 µm sizes. Also, even a small 
population of 17 µm size.  
 
Figure 4-6 : Different volumes of acetone with constant amount of the 
polymer. 
 
 
Figure 4.6a:  The particle size distribution of 1 mg PGA0 %±IONPs with 
by DLS (3 ml of acetone). 
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% Area Rh (nm) Std Dev % RSD
1 1.9 4.08 0.45 10.9
2 25.8 23.01 7.1 30.8
3 63.6 120.38 59.3 49.3
4 8.6 2200.56 572.75 26
Area % Rh  (nm) Std  Dev % RSD
1 0.9 6.73 0.27 4
2 99.1 65.29 14.12 21.6
 
 
 
Figure 4.6b:  The particle size distribution of 1 mg PGA 0%±IONPs by 
DLS with (2.5 ml of acetone). 
 
 
 
 
 
 
Figure 4.6c: The particle size distribution of 1 mg PGA 0%±IONPs by 
DLS with (2 ml of acetone). 
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Figure 4.6d: The particle size distribution of 1 mg PGA 0%±IONPs by 
DLS with (1.5 ml of acetone). 
 
Clearly, both approaches were inefficient in their own right in terms of 
producing small size nanoparticles. However, an additional experiment, using a 
range of decreasing polymer amounts and 2 ml of acetone resulted in smaller 
particles with decreasing polymer amounts.  
Using 1mg of the PGA 0% with the 2 ml of acetone to coat IONPs results in a 
large average diameter of the NPs with a bimodal size distribution, with major 
peak at 226 nm in diameter (Fig. 4.7a). The mean particle size was observed to 
fall significantly as smaller amounts of PGA 0% were used with a constant 
2 ml amount of acetone. For example, in Fig. 4.7b the decrease of the amount 
of PGA 0% to 0.5 mg resulted in small PGA 0%±IONPs in bimodal size 
distribution with one peak at 66 nm in diameter and a small one at 15 nm in 
diameter. With 0.2 mg of PGA 0% coated IONPs a distribution of particle sizes 
and small size of 57 nm in diameter were obtained and a subsequent reduced 
risk of unwanted larger nanoparticles (Fig. 4.7c). By using 2 ml of acetone and 
0.1 mg of PGA 0% to coat IONPs the majority of the PGA 0%±IONPs size 
was 85 nm in diameter with some small nanoparticles 9 nm in diameter (Fig. 
4.7d).  
Area % Rh  (nm) Std  Dev % RSD
1 0.8 1.86 0.16 8.4
2 77.6 32.05 21.56 67.3
3 14.4 918.19 146.64 16
4 7.2 8551.57 966.46 11.3
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% Area Rh (nm) Std Dev % RSD
1 8.1 20.34 2.66 13.1
2 91.9 113.37 27.84 24.6
Figure 4-7: Range of amounts of polymer with constant volume of 
acetone (2 ml). 
 
 
 
Figure 4.7a:  The particle size distribution of 1 mg PGA 0%±IONPs by 
DLS (2 ml of acetone).  
 
 
 
 
 
Figure 4.7b:  The particle size distribution of 0.5 mg PGA 0%±IONPs by 
DLS (2 ml of acetone). 
  %Area Rh (nm) Std Dev % RSD 
1 0.4 0.12 0 4.1 
2 26 7.76 1.72 22.2 
3 73.5 33.25 12.11 36.4 
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% Area Rh (nm) Std Dev % RSD
1 2.6 3 0.39 12.9
2 93.8 28.55 28.15 98.6
3 3.7 5285.7 2025.56 38.3
 
 
 
Figure 4.7c: The particle size distribution of 0.2 mg PGA 0%±IONPs by 
DLS (2 ml of acetone). 
 
 
  % Area Rh (nm) Std Dev % RSD 
1 0 0.11 0 0 
2 2 4.56 0.62 13.6 
3 98 42.74 32.42 75.9 
Figure 4.7d: The particle size distribution of 0.1 mg PGA 0%±IONPs by 
DLS (2 ml of acetone). 
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4.4.3 Morphology 
 Fig. 4.8 shows the transmission electron microscopy images of IONPs coated 
with 1mg of PGA 0% with 2 ml of acetone. This Figure shows that there is a 
distribution over a range of particle sizes 83 ± 55 nm. It can be seen there are 
many large particles with a few small particles. Particles appeared to be 
spherical. 
  
Figure 4-8 : TEM image of PGA 0% (1 mg) with (2 ml) of acetone±IONPs. 
Which is showing a large number of large particles, fewer small particles 
(Average size 83 ± 55 nm) (Scale bar 200 nm). 
 
In Fig. 4.9, the IONPs coated with 0.5 mg of PGA 0% showed a fairly narrow 
size distribution with many large particles. The mean particle size ranged was 
194 ± 81 nm in diameter. In the background a small particles can be seen.  
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Figure 4-9: TEM image of PGA 0% (0.5 mg) with (2 ml) of acetone±
IONPs. Which Showing large particles, many fewer small particles (Average 
size 194 ± 81 nm) (Scale bar 5000 nm).  
 
 
Figure 4-10: TEM images of PGA 0% (0.2 mg) with (2 ml) of acetone ± 
IONPs. Which Showing fewer large particles, many very small particles 
(Average size 16 ± 5 nm) (Scale bar 200 nm).   
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IONPs coated with 0.2 mg of PGA 0% with 2 ml of acetone are shown in the 
TEM image presented in Fig. 4.10. The micrograph depicts a large number of 
smooth, small size spherical particles well dispersed in the polymer. The size 
of the particles was uniform with most of the small coated particles in particle 
size 16 ± 5 nm in diameter. 
IONPs coated with 0.1 mg of PGA 0% prepared in this study, the shape of 
particles was spherical with good distribution, also some large particles as 
coated aggregate can be seen, and the average size was 24 ± 8 nm in diameter 
(Fig. 4.11).  
 
 
Figure 4-11: TEM image of PGA 0% (0.1 mg) with (2 ml) of acetone± 
IONPs. Showing a mixture of particle sizes, overall reduction in particle size 
(Average size 24 ±8 nm) (Scale bar 200 nm). 
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4.4.3.1 Zeta potential 
Zeta potential for 1 mg particles was 35.8 ± 7 mV, while 0.5 mg of PGA 0%± 
IONPs also exhibited a positive charge with a zeta potential of 55.6 ± 12.4 mV. 
For the 0.2 mg of PGA 0%±IONPs zeta potential became even more positive at 
62.2 ±11.3 mV. 0.1 mg PGA 0%±IONPs showed positive zeta potential of the 
particles at 39.8 ± 5.5 mV (Table 4.2).  
 
 
Table 4-2: Surface charge and sizes of the best formulations with 
different amounts of PGA 0%±IONPs.  
 
 
4.4.4 Modification of PGA polymers  
4.4.4.1 Synthesis of PGA 40% C18 by acylation of backbone PGA 
PGA backbone was modified to change its physicochemical characteristics in 
order to increase the interaction between the nanoparticles and the polymer and 
increase the stability of nanoparticles. The acylation was achieved by reaction 
of a percentage of the pendent hydroxyl group from the PGA backbone with 
Nanoparticles DLS NP 
diameter (nm) 
TEM NP 
diameter (nm) 
ȗ±potential mV ± SD 
PGA 0% 1 mg with    
2 ml of acetone±IONPs 
227   83 ± 55          35.8 ± 7.0 
PGA 0% 0.5 mg with 
2 ml of acetone±IONPs 
66   194 ± 81          55.6 ± 12.4 
PGA 0% 0.2 mg    with 
2 ml   of acetone±IONPs 
46    16 ± 5          62.2 ± 11.3 
PGA  0% 0.1mg with    
2 ml of acetone±IONPs 
84     24 ± 8           39.8 ±5.5 
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acid chloride using pyridine as acid scavenger and catalyst. The substitution of 
backbone was 40%C18, i.e. poly(glycerol adipic acid), with 40% of the free 
hydroxyl groups substituted with an 18 carbon alkyl chain, attached via an 
ester linkage. The C18 group provides a greater degree of hydrophobicity to the 
polymer. The compositions of polymer and backbone were analysed by proton 
NMR. Gel permeation chromatography, also provided data on the molecular 
weight and distribution. Following are the NMR scans of the polymer 
backbone (Fig. 4.13) and 40%C18 substituted polymers (Fig. 4.15) together 
with the annotated PGA (Fig.4.12) and PGA 40%C18 (Fig.4.14) structures.  
 
 
Figure 4-12: Structure of PGA backbone. 
 
Figure 4-13: NMR spectrum for poly(glycerol adipate) backbone. 
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The peaks of the CH2-CH2 protons apSHDU DW į ±1.72 ppm) while the 
peaks of CH2- &2SURWRQVDSSHDUDWį±2.40 ppm)$EURDGPXOWLSOHWDWį
(4.02±4.27 ppm) corresponds to the CH2-CH (OH)-CH2 methylene protons. 
 
 
 
 
 
Figure 4-14: Structure of PGA 40%C18. 
 
 
Figure 4-15: NMR spectrum for poly (glycerol adipate) 40%C18. 
 
 
The same peaks mentioned above are also apparent in the NMR spectrum of 
PGA 40%C18. However, the presence of the acyl group is indicated by the 
SHDNV DSSHDULQJ DW į í0.89 ppm) for tHUPLQDO PHWK\O SURWRQV į ± 
1.69 ppm) for OCO-CH2- CH2 protRQVDQGį ±2.42 ppm) for OCO-CH2 
protons. By NMR the proportion of hydroxyl groups substituted with acyl side 
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chains was estimated to be 48% in comparison to the expected 40% by 
comparing tKHVLQJOHLQWHQVLW\RIį±1.69 ppm) for OCO-CH2-CH2 DQGį
(2.26±2.42 ppm) for OCO-CH2.  The covalent attachment of acyl group can be 
also confirmed by the GPC chromatograms when the Mn of PGA 0% (Fig. 
4.16) increased from 10437 to 12038 for the PGA 40%C18 polymer (Fig. 4.17). 
Assuming the molecular weight of backbone Mn at 10437 while the PGA 
40%C18 at 40% substitution was estimated to have an Mn of 15757.  The 
change determined by GPC was lower than the theoretical figure.  This was 
probably due to a structural change in the polymer, but the increase of 
molecular weight indicated that the acylation had occurred.  
 
 
Figure 4-16: GPC elution profile for poly(glycerol adipate) backbone. The 
red line is the calibration curve, while peak 1 shows the retention time of the 
polymer. The peaks at the low limit are the solvent front.
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Figure 4-17: GPC elution profile for poly (glycerol adipate) 40%C18. The 
red line is the calibration curve, while peak 1 shows the retention time of the 
polymer.  The peaks at the low limit are the solvent front. 
 
 
 
The FTIR of the polymer substituted with 40%C18 (Fig. 4.19) further 
confirmed the presence of strong ester bond peaks at 1383.47and 1462.39.50 
cm-1, which were absent in the scan of the unmodified polymer (Fig. 4.18). 
The peaks for the hydroxyl groups shifted from 2916.89 in the polymer 
backbone to 2360.394 m-1 and OH appears at 3610.05 cm-1, probably due to 
the involvement of some protons in an esterification reaction. 
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Figure 4-18: FTIR of poly(glycerol adipate) backbone. 
 
 
Figure 4-19: FTIR of poly(glycerol adipate) 40%C18.  
 
Chapter 4                                          Iron oxide nanoparticles coated with PGA                           
117 
4.4.5 PGA 40%C18 coated IONPs 
 IONPs were coated with PGA 40%C18 again using the interfacial deposition 
method where IONPs were dispersed in water, and we chose 0.2 mg PGA 
40%C18  in 2 ml  of acetone as the starting point for optimisation as this was the 
optimum from the previous experiments with PGA 0%. The IONPs were 
coated with polymer and dispersed in the acetone then the polymer precipitated 
and coated the IONPs. The PGA 40%C18 polymer variant is more hydrophobic 
and so forms nanoparticles more easily, but the presence of some free hydroxyl 
groups should help nanoparticles be coated because of possible interaction 
between the hydroxyl groups and the IONPs surface.  
4.4.5.1 Particle size and morphology 
Amounts of added polymer ranged from 0.5 to 0.1 mg PGA 40%C18 with 
constant volume of acetone (2 ml) to produce coated IONPs. The particle size 
distributions measured by dynamic light scattering are shown in Figures 4.20. 
4.21 and 4.22, respectively. The size distribution of 0.5 mg of PGA 40%C18 
coated IONPs shown in Fig. 4.20 showed two narrow peaks at about 15 nm and 
113 nm in diameter. The size distribution of the 0.2 mg PGA 40%C18±IONPs 
displayed two peaks and the diameter of the small particles was determined to 
be 20 nm  in diameter and of the larger ones was 136 nm in diameter (Fig. 
4.21). For Fig. 4.22, the IONPs were coated with 0.1 mg of PGA 40%C18 and 
showed a dominant peak at about 136 nm in diameter and the minor peak 
around 17 nm in diameter, which suggested that there was aggregation among 
the particles.  
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% Area Rh ( nm) Std  Dev % RSD
1 42.8 10.11 4.29 42.4
2 57.2 68.07 25.89 38
% Area Rh ( nm) Std  Dev % RSD
1 26.6 7.93 1.47 18.5
2 73.4 56.56 14.59 26
 
 
 
Figure 4-20:   The particle size distribution of 0.5 mg PGA 40%C18±IONPs 
by DLS. 
 
 
 
 
 
Figure 4-21:  The particle size distribution of 0.2 mg PGA 40%C18±IONPs 
by DLS. 
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% Area Rh ( nm) Std  Dev % RSD
1 0.1 0.11 0 0
2 30.1 8.54 2.43 28.5
3 69.9 68.24 41.79 61.2
 
 
 
 
 
Figure 4-22: The particle size distribution of 0.1 mg PGA 40%C18±IONPs 
by DLS. 
 
The TEM images showed the morphology of different preparations of PGA 
40%C18 coated IONPs (Figs. 4.23±4.25). It can be seen from the TEM image 
Fig. 4.23 that 0.5 mg of PGA 40%C18 coated IONPs showed large particles 
about 105 ± 32 nm. However, some small PGA 40%C18 coated IONPs can still 
be seen. TEM images showed the particles are spherical.  
The image in Fig. 4.24 using 0.2 mg of PGA 40%C18 shows a huge number of 
small PGA 40%C18 coated IONPs of a diameter approximately 23 ± 7 nm 
while a few large coated nanoparticles were also present. There were very 
clearly separate, small coated particles. The morphology of the 0.1 mg PGA 
40%C18 coated IONPs is shown in Figure 4.25. The particle size was large 
particles, 80 ± 52 nm. It was also noted that there were individual small IONPs 
inside surrounded by a layer of the grey polymer. Also there were large IONPs 
aggregates coated with PGA 40%C18. By comparing with Figure 4.23 (0.5 mg 
PGA 40%C18±IONPs.) and Figure 4.25 (0.1 mg PGA 40% C18±IONPs), the 
IONPs coated with 0.2 mg of PGA 40%C18 (Fig. 4.24) were much smaller.  In 
addition, it was observed that that nanoparticles exhibit excellent dispersion for 
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all the preparations, which indicated that the polymers have the function of 
providing a repulsive force to prevent aggregation among particles. It was also 
noted that the IONPs were observed as dark spots.  In the images of the IONPs 
that had been coated, there was a mixture of small particles and big particles, 
which agreed with the DLS analysis table (4.3).  
 
 
Figure 4-23: TEM images of 0.5 mg PGA 40%C18±IONPs. Different sizes 
of larger particles are present with small coated nanoparticles (Average size 
105 ±32 nm) (Scale bar 500 nm). 
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Figure 4-24: TEM images of 0.2 mg PGA 40%C18±IONPs. The majority 
are small coated nanoparticles (Average size 23 ± 7 nm) (Scale bar 200 nm). 
 
Figure 4-25: TEM images of 0.1 mg PGA 40%C18±IONPs. Large particles 
with a few small particles (Average size 80 ± 52 nm) (Scale bar 200 nm). 
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Table 4-3: The surface charge and sizes of PGA 40%C18± IONPs. 
 
 
4.4.5.2 Zeta potential 
All formulations exhibited a net positive charge with ] potential values ranging 
from 23 ±10.5 mV to 67.7 ±11.8 mV. IONPs coated with 0.5 mg of PGA 
40%C18 showed values similar to the uncoated. In the formulations with 0.1 mg 
and 0.2 mg of PGA 40%C18±IONPs an increase in the positive charge was 
observed (Table 4.3). 
4.4.6  Particle Stability  
The stability of nanoparticles to aggregation is an important parameter in 
producing useful formulations for in vivo use. Stability can be determined by 
the addition of salt and noting the concentration at which an increase in 
turbidity appears. Salt is capable of destabilising both electrostatic and 
sterically stabilised particles. Different incubation solutions were used to 
Nanoparticles DLS NP diameter  
(nm) 
TEM NP diameter 
(nm) 
ȗ-potential mV ± 
S.D. 
IONPs          13           13     21.2 ± 73 
0.5 mg of PGA 40%C18±
IONPs 
    14  and 122       105 ±32      23.5 ± 10.5 
0.2 mg of PGA 40%C18±
IONPs 
    20  and 136          23 ± 7       67.7 ± 118 
0.1 mg of PGA 40%C18± 
IONPs 
          136         80 ± 52       50.06 ± 17.2 
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determine the stabilisation of particles achieved by the adsorption of various 
polymer, surfactant and protein over-coatings.  
4.4.6.1  0.1% Tween 80±coated PGA 0%±IONPs and PGA 40%C18±
IONPs 
IONPs were coated with PGA polymers and, to increase the stability further, 
they were over-coated with the Tween 80, a PEG containing surfactant. Tween 
80 has previously been used to improve the stability of PGA nanoparticles, 
particularly for increased stability in a biological medium.  
4.4.6.2  0.1% Albumin±coated PGA coated IONPs and PGA 40% 
C18 coated IONPs 
Putting particles into serum typically results in an adsorbed protein coating 
which can further stabilise nanoparticles. Albumin will be of great help in 
designing the system, as it is known to induce transcytosis of nanoparticles 
through the blood±brain barrier (Lu et al., 2005).  Albumin-coated gold 
nanoparticles were used as a drug carrier to cross the  blood±brain barrier and 
this makes them a good candidate for carrier in drug delivery (López-Viota et 
al., 2009). As albumin is also naturally present in serum, this may represent the 
coating actually present on nanoparticles in the presence of serum in cell 
culture and in vivo. 
4.4.7  Colloidal Stabilisation of IONP  
The turbidity of nanoparticles of different composition in the presence of 
increasing concentrations of NaCl is shown in Figs 4.26 and 4.27. The IONPs 
coated with dextran and with different formulations of PGA backbone 1.0 mg 
0.5 mg, 0.2 mg, 0.1 mg, PGA 40%C18 and overcoating with Tween and 
albumin. PGA nanoparticles (170 nm) were used as a reference because these 
particles have been used previously for drug delivery systems. 
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The IONPs and IONPs coated with these polymers were titrated with 
increasing concentrations of aqueous sodium chloride solution, and UV visible 
absorbance values at 500 nm were used to monitor the turbidity of the 
corresponding dispersion. Before coagulation the IONPs were stabilised by 
electrostatic repulsion force.  
Increasing the concentration of salt can both neutralise the surface charges or 
cause a change in the structure of the water and affect polymer chains, causing 
them to become dehydrated and resulting in coagulation. Figures 4.26 and 4.27 
show the relationships of the nanoparticle stabilities and the salt concentration 
of the medium. It can be seen that the IONPs were unstable at any salt addition. 
PGA 0%±IONPs showed some absorbance at very low salt concentration, 
suggesting some particles were poorly coated or uncoated. 
 
 
 
 
Figure 4-26 Stabilities of IONPs and IONPs coated with PGA 0% or 
dextran. Various PGA 0%±IONP formulations and dextran±IONPs were 
titrated with increasing salt concentrations and the aggregation of the 
formulations was monitored by optical density at 500 nm. 
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Dextran±IONPs became unstable at 80 mM salt concentration. However, all 
coated particles with 1.0 mg of PGA 0%±IONPs showed a higher stability than 
dextran over the range 1 mM to 120 mM salt. The IONPs coated with PGA 0% 
0.5 mg and 0.1 mg±IONPs showed a similar stability. In this study, the result 
suggests that at some point the particles aggregate. However, this is different 
for different coatings. The 0.2 mg of PGA 0%±IONPs showed excellent 
stability when compared with the other preparations, particularly over 10-100 
mM NaCl concentration range.  
The stability studies have also been carried out on the optimised coated 
nanoparticle preparations. Particles coated with 0.2 mg of PGA 40%C18± 
IONPs and coated with additional further coatings, such as Tween and albumin 
over-coatings, are shown in Figure 4.27. Note that the absorbance scale in 
Figure 4.27 is expanded in comparison to Figure 4.26. 
 
 
 
Figure 4-27: Stabilities of PGA 0%±IONPs and PGA 40%C18±IONPs 
with different concentrations of electrolytes. Various PGA 0%±IONP and 
PGA 40%±IONP formulations were titrated with increasing salt concentrations 
and the aggregation of the formulations was monitored by optical density at 
500 nm. 
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The stability of particle suspensions under the different salt concentrations 
showed an interesting set of results. The turbidity of coated particles was lower 
than that of IONPs before the critical flocculation point. The PGA 0%±IONPs 
appeared to have similar stability in the presence of NaCl with the PGA 
40%C18±IONPs. 
The main differences between preparations were found in the range 100-1000 
mM salt concentrations. It was found that the 0.2 mg PGA with 0.1% albumin±
IONPs and 0.2 mg PGA 40%C18±IONPs were significantly more stable than 
0.2 mg PGA 0% and 0.2 mg PGA 40%C18±IONPs i.e. that overcoating 
improved the stability further. The 0.2 mg PGA 0% with Tween±IONPs, and 
0.1% and 0.2 mg PGA 40%C18 with 0.1% Tween±IONPs was found to have an 
even lower turbidity and showed stability even in very high concentration of 
NaCl 600 mM which gave a further improvement in stability. This result is 
good, showing the colloidal stability of coated particles up to and above 
physiological salt concentration. Further work will be needed to assess whether 
these formulations offer advantages for in vivo biodistribution as well. 
 
4.4.8 Purification of PGA±IONPs  
The stability curves above permitted an easy separation of IONPs.  PGA 0% ±
IONPs (1 ml) were placed in a microcentrifuge tube (Fig 4.28), then a low 
concentration of NaCl (200 µL, 3 mM) was added and mixed, then the mixture 
was centrifuged immediately at 12,000 rpm for 2 min. The supernatant was 
removed and was examined by TEM.  IONPs are unstable and aggregate even 
at low salt concentration, so we can use this low salt concentration to remove 
uncoated nanoparticles and large coated nanoparticle aggregates.  
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Figure 4-28: TEM image of Purification PGA 0%±IONPs. Small coated 
particles can be seen with a high population with just a few large particles still 
present and core surrounded by a grey shell shown up the image with high 
magnification (Average size 21 ± 10 nm) (Scale bar 200 nm).  
 
The change induced by the salt treatment is evident in the TEM. In Figure 4.28, 
it is shown that most of the particles are coated and small and the sample looks 
a lot cleaner. The image shows the morphology of the coated particle 
consisting of a spherical core surrounded by a grey shell. As can be seen, the 
particles are well dispersed. The mean size and relative standard deviation are 
around 5í10 nm. These images show most of the particles with morphologies 
identifiable as small spherical particles. Many coated small particles, average 
size 21 ± 10 nm in diameter, can be seen with just a few larger particles with a 
flattened shape and size around 100 nm.  
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4.5 Discussion 
4.5.1 Different PGAs-coated Iron oxide particles using two 
different methods. 
 From the literature IONPs can be readily coated with hydrophilic polymers 
such as PEG and PVA, but for these polymers a large excess of polymer is 
required to obtain a suitable coating on the nanoparticles. IONPs have been 
coated with biocompatible and biodegradable hydrophobic polymers such as 
polycaprolactone by using the spontaneous emulsification solvent diffusion 
method with a slight modification for coating IONPs and their characterisation, 
and in vivo MRI application has been investigated (Bae et al., 2009).   
Poly(D,L-lactide-co-glycolide) has also been used as a coating IONPs material 
for use in MRI contrast agent (Lee et al., 2005). 
PGA poly(glycerol adipate) is a novel polymer that has been developed in 
response to issues encountered with polymers more commonly used in the 
produce of nano size particles, including the release of incorporated drug, it has 
pendent hydroxyl groups which can be modified with a variety of pendent 
substituents to generate different functional groups to influence the 
physicochemical properties of the polymer (Kallinteri et al., 2005). PGA 
nanoparticles and polymers modified from PGA by the coupling of acyl chains 
onto the hydroxyl group on the PGA showed good incorporation of 
dexamethasone phosphate and cytosine arabinoside anti-cancer drugs (Puri et 
al., 2008). 
The most common method used for the preparation of polymeric nanoparticles 
is the emulsification solvent evaporation technique. Preparation of sub micron 
poly(lactide coglycolide) composite particles loaded with magnetite/maghemite 
nanoparticles for intravenous drug targeting, by simple emulsion-evaporation 
process, has been described by (Ngaboni Okassa et al., 2005). 
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 In emulsification/solvent evaporation the evaporation of solvent is increased 
by increasing the temperature, under reduced pressure or by continuous stirring 
(Soppimath et al., 2001).  
 In the IDP method the evaporation of solvent takes place by stirring overnight, 
which offers a chance to precipitate the polymer and coat the particles. 
Polymer deposition on the interface between the water and the organic solvent, 
caused by fast diffusion of the solvent, leads to the instantaneous formation of 
a colloidal suspension (Quintanar-Guerrero et al., 1998). 
The evolution of nanoparticle preparation methods has been marked by three 
aspects:  ɿ) the rate and the time of the solvent evaporation, ɿɿ) the amount and 
the nature of the polymer and (ɿɿɿ) simplification of the procedure and 
optimisation to decrease the size and increase the coating efficiency.  
Parameters affecting the particle sizes of poly(DL-lactide-co-glycolide) 
nanospheres produced by the Emulsion Solvent Diffusion method, the mean 
particle diameter decreased with an increase in stirring rate.  While with 
increase the stirring rate could improve the droplet dispersion, prevent droplet 
coalescence and result in the smaller apparent particle size of PLGA 
nanospheres (Tsukada et al., 2009). In preparation of PLA nanoparticles where 
acetone was used as a solvent with water as non solvent DQGHYDSRUDWHGDWÛ&
under pressure, it was found the amount of aggregation was high (Peltonen et 
al., 2002). 
 
The size and shape of PVA coated IONPs were affected by  different ratios of 
the polymer/iron and the stirring rate on the particles (Mahmoudi et al., 2009). 
There are now numerous preparation methods available for  production  and 
more investigation will be needed subsequently after producing the 
nanoparticles, such as into purification and preservation and residual solvent 
(Pinto Reis et al., 2006). The important parameters that affect particle size and 
synthesis are stirring time, solvent, rate of the stirring and concentration of 
polymer. 
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Composite nanoparticles made with IONPs and PLGA were produced by using 
the double emulsion (w/o/w) method. Under mechanical stirring the solvent 
was rapidly eliminated by evaporation under reduced pressure (Lee et al., 
2005). The disadvantage of this method is the residual organic solvent which 
will have toxicological implications. It will also be difficult to remove the 
excess surfactant. Moreover, the surfactant must be present for preparation of 
nanoparticles in order to stabilise the system and scaling up is therefore 
difficult due to the huge amount of the organic phase required (Lin et al., 
2008).  
Spray drying is also used to coat or produce particles. The main problem of this 
method is that it produces particles that are in the micrometer size range  (Kim 
et al., 2007). The co-precipitation method has also been used to coat 
nanoparticles. However, the main drawbacks of this method are the need of a 
large amount of water and polymer, it is not suitable for all polymers, and only 
those that are soluble in water was be used. The major drawback of the 
microemulsion technique is the adverse effects of residual surfactants on the 
properties of the particles, along with the difficulty in their scale-up (Teja and 
Koh, 2009). 
In thermal decomposition methods, the presence of residual surfactant may be 
an obstacle to the efficiency of surface modification, besides the use of toxic 
solvents and surfactants could affect the biocompatibility of the particle 
(Majewski and Thierry, 2007 and Pinna et al., 2005). Because of by products, 
contamination occurs and as a result, the particles need post±treatment. This is 
the main disadvantage of the sol-gel method. Gas phase methods also tend to 
be expensive (Teja and Koh, 2009). 
Initial experiments in this project took a range of PGAs with different acyl 
modifications and investigated coating of IONPs using two different methods, 
the interfacial deposition method and the sonication method. The main 
advantages of the interfacial deposition method are that it is reproducible, low 
cost and simple, can produce particles in the nanometre size range and also 
allows nanoparticles to be prepared without any surfactant or residual solvents 
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left in the system, which is important from a toxicological point of view.  
Nanoprecipitation does not require a source of external energy and would be 
easy to scale-up relative to homogenisation and sonication, which require an 
energy source. Moreover, in nanoprecipitation acetone used as organic solvent 
is considerably less toxic (Budhian et al., 2007). 
In the sonication method not all the solvent evaporated immediately, resulting 
in a decreased precipitation of polymers leading to aggregates of the particles, 
therefore uncoated particles or poor coating because the polymer was still in 
the solvent. Slow evaporation leads to the production of spherical particles, but 
in this method the quick evaporation leads to produced non spherical particles. 
The modified emulsification solvent evaporation method (sonication method) 
has been used by our research group to coat the particles. Increase in the 
sonication to 25 min time leads to a reduction in the nanoparticles mean 
diameter to 255 ± 10 nm (Mainardes and Evangelista, 2005a). 
On comparing the coated particles produced by the interfacial deposition 
method and sonication methods, a smaller size was seen for particles coated 
using the IDP method (Figs. 4.1 and 4.2). The nanoprecipitation  method is 
also more flexible. Different polymers can be used to produce nanocapsules 
using the IDP method (Barratt et al., 1994). The most commonly used method 
for the preparation of PLGA nanoparticles is nanoprecipitation. Acetone 
dissolved polymer are added drop-wise into a continuously stirring aqueous 
phase with or without emulsifier/stabiliser, and consequently the organic phase 
is evaporated under reduced pressure (Kumari et al., 2009).  To our knowledge 
no work has been done using the IDP method for coating iron oxide 
nanoparticles.  
The 2 mg of PGA 40%C18 and backbone PGA 0% in 2 ml of acetone produced 
coated IONPs of a small size (Figs. 4.10 and 4.24). Also with using different 
acyl substitutions of polymer to increase the hydrophobicity there was no 
increase in particles sizes. This result was the opposite of work by Piskin et al., 
(1995) who reported that an increase in the number of hydrophobic domains 
was found to be associated with larger coated nanoparticles. 
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The sonication method produced large nanoparticles which could suggest that 
the time of stirring and the temperature are not enough to evaporate the solvent. 
This leads to the formation of just polymer nanoparticles which increases the 
size of coated aggregated iron oxide nanoparticles. The methods detailed above 
are the main methods extensively employed in the synthesis of nanoparticles. 
For different purposes, we found the best one suitable for our nanoparticles 
was the interfacial deposition method, but also we needed more modifications 
of method to improve the nanoparticle size (size reduction) and to reduce the 
polydispersity index based on slight modifications of standard interfacial 
deposition method.   
4.5.2 Particle Size and Zeta Potential  
The sizes of  PGA±IONPs  prepared using the sonication method were between 
160 nm to 240 nm and  with IDP method were between 126 nm to 210 nm 
using DLS measurements (Fig. 4.1 and 4.2). Budhian et al., (2007) have 
reported that sonication is better suited to produce small size nanoparticles 
< 300 nm diameter with a narrow size distribution. 
In the interfacial deposition method, PGA±IONPs were still producing large 
particles, even though smaller than the particles prepared by sonication. 
Polymers with a large amount and long length of chain are thought to 
precipitate out of the water phase and aggregate to form polymer particles, 
which increases particle size. TEM (Fig. 4.3 and 4.4) studies showed polymer-
coated nanoparticles, prepared from the various formulations of PGAs, to be 
spherical and discrete. The morphology of PGAsíIONPs  changed both at low 
and high amounts of polymers and solvent. In TEM images, it was noted that 
the particles were spherical with a relatively narrow polydispersity. Polymer 
coating was demonstrated by TEM by the presence of black dots of dense iron 
oxide, in most cases showing a single spot inside the polymer.  
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In conclusion, different PGA substituted polymer±IONPs resulted in different 
particle sizes. The aim of this experiment was to find which method was most 
suitable and the particles produced were spherical to give a good coating with 
no aggregation. The amount of PGA polymer and the method were found to be 
important factors in the particles sizes and coating. A layer of polymer can be 
clearly seen surrounding the particles. In addition, we found that the PGA 
backbone was a good starting point to coat the IONPs, with the interfacial 
deposition method being most useful to coat the particles. Further optimisation 
of the coating procedure was, however, necessary. 
4.5.3 Optimisation of Nanoparticle Coating Produced with 
PGA 0% 
Based on the investigation of PGA±IONPs, the amounts and volumes of both 
the solvent and the polymer have major effects on the size of coated NP. We 
prepared  PGA 0% coated IONPs from PGA 0% polymer masses between 1 
mg and 0.1 mg from acetone solutions at different concentrations (1 mg/ml to 
0.1 mg/ml) using different volumes of organic solvent (1 ml to 3 ml) for one 
volume of aqueous solution containing IONPs suspension (5 ml). 
The low starting amount of PGA 0% (2 mg instead of the 20 mg reported in the 
literature) was based on results in this work when used different amounts of 
polymers showed that using a much smaller amount of PGA 0% decreased the 
coated IONPs size. 
Poly(lactic acid) (PLA) and D-Į-tocopherol polyethylene glycol 1000 
succinate (TPGS)  coated  IONPs core with  size 10 nm  were prepared by two 
methods, first the single emulsion solvent extraction/evaporation method, and 
secondly the nanoprecipitation method. In the single emulsion method, 100 mg 
of the polymer along with 2 % loading of IONPs and 8 ml of DCM were added 
and the solution was the emulsified at a given concentration of TPGS of 15, 5 
and 1% w/v.  The sizes of particles were 352.03 േ18.28 nm, 307.44 ± 16.46 
nm and 282.2 ± 14.70 nm  respectively, while in the nanoprecipitation method, 
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using the same amount of polymer and IONPs in an aqueous phase containing 
a known concentration of the emulsifier TPGS of 15,5 and 1% w/v 
showed different particle sizes of 302.53 ±15.83 nm, 272.80 ± 02.53 nm and 24
9.43 ± 19.89 nm respectively (Prashant et al., 2010). 
An increase in polymer concentration, while keeping other parameters 
constant, was found to increase overall nanoparticle size mainly because an 
increase of the shell of polymer on the coated iron oxide nanoparticles, and 
thus to induce a larger size and polydispersity (Hamoudeh et al., 2007).  
Using a constant volume of solvent of just 1ml with different amount of 
PGA 0% to coat IONPs produced large coated nanoparticle sizes. This could 
be due to the volume of solvent not being enough to drive the polymer to coat 
the particle, resulting in multiple IONPs cores being coated by the PGA 0% in 
the same particle, while other particles were still naked or poorly coated. The 
increased diameters of PGA 0% coated IONPs could be due to slight 
aggregation caused by the reduction of negative surface charge and a reduction 
in repulsion forces between particles. The interaction between solvent, polymer 
and particle must be taken into account to improve the polymer participation 
and the coating of particles.  
The volume of solvent used was found to be important in forming small coated 
IONP with a low polydispersity. The optimum was at 2 ml with both small and 
larger amounts being less useful. A larger amount of organic solvent was 
reported to prevent formation of nanoparticle coatings due to diffusion rates in 
the o/w emulsion (Mainardes and Evangelista, 2005b). There are a number of 
factors which could be involved. It could be that the amount of solvent speeds 
up the precipitation of polymer. In the case when the volume of solvent was 
increased further with a constant amount of PGA 0% the particle size of 
PGA 0% coated IONPs was larger. The difference in particle size may be 
caused by the amount of solvent in the water and the solubility of the polymer 
in the solvent. The physico-chemical parameters affecting the particle diameter 
are the viscosity and the interfacial tension of organic polymer solutions in 
contact with water (Chernysheva et al., 2003). Additionally acetone does cause 
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aggregation of the IONPs and this could also result in larger particle sizes. Also 
the large amount of solvent may cause a barrier between the IONPs and 
polymer preventing the polymer from precipitating around the IONP.   
Decreasing the amount of PGA 0% to 0.2 mg with 2 ml of acetone for coating 
IONPs produced smaller nanoparticles which is the smallest batch, while 
decreasing the amount of PGA 0% still further to 0.1 mg produced larger 
particles. The general explanation for this phenomenon with change of the 
polymer amount is quite complex. In the absence of iron oxide nanoparticles, a 
high concentration of polymer is necessary for good nanoparticles formation 
and all nanoparticles are large. In the presence of IONPs, these IONPs are just 
incorporated into the large polymer nanoparticles, and the other parameters 
have little effect on particle size. There is too much polymer present to form 
just a small coating of polymer around the iron nanoparticles. Prozorov et al., 
(1999) have reported that a large amount of the polymer leads to an increase in 
the particle size. When the PGA 0% amount comes down to low levels (1.0 mg 
or lower) mixtures of both large polymer nanoparticles and individually coated 
IONPs.  
At less than 0.2 mg the amount of PGA 0% polymer (0.1 mg of PGA 0%), is 
small enough just to coat all individual IONPs and at still lower amounts there 
is insufficient polymer to coat all nanoparticles individually, resulting in the 
appearance of some aggregates of particles which appear to be coated. The size 
and shape of polyvinyl alcohol PVA coated IONPs were affected by the 
amount of the polymer when the amount of iron was fixed (Mahmoudi et al., 
2009).  
In summary, we have shown that by adjusting the amount of PGA 0% and 
volume of acetone, it is possible to control the size of coated IONPs and all 
have been shown by TEM to have a spherical shape and uniform size. 
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4.5.4 Zeta Potential 
The zeta potential of PGAs±IONPs was slightly positive. This was unexpected 
as PGA would be expected to be negative due to the free terminal carboxyl 
groups of the polymer. Nanoparticles made by polymers substituted with C8 or 
C18 acyl groups in the range between 0 % and 100 % in the absence of 
surfactant had a negative zeta potential (Kallinteri et al., 2005). It is possible 
that the carboxyl groups of the polymer could interact with the iron oxide and 
become non free groups, which would result in a less negative surface charge. 
Buffer conditions can also affect zeta potential measurement, and further work 
may be required to optimise the choice of buffer to obtain the expected results. 
4.5.5 Modification of PGA Polymers 
4.5.5.1 Synthesis of PGA 40%C18 by Acylation of Backone PGA 
The synthesis of PGA 40%C18 was successful as analysis by NMR, FTIR and 
GPS all confirm that the acylation happened.  Improvements to the properties 
of polymers are typically limited by their chemical properties; some 
modifications of PLGA polymer have been reported, e.g. poly(lactic acid co-
lysine) was synthesised with pendant amino groups. However, only 2 mol% 
lysine units were incorporated into the polymer backbone (Barrera et al., 1993). 
Polymerised (D, L) lactic acid or caprolactone with  poly(ester amide) with 
pendant carboxy or amine groups was also investigated (Veld et al., 1992). 
Lipase which was used to produce the polymeric material, used in this study 
has the advantage that the enzyme catalysed reaction proceeds without the need 
for protection of the pendant functional groups. This advantage has been used 
for preparation of polyesters by  polycondensation reactions (Tian et al., 1997).  
The PGA pendent hydroxyl group can be modified with different pendent 
substituents to a functional group of great variety to improve the 
physicochemical properties of the polymer and influence drug incorporation 
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(Kallinteri et al.,2005).  PGA 40%C18 was used to increase the hydrophobicity 
and stability of the nanoparticles, but still to allow the presence of some 
hydroxyl groups for interaction with the IONPs surface. 
4.5.6 PGA 40%C18 Coated IONPs 
More hydrophobic PGA 40%C18 polymer coated IONPs were produced to 
increase their stability in both the biological and physical state. The metallic 
core has been coated with a hydrophobic layer instead of surfactant coating to 
improve the lifetime of the nanoparticles in aqueous environments and prevent 
oxidisation (Ge et al.,2009). The most important characteristic in the 
preparation of core/shell nanoparticles is their final size. This property not only 
affects their magnetic moment but also the biological behaviour of the particles 
when they are injected into the body (Arias et al., 2008b). 
Different amounts of PGA 40%C18 were chosen to coat the IONPs to check the 
influence of the ratio of solvent and polymer on mean diameter.  IONPs present 
as a suspension aqueous phase were fixed at 5 ml. As can be seen in Figures 
4.20, 4.21 and 4.22 and also TEM images (fig. 4.23, 4.24 and 4.25) show that 
the mean diameter was noticeably affected by the ratio of polymer and solvent. 
The increase or decrease of PGA 40%C18 concentrations affect on the 
formation of the nanoparticles. Lee et al., (2005) have reported that the 
homogenisation strength and the optimal polymer concentration were the 
dominant factors in controlling the size for emulsification methods. 
As already found with PGA backbone coated IONPs, the particle size of coated 
IONPs decreased as the amount of PGA 40%C18 decreased with a constant 
volume of acetone (2 ml). The acylation should increase the solubility of the 
PGA in organic solvent therefore, using the full amount of polymer should be 
available to improve the coating of the particles.  
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The amount of PGA 40%C18 0.2 mg with 2 ml of acetone gave the best coating 
of IONPs. These particle sizes appear to be very good in comparison with other 
polymer-coated particles reported in the literature, as follows. 
IONPs have been coated with different types of polyacrylates, i.e. 
poly(alkylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), 
poly(hexycyanoacrylate) and poly(octycyanoacrylate). Using methods based 
on the emulsion/polymerisation method resulted in average diameters of 160 
±15 nm, 140 ±20 nm, 150 ±30 nm and 155 ± 20 nm respectively (Arias et al., 
2008a). 
In the literature it has been reported that other hydrophobic polymers have been 
used for coating iron oxide nanoparticles. PCL and PLGA have hydrolysable 
ester linkages which are similar to PGA. Magnetic poly İ-caprolactone (PCL) 
nanoparticles have smooth surfaces and moderately uniform size distributions 
(160 ±5 nm) (Yang et al., 2006).   
Magnetic poly(D,L-lactide-co-glycolide) nanospheres were prepared by a 
modified single oil-in-water emulsion±solvent evaporation method with a mean 
diameter 360±370 nm which showed high magnetisation (Liu et al., 2007).    
IONPs coated with poly(ethyleneimine) (PEI) at different iron oxide to 
polymer weight ratios of PEI magnetite of 0.4, 0.8, 1.2, 1.6 and 2.0 resulted in 
a range of sizes between 200 nm to 800 nm at pH 7. When the particle coating 
was carried out at pH 2, the particle size decreased to 80 nm (Wang et al., 
2009).  
The availability of different characterisation techniques makes the detailed 
analysis of the nanoparticle system possible. The nanoparticle size is affected 
by many parameters, and researchers are continually attempting to decrease the 
average nanoparticle size. Considering the synthesis of PGA 40%C18 coated 
IONPs the average size over all batches was between 23 to 105 nm in diameter, 
and in the optimum batch (0.2 mg PGA 40%C18 coated IONPs) the average 
size was 23 ±7 nm (Figure 4.24). Such small nanoparticles are not common by 
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the methods detailed above however, the advantages of smaller sizes should be 
studied designed for in vitro. 
4.5.7 0.1% Tween 80% Coated PGA 0%±IONPs and PGA 
40%C18±IONPs 
A nanoparticle coating with Tween not only prevents the uptake by the 
mononuclear phagocyte system (MPS) but also ensures that nanoparticles do 
not form aggregates in cells and also in vivo. Tween 80 has previously been 
used at Nottingham as a stabiliser for PGA nanoparticles (Meng et al., 2006) 
and (Puri et al., 2008), and has been shown to result in improved nanoparticle 
biodistribution in rats (Kallinteri and Garnett, unpublished results).  Tween 80 
(polysorbate 80) has also been shown to have other useful delivery properties. 
Polysorbate 80 has the ability to transport nanoparticle loaded drugs across 
blood±brain barrier when nanoparticles are overcoated with it (Kreuter, 2001, 
Kreuter et al., 1995 and Olivier et al., 1999). Tween 80 has a specific role in 
brain targeting which relates to interaction between the Tween 80 as coating 
and brain micro-vessel endothelial cells (Sun et al., 2004b). Polysorbate 80 
coated poly(butylcyanoacrylate) (PBCA) nanoparticles and polysorbate-80 
coated poly(methyl methacrylate (PMMA)  showed an ability to cross and 
increase uptake across the blood brain barrier (Ambruosi et al., 2006 and 
Borchard et al., 1994). 
Tween plays an important role as surfactant to penetrate the cell membrane. 
Polysorbate80 coated Polyethylcyanoacrylate  nanoparticles with a particle size 
of 240 nm had an effect on drug permeation across the biological membrane 
(Cavallaro et al., 1994).  However, to the best of our knowledge, Tween 80 
overcoated IONPs have not been reported yet.  
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4.5.8  0.1% Albumin Coated PGA 0% Coated±IONPs and 
PGA 40%C18 Coated IONPs. 
Albumin has the ability to interact with cell and cell membrane when 
nanoparticles are administered in vitro and in vivo and increase the stability of 
the particles. Albumin can also improve the ability of nanoparticles to cross 
cell and tissue barriers and protect the particles from biodegradation and 
agglomeration. Albumin is nontoxic. Magnetic nanoparticles are generally 
surface-modified with hydrophilic polymers such as albumin (Perry et al., 
1986). Surface-modified albumin nanoparticles offer the potential of being able 
to avoid uptake by the Reticuloendothelial system (RES) and being used as 
drug carriers to target sites outside the vascular circulation. (Lu et al., 2005). 
Human serum albumin has been used in vitro and in vivo and was shown to 
overcome some problems with transfection (Orson et al., 2002 and Orson et al., 
2000).  
Wilhelm et al., (2003) have also reported that albumin coating of particles can 
inhibit the interaction with cell membrane. It has been reported that with 3-
aminopropyltriethoxysilane APTES coated iron oxide nanoparticles, human 
serum albumin was covalently immobilised on the particles and showed high 
saturation magnetisation (Can et al., 2009). In a study performed by Xia et al., 
(2008)  albumin was shown to be a good stabiliser for aqueous fluids with low 
viscosity and  useful for gene therapy.  Chunfu et al., (2004) suggested that 
human serum albumin-coated iron oxide was stable up to 72 h in Bovine serum 
albumin (BSA) and was promising for magnetically targeted radiotherapy. Pan 
et al., (2005) studied the effect of serum albumin binding with the dendrimer-
coated IONPs with amino surface groups. All these studies showed the 
potential for using albumin as a coating or overcoating for IONPs.   
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4.5.9 Stability of IONPs Coated with Polymers 
This part of the work was carried out to examine the ability of polymers and 
the surfactant Tween 80 and the serum protein albumin to provide an effective 
coating and as steric barriers to prevent aggregation. The turbidity of iron oxide 
particles in different concentrations of NaCl studies were investigated. This 
study not only mimics the stability in a physiological environment but also 
provides data on the general stability of these coated nanoparticles.  
With increasing concentrations of NaCl, the PEG moieties of the coating 
become more dehydrated by releasing the water molecules, and the interaction 
between the layers increasingly leads to flocculation. At the critical 
flocculation point (CFPT) the PEG chains become dehydrated, chain-chain 
interactions become attractive and flocculation occurs (Riley et al., 1999). 
Polymeric chains on the surface of nanoparticles have a very important role in 
colloidal stability, especially at a high ionic strength, therefore the polymeric 
chains act as steric barriers against aggregation (Rotureau et al., 2008).  
The normal salt concentration in blood is 150 mM, while the range of NaCl 
was varied from 0.1 mM to 600 mM in the experiment in this chapter. 
Uncoated particles were not stable even in very low salt concentration and this 
is likely to be due to the significant van der Waals attraction between the iron 
oxide cores. All the PGA coated nanoparticles showed high stability, and 
aggregation only occurred at high salt concentration. The explanation for the 
instability of nanoparticles at the high concentration is a less than complete 
surface coverage of PGA chains, leading to a different stability of particles 
according to the amount of coating. The coated IONPs with PGA 0 % and 
PGA 40 %, along with those overcoated with 0.1 % albumin and 0.1 % Tween, 
showed high stability overall, better than IONPs coated with dextran where the 
Tween and albumin with 0.2 mg PGA 40%C18±IONPs showed the best 
stability. Barrera et al., (2009), have reported that PEG±silane coated IONPs 
were stable in NaCl concentration from 38 mM to 320 mM with no 
precipitation.  All our coated nanoparticles with PGAs and with overcoatings 
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showed high stability up to 120 mM, which means the particles were well 
covered and the modifications maintained the repulsive force between the 
particles. The increased stability of PGAs±IONPs and with the overcoatings 
compared to dextran±IONPs under conditions mimicking the physiological 
environment could make them a useful candidate as a contrast agent in MRI. 
4.5.10 Purification of PGA 0% Coated IONPs 
Even after optimisation of the coating process, there may still be some 
uncoated nanoparticles present, as well as small numbers of particle 
aggregates. To remove these uncoated nanoparticles, a simple method 
involving addition of a low salt concentration and centrifugation can be used to 
purify the coated nanoparticles. The small PGA0%±IONPs could clearly be 
seen in the TEM image (Fig.4.28). However, the excess polymers coated 
IONPs and large coated IONPs were removed, and the polymer shell did not 
collapse when the coated IONPs were centrifuged.  
4.6 CONCLUSIONS  
The interfacial deposition method allowed us to easily obtain PGA±IONPs 
with a good yield with size smaller than particles prepared by sonication 
method. This chapter has examined the size and surface charge of 
nanoparticles coated with PGA polymer backbone and the substituted PGA 
40%C18.  Also particles were over-coated with Tween 80 (0.1%) and albumin 
in order to increase the stability. Purification of coated IONP was also 
investigated.  
The preparation of coated IONPs with PGA 0% under optimum conditions is 
important In terms of the physicochemical properties of coated nanoparticles, 
the amount of polymer and the amount of solvent ratio used were two of the 
parameters with the greatest effect on the coated nanoparticles size. 
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By choosing the right method small coated nanoparticles can be produced with 
small amount of polymers. The coated IONPs prepared using 0.2 mg of  
PGA 0% with 2 ml of acetone were found be an average size 16 ± 5 nm which 
is smaller than the other formulations in the particle size study. Transmission 
electron micrographs showed nanoparticles were spherical and smooth with 
very few aggregates and separate in the nanometre size range.  PGA 0% was 
substituted by C18 chains and coated IONPs with small size were still obtained 
using the IDP method. The IONPs were clearly detected in the PGA 0% and 
PGA 40%C18 by TEM. Depending on the preparation conditions, individual 
IONPs coated with the or aggregates of IONPs coated with polymers could be 
seen. The analysis of the TEM pictures correlates very well with the data 
obtained by dynamic light scattering. The zeta potential study showed that the 
surface charge of the IONPs changed when coating had occurred.  
The stability of the IONP and coated IONP in biological medium were 
investigated. The PGA 0% coated IONPs and PGA 40%C18 coated IONPs were 
remarkably stable even in high sodium chloride concentration and showed 
more stability than dextran coated IONPs. It was shown that the stability of the 
coated nanoparticles increased further when overcoated with Tween or 
albumin. The overcoatings were found to be stable under conditions mimicking 
physiological medium. Thus, 0.2 mg of PGA 0% and PAG 40%C18 coated 
IONPs and 0.1% Tween and 0.1 % albumin would be useful to stabilize the 
nanoparticles in vivo. Treatment of PGA 0%±IONPs with a low concentration 
of NaCl followed by a brief centrifugation particle removed large and poorly 
coated nanoparticle, this technique seems to be suitable for the purification of 
coated nanoparticle.  
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CHAPTER 5 
5. PEGYLATED POLY (GLYCEROL ADIPATE) 
40%C18 COATED IRON OXIDE 
NANOPARTICLES 
5.1 INTRODUCTION  
Many studies have reported that the biodistribution of different contrast agents 
depends on the size, charge and thickness of the coating of the particles (Chouly et 
al., 1996b). Poly(ethylene glycol) (PEG) is now the most common material to modify 
particle surfaces in order to avoid recognition by cells of the MPS. The attachment of 
these polymers onto the particle surface often involves physical adsorption (Storm et 
al., 1995).  
Particles made from or coated with hydrophobic polymers tend to be opsonised by 
protein adsorption and rapidly cleared from systemic circulation by the phagocytic 
system, ending up in the liver or the spleen. The level of protein absorption can be 
decreased by changing the density and molecular weight of PEG on the surface (Gref 
et al., 2000). The presence of a PEG coating on the surface of nanoparticles enhances 
their specific uptake by minimizing the RES recognition and consequently increases 
the time of nanoparticle circulation in the blood (Akerman et al., 2002). PEG is a 
widely used polymer, having  many beneficial properties, such as being non-toxic 
(Hern and Hubbell, 1998) . 
Particle size and surface properties have a strong effect on the pharmacokinetics of 
particles, and the main disadvantages for in vivo applications of magnetic 
nanoparticles are large particle size, quick blood clearance and non-specific uptake 
by macrophages. Small particles (< 50 nm) and poly(ethylene glycol) (PEG) surfaces 
have been shown to be effective in extending blood circulation time (Acar et al., 
2005). The disadvantage of dextran as a coating seems to be the high cost and huge 
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amount of polymer needed to coat the particles. Also dextran is less effective than 
PEG as a coating for this purpose. Dextran coated liposomes showed shorter 
circulation time than PEG coated liposomes (Pain et al., 1984).  
 Dextran-coated poly(butyl cyanoacrylate) nanoparticles failed to prevent the 
nanoparticles accumulating in the RES, and were found mainly in the liver (Douglas 
et al., 1986).  
5.2 Aims of the Chapter  
In Chapter 3 it was shown that PGA coated IONPs could be manufactured with both 
PGA 0% with size 16 ±5 nm and PGA 40%C18 23 ±7 nm This process was optimised 
in order to produce small particles. It was also shown that coating nanoparticles with 
copolymer can have a dramatic effect on the colloidal stability of the nanoparticles. 
The PEGylation of PGA 40%C18 is desirable for the assessment of uptake of 
particles into cells, for the stability of the particles and to increase the circulation 
time.   In this chapter the preparation and use of PEGylated PGA 40%C18 (PEG±
PGA 40%C18) in a coating procedure will be developed to produce nanoparticles 
with a small size and acceptable morphology. A PEGylated PGA copolymer is 
expected to arrange into two layers on the nanoparticle surface, the inner layer being 
composed of the hydrophobic acylated PGA covering the surface of the iron oxide 
core, the outer layer being composed of the hydrophilic polymer PEG that provides 
stabilisation through steric repulsion through the hydrated polymer chains. Having 
synthesised PGA 40%C18, the next stage was to couple it to the PEG. PEG MW 2000 
functionalised with an amine group was commercially available. This permitted the 
coupling of the PEG to the core polymer via carbonyldiimidazole to activate the 
PGA carboxyl group for coupling with the amine group.  
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5.3 Methods 
PEGylated PGA 40%C18 (see 2.2.13). 
PEGylated PGA 40%C18 coated IONPs (see 2.2.14). 
Stability of IONPs FRDWHGZLWK3(*íPGA 40%C18 (see 2.2.15). 
5.4 Results  
5.4.1 PEGYLATED PGA 40%C18   
The reaction between the free NH2 of the PEG and the carboxyl group of the PGA 
was used to synthesise the PEG-PGA 40%C18. The reaction scheme is shown below 
in Fig 5.1. The product of synthesis of PEG-PGA 40%C18 was then characterised by 
NMR, FTIR and GPC. 
The NH2 -PEG was added at 1: 1 molar ratio to the PGA 40% C18 and the yield was 
77% (366 mg)
.   
Polymer molecular weight was measured using GPC. Figures 5.2 and 
5.3 show that the molecular weight was increased from Mn 12,038 to Mn 16,331 
implying that 2 molecules of PEG 2000 were added per molecule of PGA.  
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Figure 5-1: Synthetic scheme for poly(ethylene glycol) coupled to 40%C18 
substituted poly(glycerol adipate). 
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Figure 5-2: GPC elution profile for poly(glycerol adipate) substituted with 
40%C18. The red line is the calibration curve, while the peaks (1 and 2) are related to 
the polymer retention time.
 
 
Figure 5-3: GPC elution profile for poly(ethylene glycol) coupled to 
poly(glycerol adipate) substituted with 40%C18. The red line is the calibration 
curve, while the peaks (1 and 2) are related to the polymer retention time.  
The PGA 40%C18 polymer is expected to have an average of one carboxyl group per 
polymer, but some of the polymers will have 2 carboxyl termini and some will have 
two hydroxyl termini, suggesting that the ratio of PEG to PAA may be a little high.  
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5.4.2 NMR Analysis 
 
Figure 5-4: Structure of poly (ethylene glycol) (PEG). 
 
 
 Figure 5-5: NMR spectrum for poly (ethylene glycol) (PEG). 
 
Figure 5.4 shows the annotated structure for PEG and Figure 5.5 the NMR trace. The 
amine protons appear DWįZKLOHCH2-NH2 protons appear as a broad multiplet 
DWįí0HWKR[\SURWRQVDSSHDUDVDVKDUSVLQJOHWDWįDQGHWKylene 
R[LGHSURWRQVDWįí3.78). The peak of NH2-CH2- CH2- O protons appear as a 
triplHWDWįí3.85).  
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Figure 5-6: Structure of poly (ethylene glycol)±PGA 40%C18. 
 
 
Figure 5-7: NMR spectrum for PEG±PGA 40%C18. 
 
Figure 5.6 shows the annotated structure for PEG-PGA 40%C18. In Figure 5.7 the 
peaks annotated as a, b, c, d and g correspond to the same groups discussed for PGA 
40% C18, the peak of methoxy SURWRQVDSSHDUDVDVKDUSVLQJOHWDW į, while 
ethylene glycol CH2-CH2-O protons shoZ XS DW į í3.86). These two groups 
indicate the presence of PEG which was covalently attached to PGA chains. H NMR 
confirmed the presence of the PGA and PEG. Comparing the area of the PEG peaks 
4.9í4.16 with that of the PGA 0.5í1.31 revealed a coupling ratio of PEG to the PGA 
40%C18 of approximately 0.7 PEG moieties per PGA moiety. 
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Figure 5-8 : FTIR for PGA 40%C18.  
 
Figure 5-9: FTIR of PEG±PGA 40%C18. 
Chapter 5                                                                                PEG-PGA Coated IONPs 
152 
FTIR confirmed the amine group at 2916.68 cm-1 and 3004.23cm-1 shifted to 3412.76 
cm-1 and 3610.05 cm-1 as the amine was converted to amide (Figs. 5.8 and 5.9). 
 
5.4.3 PEGylated PGA 40%C18±IONPs  
The coating of IONPs with PEG may offer advantages over other delivery systems. 
PEG-coated IONPs are expected to increase the blood circulation time of 
nanoparticles. The formulation strategies are to control the size of PEG±PGA 
40%C18±IONPs during synthesis. The ability to control NPs size may be broadly 
important to their use in various clinical applications, allowing for the optimisation 
of NPs delivery vehicles for systemic administration. IONPs were coated by different 
amounts of PEG±PGA 40%C18 (0.2 mg, 0.1 mg and 0.05 mg) and characterised by 
TEM and DLS. 
5.4.3.1 TEM photomicrographs and DLS analysis 
The TEM photomicrograph from batches using 0.2 mg, 0.1 mg and 0.05 mg co-
polymer PEG-±PGA 40%C18 coated IONPs are shown in (Figs. 5.10, 5.11 and 5.12) 
and the DLS results in (Figs. 5.13, 5.14 and 5.15). These images show both the size 
and morphology of the particles formed in each batch.    
The relatively spherical structure and the narrow size distribution of the small 
particles in the 0.2 mg PEG±PGA 40%C18±IONPs batch can be seen in the TEM 
image (Fig. 5.10). Here the polymer appears as a translucent layer on the coated 
IONPs (the dark core). All the particles are formed into a spherical shape with a size 
around 16 ± 4 nm, which is still very small. 
According to chapter 3 the nanoparticles size of IONPs is 13 ± 9 nm (Fig. 3.2), while 
that of the coated ones shown here is 41± 19 nm with CMD and 40 ± 12 nm with 
dextran (Figs. 3.9 and 3.12).  
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The TEM image in Figure 5.11 shows the particles coated with 0.1 mg of PEG-PGA 
40%C18±IONPs. In this case, particle diameter increased to a plateau value at 
46 ±13 nm. The particles were spherical in shape and uniform.  Both aggregates of 
IONPs coated by polymer and also individual coated nanoparticles were seen, 
however, they are well-formed particles.  
Figure 5-10: TEM image of 0.2 mg PEG±PGA 40%C18 ± IONPs. The majority 
of the particles are small (Average size16 ± 4 nm) with some aggregates forming, but 
only rarely (arrow). The particles highlighted by the arrows in the figure may just be 
small particles stuck together. (Scale bar 200 nm). 
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Figure 5-11 : TEM image of 0.1 mg PEG±PGA 40%C18 ±IONPs.  Both small and 
large particle sizes are present, but with an increased number of larger particles. 
(Average size 46 ± 13 nm), and it can be seen that the IONPs have been coated and 
that the larger particles contain aggregates of IONPs. (Scale bar 200 nm). 
 
 
The typical TEM image of nanoparticles in 0.05 mg of PEG±PGA 40%C18±IONPs 
is shown in Figure (5.12).  The image revealed that the PEG±PGA 40%C18±IONPs 
dispersed as individual NPs with a well-defined spherical shape and homogeneously 
distributed around 20 ± 14 nm in diameter. The image showed different range sizes 
of PEG±PGA 40%C18±IONPs, small and large, a large number of IONPs coated with 
PEG±PGA 40%C18 as aggregates, and a huge number of small PEG±PGA 40%C18±
IONPs. 
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Figure 5-12 : Image of 0.05 mg PEG±PGA 40%C18±IONPs.  Ranges of particle 
sizes are displayed. Many small coated particles can be seen in the background, but 
also coated aggregates are present (shown by arrows) (Average size 20 ± 14 nm). 
(Scale bar 200 nm). 
The layer of polymer was very clearly seen in TEM images in all the PEG±PGA 
40%C18±IONP formulations and well-formed particles of an optimum size. They 
have a good morphology and are not aggregated, and it is very easy to see individual 
particles which are clean. 
The DLS showed the different sizes of the formulations. Figures 5.13, 5.14 and 5.15 
show a mixture of sizes. The 0.2 mg of PEG±PGA 40%C18±IONPs batch (Fig.5.13) 
had a bimodal distribution of nanoparticles. There was a large amount of 
PEG-PGA 40%C18±IONPs around 136 nm in diameter, but there were also many 
small particles with size of  22 nm in diameter, with the size range of the particles in 
the 0.2 mg of PEG-PGA 40%C18±IONPs batch between 22 and 136 nm in diameter. 
The 0.1 mg of PEG±PGA 40%C18±IONPs batch (Fig.5.14) also had a bimodal size 
distribution, with a majority of the nanoparticles being large (about 136 nm in 
diameter) and a high proportion of these being less than 50 nm. The size range of 
nanoparticles in the 0.1 mg PEG±PGA 40%C18±IONPs batch was between 17 and 
136 nm in diameter. The majority of the nanoparticles formed in the 0.05 mg of 
PEG±PGA 40%C18±IONPs batch (Fig. 5.15) were about 112 nm in diameter, though 
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% Area Rh (nm) Std Dev % RSD
1 42.8 10.11 4.29 42.4
2 57.2 68.07 25.89 38
% Area Rh (nm) Std Dev % RSD
1 0.1 0.11 0 0
2 30.1 8.54 2.43 28.5
3 69.9 68.07 41.79 61.2
there are some small particles at 15 nm in diameter, a reflected in the TEM image. 
The particle size distribution of this batch was 15 and 122 nm. 
 
 
 
Figure 5-13: The particle size distribution of 0.2 mg PEG-PGA 40%C18±IONPs 
by DLS. 
 
 
 
Figure 5-14 : The particle size distribution of 0.1 mg PEG-PGA 40%C18±IONPs 
by DLS. 
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% Area Rh (nm) Std Dev % RSD
1 26.6 7.93 1.47 18.5
2 73.4 56.05 14.59 26
 
 
 
 
Figure 5-15 : The particle size distribution of 0.05 mg PEG±PGA 40%C18±
IONPs by DLS. 
The sizes of the nanoparticles determined by the DLS technique were slightly bigger 
than seen in the TEM photomicrographs. The reason for this larger diameter is that 
DLS measures the diameter of hydrated particles including the surface adsorbed 
water molecules, while TEM shows the unhydrated size of dry particles.  
In conclusion, all the formulations showed small particles overall with minimum 
aggregation. The change of the amount of polymer with the different formulations 
affects the formation of smaller nanoparticles. These particle sizes for the different 
formulations are summarised in Table 5.1.  
Table 5-1: Sizes of PEG-PGA 40%C18±IONPs measured by DLS and TEM. 
Nanoparticles  
 
DLS NP diameter (nm) TEM NP diameter (nm) 
0.2 mg PEG±PGA 40%C18±IONPs        20 and 136         16 ± 4 
0.1 mg PEG±PGA 40%C18±IONPs        17 and 136         46 ± 13 
0.05 mg PEG±PGA 40%C18±IONPs        15 and 122         20 ± 14 
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5.4.3.2 Zeta potential  
The results of zeta potential measurements showed the surface charge of 
nanoparticles was increased compared to the uncoated nanoparticles where the buffer 
was water (Table 5.2). Increasing the amount of added polymer resulted in an 
increase in the zeta potential. The increase was relatively small for the 0.05 mg 
amount of PEG±PGA 40%C18±IONPs and not very different from the IONPs, and 
was maximal after a 0.2 mg polymer addition of PEG±PGA 40%C18 coated IONPs. 
Table 5-2: Zeta potential of different formulations of PEG-PGA 40%C18±
IONPs. 
Nanoparticles  ȗSRWHQWLDO mV± S.D  
IONPs          21.2 ± 7.3 
0.2 mg PEG±PGA 40%C18±IONPs          67.7.7 ± 11.8 
0.1 mg PEG±PGA 40%C18±IONPs         50.6 ± 17.2 
0.05 mg PEG±PGA 40%C18±IONPs         23.5 ± 10.5 
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5.4.4 Stability of PEG±PGA 40%C18 Coated IONPs  
The stability of the coated nanoparticle dispersions was determined at NaCl 
concentrations varying from 1mM to 600 mM, as shown in Figure 5.16. The iron 
oxide nanoparticles were coated with different amounts of PEG±PGA 40%C18 
coated IONPs (0.2 mg, 0.1 mg, and 0.05 mg). UV visible absorbance spectra were 
used to monitor the turbidity of the corresponding dispersion solutions containing 
polymer-coated IONPs. With the change in sodium chloride concentration. All the 
samples showed high stability over all the concentrations of the NaCl, with no 
significant differences. The 0.1 mg of PEG±PGA 40%C18 coated IONPs batch, 
which has relatively low polymer content, was highly resistant to NaCl induced 
aggregation and gave slightly lower absorbances than either the 0.2 mg or 0.05 mg 
formulations PEG±PGA 40%C18 coated IONPs. In conclusion, all three formulations 
showed the high stability suitable for use with biological media. 
 
 
 
 
 
 
Figure 5-16 : Stabilities of different formulations of PEG-PGA 40%C18±IONPs.  
Various PEG±PGA 40%C18±IONP formulations were titrated with increasing salt 
concentrations and the aggregation of the formulations was monitored by optical 
density at 500 nm. 
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5.5 Discussion  
5.5.1 PEGYLATED PGA 40%C18  
PEGylated PGA 40%C18 was successfully synthesised. Analysis by NMR, FTIR and 
GPC confirmed that PEGylated polymer was formed successfully, resulting in a final 
yield of 78%. The reaction was between the amine group of PEG and the COOH of 
PGA, using carbonyldiimidazole (CDI) to produce a stable carbamate bond linking 
the PEG and the 40%C18 substituted PGA. CDI is a well-known coupling reagent. 
Oster et al., (2004) have reported that it had been used to attach an amine 
functionalised chemical to a poly(vinyl alcohol) through a hydroxyl group.  
CDI has the ability to react with amino groups and carboxylic acid to give reactive 
carbonyl imidazole intermediates, which are more easily handled and can be isolated. 
The carbonyl imidazole might consequently undergo selective reaction with primary 
amines or alcohol to form amide, carbonate or ester derivatives (Rannard and Davis, 
2000 and  Rannard and Davis, 1999). The PGA would be expected to consist of 50% 
monocarboxyl, 25% dicarboxyl and 25% with no carboxy termini. The yield of 78% 
would suggest that the carboxy terminal is the preferred site of coupling. 
From the yield and from the proportion of PGA which cannot react, which is 
expected to be 25%, the maximum ratio achievable is 1.25 PEG: 1 PGA 40%C18, 
where the results of GPC suggest 2 PEG: 1 PGA 40 %C18 and NMR 0.7 PEG: 1 
PGA 40%C18. It seems most likely that the PEG-PGA ratio achieved is between that 
determined by GPC and NMR. 
PEGylated polymers may improve the stability of the drug delivery system in the 
blood by preventing protein absorption and uptake by the reticuloendothelial system 
(RES). To provide further functionality on the coated IONPs surface, PGA 40%C18 
was chosen as it is very hydrophobic and forms good nanoparticles and because it is 
biodegradable and non-toxic. PEG was chosen as the hydrophilic segment, acting as 
a modifier for preparing surfaces with protein adsorption resistance, it is also a non-
ionic, highly hydrophilic and flexible polymer (Sofia et al., 1998 and Kim et al., 
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2005b). PEG has a range of chain lengths and with its functionalised termini makes 
the chemical coupling to another polymer simple. A PEG chain with M.W 2000 
functionalised with an amine group at one terminus
 
was commercially available, and 
was coupled to the core polymer via amine activation using CDI. In the 1H, NMR   
was clearly both peaks of the PEG and PGA. Comparing the areas of the PEG and 
PGA gave an estimate of the PGA: PEG ratio. Copolymers could increase the time in 
circulation and increasing the chance to avoid the defence system in the body when 
they are hydrophilic and hydrophobic. 
5.5.2 PEGylated PGA 40% C18±IONPs  
There have been many reports of nanoparticulate drug delivery with PEG surfaces to 
improve biodistribution and drug delivery. It has been reported that PEG stabilises 
poly(lactic acid) nanoparticles in the presence of lysozyme (Vila et al., 2002). 
The physicochemical characteristics of the different formulations prepared with a 
PEG±PGA 40%C18 coating were investigated. The size of the nanoparticles 
characterised by TEM was approximately 20±59 nm over all the formulations and 
showed spherical-shaped particles with a narrow size distribution. Unlike the PGA 
coatings, there was no population of bigger particles when an excess of polymer was 
added to the iron oxide nanoparticles. When the copolymer solution was added 
dropwise into iron nanoparticles in water under magnetic stirring the organic solvent 
would diffuse into the water, and phase separation occurs in this system. The PEG 
block is soluble in water but not in the organic phase, and the hydrophobic PGA 
block is not water soluble but is highly soluble in organic solvent. Consequently, the   
acetone goes out while the water goes in as result the droplet breaks up and the 
polymer is precipitated. The solvent evaporates and the core solidifies, and the core-
shell structured nanoparticles are formed.
 
The presence of the PEG prevents the layer 
from getting too thick. The TEM clearly shows a layer of the PEG±PGA 40%C18 is 
coating the IONPs in all batches. PEG attachment to nanoparticles can be carried out 
either by physical adsorption or by covalent grafting (Stolnik et al., 1995 and 
Jaeghere et al., 2000). 
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IONPs coated with PEG-polyanion block copolymer via electrostatic interaction had 
a longer half-life in the blood stream compared to dextran±IONPs, allowing the 
improved MR imaging of the liver by their intravenous administration (Thünemann 
et al., 2006 and Lutz et al., 2006). PEG coating and stability make these particles 
suitable for in vivo applications. Particle sizes were affected by the method of 
preparation and dictated by the quantity of the copolymer-coated particles. Work was 
done by Gref et al., (1994a) who prepared PEG±PLGA nanoparticles smaller than 
200 nm using a nanoprecipitation method. 
Work that was done by Hu et al., (2007) also used a nanoprecipitation method to 
obtain polycaprolactone poly(ethylene glycol)  PCL±PEG. The morphology and size 
of nanoparticles were measured by field emission scanning electron microscopy 
(FESEM) and laser light scattering (LLS). All the nanoparticles were spherical in 
shape and the sizes were less than 200 nm. The sizes of the nanoparticles increased 
with increasing PCL segment length. The PEG outer shell of the nanoparticles 
reduced surface absorption of proteins and escape from reticuloendothelial system 
(RES) after intravenous administration (Jones and Leroux, 1999 and Zambaux et al., 
1999).    
Using IONPs coated with PEG silane copolymer, MR imaging of solid tumour has 
recently been demonstrated (Lee et al., 2006). The coating of iron nanoparticles 
should be an adsorption mechanism other than simple electrostatic interaction, The
 
PEG chain may affect the hydrodynamic size and hydrophilicity as well as the anti-
opsonisation properties of the particles (Xie et al., 2009,  Xie et al., 2007 and Harris 
and Chess, 2003).    
Decuzzi et al., (2006) produced models suggesting that smaller sized, spherical NPs 
observed higher diffusion rates, increasing the NP concentration at the centre of a 
blood vessel, thus limiting interactions with endothelial cells and prolonging the NP 
blood circulation time. For the PEG-PGA 40%C18±IONPs described in this chapter, a 
remarkably small size was witnessed, which is rarely reported for IONPs with other 
types of biodegradable polymer coatings. 
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Veiseh et al., (2009) reviewed many studies reporting that the hydrodynamic size 
plays a very important role in the NPs clearance from circulation. Small particles 
around 20 nm are excreted renally while medium size particles from 30±150 nm 
accumulate in the bone marrow, stomach, kidney, liver and spleen. On the other 
hand, large sizes from 150 nm to 300 nm have been found in spleen and liver.  
In conclusion, the size and shape of the PEG-PGA 40%C18±IONPs were perfect and 
small, and these parameters can be tuned to achieve the enhanced biodistribution of 
the coated nanoparticles.  
5.5.2.1 Zeta potential 
Increase of zeta potential seems to be an indicator for the PEGPGA 40%C18±IONPs. 
The 0.05 mg of PEG±PGA 40%C18±IONPs were similar to the IONPs, while the 
other formulations were more positive. The continued increase in the zeta potential 
may indicate that the thickest coating was achieved with the highest amount of 
polymer. However, the PEG±PGA 40%C18±IONPs should have given a more 
negative or neutral rather than positive potential, and this could be due to the use of 
water rather than a low concentration of buffer for this measurement.  
5.5.3 Stability of PEG±PGA 40 % C18±IONPs 
The PEG±PGA 40%C18±IONPs showed excellent stability due to steric stabilisation. 
Electrostatic and steric stabilisation are now extensively accepted as being two 
mechanisms by which it is possible to generate colloidal stability  (Napper, 1977 and 
Vincent, 1974).1The 0.1 mg PEG-PGA 40%C18 coating produced very stable 
particles and contrary to the zeta potential results appeared to be more stable than 
even the 0.2 mg and 0.05 mg coatings, but there was not a great difference  between 
them. The 0.1 mg polymer coating also seemed to be even more effective than the 
0.1% Tween coated PGA 0%±IONPs reported in the previous chapter. Steric 
stabilisers have long been used to achieve greater stability of colloidal particles or to 
prevent capture by phagocytic cells (Illum et al., 1987). The flocculation of the 
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particles at high concentration of the salt NaCl is attributed to the dehydration effects 
and the high stability of the coated nanoparticles attributed to a good coating and the 
reaction between the particles and the polymer to enhance the stability, strong 
interactions between the PGA chains and the nanoparticle. The surface can produce 
anchoring at many points in the stabilisation (Napper, 1977). 
The study shows that a range of IONPs coated with a thin PEG±PGA 40%C18 layer 
demonstrated significant colloidal stability and the layer coating was enough to 
prevent aggregation. If the thickness of the polymer is large enough, the van der 
Waals attraction between the particles is unimportant in comparison to the Brownian 
thermal energy7KLVLVWKHRULJLQRIWKHWHUPµVWHULF¶VWDELOisation (Vincent, 1974 and 
Napper, 1977). 
PEGylated PGA 40%C18 increased the stability of the nanoparticles in comparison to 
the stability of PGA and PGA 40%C18 also those with Tween 80 and albumin 
overcoating as described in chapter 4. 
Bazile et al., (1995) reported the advantage of PEGylated  poly(d,l-lactic acid) PLA 
in comparison with colloidal systems like PLA nanoparticles by covalently coupling 
the PEG to PLA, thus minimising uptake by the MPS. 
5.6  CONCLUSION  
The aim of this  chapter  was to synthesise PEGylated PGA 40%C18 with PEG 2000 
to give surface modified layer of IONPs with PGA 40%C18 to the surface of the  
IONPs.  PEG±PGA 40%C18±IONPs were prepared using our modified interfacial 
deposition method to determine the optimum conditions resulting in a small size. The 
best condition was found to be 0.2 mg polymer, which produced clean and smooth 
particles with only rare aggregates. Decreasing the amount of the polymer used 
caused an increase of the size of PEG-PGA 40%C18±IONPs. The best particle size 
was determined by both TEM and DLS. All the formulations had a small size 
approximately from 20 to 59 nm diameter. The PEGylated PGA 40%C18±IONPs was 
shown to be an effective stabiliser at high concentrations of NaCl (600 mM) which 
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makes these particles suitable for both in vitro and in vivo applications. Small size of 
PEG-PGA 40%C18±IONPs can be produced by a simple coating method which is the 
modified interfacial deposition method 
 
 
. 
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CHAPTER 6 
6. INTERACTION OF COATED 
NANOPARTICLES WITH CELLS IN CULTURE 
6.1 INTRODUCTION 
IONPs have been used widely in studies for potential applications in biology and 
medicine such as enzyme and protein immobilisation, magnetic resonance imaging 
(MRI), RNA and DNA purification, magnetic cell separation, purification, 
magnetically controlled transport of anticancer drugs, and also hyperthermia 
generation (Matsunaga et al., 1999 and Reetz et al., 1998). 
 
Many factors affect the efficacy of the IONPs as contrast agent, such as the size of 
the iron oxide crystals. Also, the charge, the nature of the coating, and the 
hydrodynamic size of the coated particle affect the stability, biodistribution, 
opsonisation and metabolism of different contrast agents (Corot et al., 2006). IONPs 
should have a narrow size distribution, and be coated with biocompatible non-toxic 
and biodegradable polymer to provide stability in a physiological medium and 
biological environment. Also these properties will affect cellular uptake and hence 
biodistribution. 
For polymer-coated IONPs with a diameter larger than 50 nm, the NPs would be 
trapped in the liver or spleen. However, smaller than 30 nm would rapidly circulate 
in almost the whole body. Normally, these small 30 nm NPs are more likely to enter 
the lymphatic system and be eliminated slowly. The properties of nanoparticles 
coated with a layer of polymer are important. Coated nanoparticles with a 
hydrophobic surface may improve the uptake of the nanoparticles by the liver or 
spleen, while with a hydrophilic surface they may increase the time of  circulation in 
the blood and increase the chance to penetrate into marrow and enter the lymph (Li et 
al., 2005).  
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Cell labelling with magnetic nanoparticles is a common method which has been 
widely used for in vitro cell separation and also for in vivo imaging because of their 
properties to improve the signal in magnetic resonance imaging (Wilhelm et al., 2003 
and Lok, 2001). Two current cell labelling nanoparticle techniques can use either 
internalisation of the nanoparticles by fluid phase endocytosis, receptor mediated 
endocytosis or phagocytosis, or alternatively by attaching magnetic nanoparticles to 
the cell surface (Weissleder et al., 2000 and Tzu-Chen et al., 1993).  
MR contrast agents are used increasingly to detect diseased and defective cells and to 
increase and enhance the resolution of the image, but they are dependent on their 
particle size and coating. Using drug delivery techniques it should be possible not 
only to deliver diagnostic agents to the target site with maximum uptake by target 
cells, but also to minimise the side-effects. Understanding the cellular uptake of 
nanoparticles is therefore important in both cell labelling and for MRI contrast 
agents.  
In this study, we incorporated a rhodamine B isothiocyante RBITC label into our  
PGA 40%C18±IONPs with size  23 ± 7 nm and PEG-PGA 40%C18±IONPs with size 
16 ± 4 nm for labelling cells to investigate the intracellular uptake of nanoparticles 
with different coatings in cell monolayers and cell aggregates using the C6 brain 
glioma cell line.  Particles were examined using a range of techniques, such as TEM, 
fluorescence microscopy, confocal microscopy and flow cytometry.  
The aim of the present investigation is to determine the uptake of small coated 
IONPs to get some idea of how these properties may be used for detecting 
morphological and physiological tissue in vitro and can be a good contrast agent for 
MR images. 
 The cell culture studies investigated the two best formulations developed during this 
project, i.e IONP produced as described in chapter 3 and subsequently coated with 
either PGA 40%C18 as described in chapter 4 or PEG-PGA 40% C18 as described in 
chapter 5. 
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6.2 Methods 
Routine monolayer cell culture (see 2.2.18.4). 
 RBITC labelled 3*$ícoated iron oxide nanoparticles (see 2.2.16). 
Determination of fluorescent dye loading (see 2.2.17). 
Preparation of the nanoparticles for cell work (see 2.2.18.1). 
Qualitative Nanoparticle uptake by cells study (see 2.2.18 .9). 
Qualitative uptake of nanoparticles in C6 cells (see 2.2.18.10). 
Qualitative uptake and metabolism of nanoparticles in C6 cell (see 2.2.18.11). 
Evaluation of time±dependent uptake of NPs by cells growing in monolayer culture 
using TEM (see 2.2.18.12). 
Quantitative NP uptake study dependent on dose and time (see 2.2.18.14). 
Quantitative determination of loss of nanoparticles from cells (see 2.2.18.15). 
Aggregate cultures (see 2.2.18.16). 
Cell aggregate uptake of RBITC NPs (see 2.2.18.17). 
 
 
CHAPTER 6                                                    Interaction of nanoparticles with cell 
169 
6.3 Results  
6.3.1 Qualitative Nanoparticle Uptake Study: Dose-dependent 
uptake of RBITC labelled NPs by cells 
6.3.1.1 0.1 % Tween±PGA 40%C18 coated IONPs 
As shown in Figure 6.1, the uptake level progressively increased with increased dose 
of RBITC labelled NPs and did not reach saturation up until the highest dose of the 
polymer coated IONPs. To confirm the uptake resulted from cellular uptake of 
fluorescently labelled NPs, untreated cells as a control with 2 h incubation time were 
also used. The controls in Figure 6.1e show, firstly that in cells not incubated with 
NPs there was no significant autofluorescence. After 2 h incubation time of cells 
with medium with serum containing NPs, fluorescence was seen to increase with 
dose, clearly confirming that nanoparticle uptake occurred into cells. These 
nanoparticles are too fine to be resolved individually in the light microscope, but the 
fine distribution suggests that the particles were not significantly aggregated on 
uptake. 
Cells incubated with PGA 40%C18±IONPs show very fine particles distribution all 
across the cell and over the nuclei. However, there was an apparent difference in 
subcellular localisation shown by all doses and the PGA 40%C18±IONPs were 
located mainly on the periphery of the nuclei. 
 
CHAPTER 6                                                    Interaction of nanoparticles with cell 
170 
 
Figure 6-1: Fluorescence microscopy images of PGA 40%C18±IONPs without 
Tween incubated with C6
 
cell for 2 h in the presence of serum. (A) 0.1ml, (B) 0.2 
ml, (C) 0.5 ml, (D) 1ml and (E) control untreated cells. (Scales bar 20 µm).  
Different conditions were used in this experiment to see how it affects the uptake, the 
blue is DAPI which stained the cell nuclei while the red is the fluorescence labelling 
the PGA 40%C118±IONPs. Our experiment above showed that the uptake of RBITC 
labelled PGA 40%C18±IONPs in the presence of the serum in the medium is high. To 
further investigate the effect of overcoating on the surface of the PGA 40%C18±
IONPs on the uptake we tested the cellular uptake of different NPs. Figures 6.2 and 
6.3 show the typical images of PGA 40%C18±IONPs overcoated with 0.1% Tween in 
A
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the presence of serum and PGA 40%C18±IONPs without Tween and in the absence 
of serum in the cell medium respectively. 
 
Figure 6-2 : Fluorescence microscopy images of PGA 40%C18±IONPs with 
Tween 0.1% incubated with C6
 
cell
 
for 2 h in the presence of serum. (A) 0.1 ml, 
(B) 0.2 ml, (C) 0.5 ml and (D) 1 ml.  ( Scales bar 20 µm). 
The uptake here again increased with increasing dose for both of the two 
experiments. In all doses the fine particles were across the cell and throughout the 
cytoplasm. Cell uptake of nanoparticles was shown as highly fluorescent patterns, 
preferentially distributed in the cytoplasm or around nucleus but without the obvious 
perinuclear distribution frequently seen with larger particles. There are spots on the 
nuclei but it is difficult to see if these are in or merely above the nuclei. The presence 
of Tween seemed to reduce the uptake of the nanoparticles. In Figure 6.3, 
PGA 40%C18±IONPs appeared to be taken up to a greater extent in the absence of 
serum without Tween. There also appeared to be less effect of the dose, but the 
nanoparticles showed very high concentration and accumulation. This may be partly 
due to the cells having a more rounded up appearance, possibly due to the absence of 
A B
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serum. Figure 6.3e showed untreated cells again demonstrating the lack of 
background fluorescence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-3 :  Fluorescence microscopy images of PGA 40%C18±IONPs without 
Tween incubated with C6
 
cells for 2 h in the absence of serum.  (A) 0.1 ml, (B) 
0.2 ml, (C) 0.5 ml, (D) 1 ml and (E) control untreated cells. (Scales bar 20 µm). 
6.3.1.2 PEG±PGA 40%C18 coated IONPs 
In order to visualise the distribution of the modified IONPs, the PEG±PGA 40%C18 
coated IONPs were fluorescently labelled by RBITC. Here (Fig.6.4) four samples of 
C6 cell cultures in the presence of serum, each containing PEG-PGA 40%C18±IONPs 
at different doses, were incubated under the same conditions (2 h, 37°C).  
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Figure 6-4 :  Fluorescence microscopy images of 3(*íPGA 40%C18±IONPs in 
different concentration incubated with C6 Cell for 2 h in the presence of serum. 
(A) 0.1ml, (B) 0.2 ml, (C) 0.5 ml, (d) 1 ml and (E) control untreated cells. (Scales bar 
20 µm).   
 
It can be seen from Figure 6.4 that the fluorescence intensity gradually increased 
with increasing concentration of the labelled nanoparticles. From the lowest dose 
(0.1 ml) fine particles were clearly visible in the cytoplasm.  
One can see from Fig 6.4d that the fluorescence of the 1 ml loaded 
PEG-PGA 40%C18±IONPs  is closely located around the nuclei area, which indicates 
that the  3(*íPGA 40%C18±IONPs  have been taken up by the cells. The signal in 
the nuclear area was very strong, particularly at the 0.5 ml dose. The PEG- 
PGA 40%C18±IONPs overall showed a higher fluorescence than the particles without 
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PEG, whether PGA 40%C18±IONPs with Tween or in the presence or absence of 
serum. However, cells incubated with the control showed no fluorescence.   
6.3.2 Time-dependent Uptake of RBITC Labelled NPs by Cells  
6.3.2.1 0.1% Tween±PGA 40%C18±IONPs 
Cells were treated with labelled particles over different time periods from 2 h to 24 h 
before washing and fixing the cells after the end of the incubation time. Figure 6.5 
shows the fluorescence images of 0.1% Tween±PGA 40%C18±IONPs for different 
times without washing. The uptake increased with increasing time. The distribution 
was clear from the early time incubation and the fine particles can be seen around the 
nuclei. High accumulation was observed in the longer incubation times at 12 h and 
24 h, with very intense fluorescence observed at 24 h incubation time (Fig. 6.5 f). 
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Figure 6-5: Fluorescence microscopy images of 0.1% Tween±PGA 40%C18±
IONPs incubated with C6
 
cells for different time periods without washing. (A) 2 
h, (B) 4 h, (C) 6 h, (D) 8 h, (E) 12 h and (F) 24 h. (Scales bar 20 µm).   
6.3.2.2 PEGíPGA 40%C18±IONPs 
The uptake of PEGíPGA 40%C18±IONPs was monitored by fluorescence 
microscopy Figure 6.6, over time. Up to the shortest practical incubation time of 
about 2 h, uptake had occurred already and a good distribution with very fine 
particles was seen. All of the nanoparticles with different time incubation had a 
uniform distribution in what is most likely the cytoplasm. Accumulation increased 
significantly from 6±8 hours onwards (Figure 6.6c and d), with a very intense 
accumulation by 24 h. 
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Figure 6-6: Fluorescence microscopy images of 3(*íPGA 40%C18±IONPs 
incubated with C6
 
cells for different time periods without washing. (A) 2 h, (B) 4 
h, (C) 6 h, (D) 8 h, (E) 12 h, and (F) 24 h. (Scales bar 20 µm).   
 
6.3.3 Time-dependent Metabolism of RBITC Labelled NPs by Cells. 
6.3.3.1 0.1 % Tween±PGA 40%C18 coated IONPs 
The uptake of the 0.1% Tween±PGA 40%C18±IONPs by C6 cells with incubation 
times of 1 to 24 h was visualised using fluorescence microscopy, after incubation of 
2 h and then reincubation for varying periods. This experiment shows the retention of 
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fluorescence with time after exposure of cells to labelled 0.1% Tween±PGA 
40%C18±IONPs. The effect of incubation time on the cellular uptake is clearly shown 
in (Fig. 6.7). The images showed that the cells started with a surprisingly even 
labelling of the cells throughout the cytoplasm. Fluorescence was not detected in 
control cells that had not been exposed to the RBITC labelled nanoparticles. 
Figure 6-7 : Fluorescence microscopy images of 0.1% Tween±PGA 40%C18±
 IONPs incubated with C6 cells for different time periods in presence of serum. 
(A) 1 h, (B) 2 h, (C) 4 h, (D) 6 h, (E) 8 h, (F) 12 h, (G) 18 h and (H) 24 h. (Scale bar 
20 µm). 
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The images in the early time periods 1 to 2 h show that in the cells the highest 
concentration was in the perinuclear area and in some cases overlying the nucleus. 
Red fluorescence intensity was only retained for the first two hours but had started to 
disappear by 4 h incubation although it can be still detected inside the cells (Fig. 
6.7c). 
In the case of 6h and 8 hr, most of the cells showed no fluorescent patches but some 
fluorescence was retained in a few cells as a small amount of fine particles (Fig. 6.7d 
and e). In the case of 12 h, 18 h and 24 h the fluorescence had disappeared entirely.  
Cells in this case must be investigated by TEM to determine whether it is the 
fluorescence or the iron particles which have disappeared. 
6.3.3.2 PEGíPGA 40%C18±IONPs  
Figure 6.9 shows the cellular disappearance for different incubation time using C6 
cells treated with 1 PORI3(*íPGA 40%C18±IONPs 
Figure 6.9 a, b and c clearly shows the nanoparticle presence in C6 cells as a 
widespread and fine distribution throughout the cytoplasm but with some perinuclear 
accumulation. Significant fluorescence also appeared over the nucleus.  
The flXRUHVFHQFH LQWHQVLW\ 0), RI 3(*íPGA 40%C18±IONPs was high for the 
initial 30 min to 1 h of incubation time. After that, fluorescence started to disappear. 
The disappearance again being higher in some cells than others, it remained 
relatively stable over the next few hours. Then the fluorescence started disappearing 
at 8 h. In Figure 6.9d, the fluorescence still appears in just a part of the cell and in the 
majority of the cells the fluorescence has disappeared.   
No red fluorescence was detected in the cell in 12 h and 24 h time of incubation 
(Fig.6.9 g and h). Sample control (Fig. 6.8) was used for both experiments as control. 
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Figure 6-8: Fluorescence microscopy images of untreated C6 cells as control 
for both 0.1% Tween±PGA 40%C18 DQG 3(*í3*$ 40%C18 coated IONPs 
time-dependent metabolism studies.  (Scale bar 20 µm).  
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Figure 6-9 : Fluorescence microscopy images RI3(*íPGA 40%C18±IONPs incubated with C6 cells for different time periods. (A) 
0.5 h, (B) 1 h, (C) 2 h, (D) 4h, (E) 6 h, (F) 12 h and (G) 24 h.  (Scales bar 20 µm).
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6.3.4 Dose-dependent uptake of RBITC Labelled NPs by Monolayer 
using Confocal Fluorescence Microscope 
6.3.4.1 0.1% Tween±PGA 40%C18±IONPs   
Confocal microscopy was employed to visualise the interaction of fluorescently 
labelled NPs within cells in RBITC labelled NPs uptake studies. Figure 6.10 shows 
confocal images of C6
 
cells  incubated with different doses 0.1 ml, 0.5 and 1 ml of 
RBITC labelled PGA 40% C18±IONPs for 2 h. 
Figure 6-10 : Confocal laser micrograph of C6 cell monolayer incubated with   
0.1 % Tween±PGA 40%C18±IONP for 2 h. (A) 0.1 ml, (B) 0.5 ml, (C) 1 ml and 
(D) control. (Scales bar 10 µm). 
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The spherical bright red fluorescent spots could be observed in cytoplasm and in 
discrete areas surrounding the nucleus. It should be noted that, as the size of 
PGA 40%C18±IONP are below 30 nm in diameter, fine PGA 40%C18±IONP would 
appear very small under confocal microscopy. There are many small dots and some 
large red fluorescent spots representing large collections of PGA 40%C18±IONP. The 
latter almost certainly indicate an intracellular location and the intercellular 
localisation increased with increasing doses. When comparing the three doses, 
uptake was visibly more extensive for the cells treated with 1ml rather than the 0.1 
and 0.5 ml PGA 40%C18±IONP suspension (Fig. 6.10a and b). In Figure 6.10c 
showing the 1.0 ml dose, there was extensive localisation of the PGA 40%C18±IONP 
around the nucleus, but also in some cells some dark patches could be inside the 
nucleus indicating uptake into the nucleus itself. Figure 6.10d shows the control was 
clear, there were no dark patches, just the DAPI which stained nuclei. 
6.3.4.2 PEGíPGA 40%C18±IONPs  
C6
 
cells were incubated with different doses also of PEGíPGA 40%C18±IONPs and 
visualised using confocal microscopy (Fig. 6.11). In general, uptake with the PEGí 
PGA 40%C18±IONPs appeared to be lower than the PGA 40%C18±IONPs. PEGí 
PGA 40%C18±IONPs uptake into the cytoplasm was only clear at the 0.2 ml dose 
with the nanoparticles distributed through the cytoplasm and around nuclei (Fig. 
6.11a). At the highest 1.0 ml dose, some nuclei exhibited some significant dark areas 
and this may represent some PEGí PGA 40%C18±IONPs uptake. The control sample 
showed just cells stained with DAPI in (Fig. 6.11d).   
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Figure 6-11: Confocal laser micrograph of C6 cell monolayer incubated with 
3(*íPGA 40%C18±IONPs for 2 h. (A) 0.1 ml, (B) 0.5 ml, (C) 1 ml and (D) 
control without labelled 3(*íPGA 40%C18±IONPs. (Scales bar 20 µm).  
 
6.3.5 Metabolism and Redistribution of RBITC Labelled NPs by C6 
Cell Monolayers using Confocal Fluorescence microscopy 
The intracellular uptake of nanoparticles by cell was estimated by using different 
incubation times for the cells at 1 h, 4 h and 24 h using monolayer cells. 
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6.3.5.1 0.1% Tween±PGA 40%C18±IONPs 
Confocal microscope images showed that 0.1% Tween±PGA 40%C18±IONPs were 
initially internalised into the cells and mainly stayed in the cytoplasm. The 
appearance of the cells was different each time and exhibited a strong dependence on 
the length of the observation period (Fig. 6.12). Images showed that huge numbers of 
nanoparticles were present in the cell at 1 h with a wide distribution in the cytoplasm 
and distributed around the nuclei. There were some small dark patches within the 
nuclei. By 4 h and 24 h (Figs. 6.12b and 6.12c) there was less fluorescence visible in the 
cytoplasm and the fluorescence present was more localised into one place in the cytoplasm. 
Also the DAPI was less visible in the nucleus, with the whole centre of nuclei appearing 
black suggesting nanoparticle uptake into the nucleus.  
 
Figure 6-12:  Confocal laser micrograph of C6 cell monolayer incubated with 
0.1% Tween±PGA 40%C18±IONPs for different time periods.  (A) 1 h (Scale bar 
10 µm), (B) 4 h (Scale bar 10 µm), (C) 24 h with (Scale bar 10 µm) and (D) control 
with (Scale bar 20 µm). 
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6.3.5.2 PEG±PGA 40%C18±IONPs  
The metabolism and redistribution of PEGíPGA 40% C18±IONPs into C6 cells was 
monitored by confocal laser scanning microscopy Figure 6.13. The PEG-PGA 
40%C18±IONPs localisation was time-dependent. After 1 h of incubation, PEG-PGA 
40%C18±IONPs identified as many fluorescent spots, were observed on the periphery 
of the cells (Fig. 6.13a).  
Figure 6.13b shows the image obtained by the second period of 4 h. It can be 
observed from this Figure that the fluorescence of PEGíPGA 40%C18±IONPs are 
closely located around the nuclei in very small, evenly distributed and punctate 
patches of fluorescence. Also seen were dark spots and fine particles in nuclei which 
are likely to be nanoparticles. It was evident that many more particles had entered the 
nuclei and on the periphery by the cells after 24 h incubation (Fig.6.13c)  than after 1 
h and 4 h because of the extended exposure time. 
 
 
 
 
 
 
 
 
 
 
Figure 6-13:  Confocal laser micrograph of C6 cell monolayer incubated with 
3(*íPGA 40%C18±IONPs for different time periods.  (A) 1 h (Scale bar 25 µm), 
(B) 4 h (Scale bar 10 µm), (C) 24 h (Scale bar 25 µm) and (D) control (scale bar 10 
µm). 
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6.3.6 Uptake of RBITC Labelled NPs by C6 Cells Cultured as a 
Spherical Aggregate using Confocal microscopy  
After harvesting C6 monolayer
 
cells, cell suspensions were seeded at 1× 106 cells/ml 
in rotation culture. In this culture the cells formed spherical aggregates within 24 h.  
To visualise aggregates under the confocal microscope, aggregates were transferred 
into a 24-well plate with PDL-coated coverslips after 1 day of culture by the rotation 
method, and then cultured for 24 h in a 24-well plate (Fig. 6.14 a, b). As can be seen, 
the aggregates were well formed and individual cells could still be distinguished in 
the periphery of the aggregates. C6 aggregates appeared larger in size and denser 
with less translucence under a light microscope. The mean diameter of the aggregates 
was 150 ȝP 6RPH FHOOV RQ WKH HGJH RI the aggregate grew onto the coverslip, in 
which the shape of single cells could be clearly seen (Fig. 6.14b), and cells in the 
middle of the aggregate stayed within the spheroid shape. 
 
Figure 6-14 : Phase-contrast micrographs illustrating the aggregates formed by 
the rotation method and C6 monolayer cells. (A) and (B) a phase±contrast 
micrographs showing  C6 cells in aggregates formed  from (C) using rotation method 
(Scale bars 20 µm and 50 µm); (C) a phase±contrast micrograph illustrating C6 cells  
in monolayer culture  (Scale bar 50 µm). 
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6.3.7 Time-dependent Uptake of RBITC Labelled NPs by C6
 
cell 
Aggregates Using Confocal Fluorescence microscope 
6.3.7.1 0.1% Tween±PGA 40%C18±IONPs 
Confocal fluorescence micrographs (Fig. 6.15) show cell aggregates incubated with    
1 ml of 0.1 % Tween±PGA 40%C18±IONPs. The micrographs, which were taken 
from the middle of aggregates (Fig. 6.15a, b and c), and (Fig. 6.16 a1, b1 and c1) 
revealed the influence of the increasing diffusion distance of NPs on intracellular 
fluorescence intensity and the flurescence activity in the the different parts of the C6 
through a series of z-sections of the C6 cells. In the first hour of incubation time, the 
intensity of fluorescence in the periphery of aggregates was high (Fig. 6.15a,) and the 
nanoparticles penetrated at least 15 micrometres into the aggregates. With increased 
incubation time, the intensity of fluorescence in the centre of aggregates was 
increased. Compared with 4 h and 24 h incubation time, it was found that the 
difference in intracellular fluorescence intensity between them in the periphery of the 
aggregates and in the centre of the aggregates was greater as shown in (Fig. 6.15b 
and c). Also the images gallery (Fig. 6.16 a1, b1 and c1) showed the level of the 
uptake in all the doses, whereas in 0.1 ml showed a low level while the other doses 
showed the penetration of the nanoparticles throughout the layers of the aggregates. 
The fluorescence intensity level was much higher after 24 h incubation time than 
either 1 h or 4 h. The control sample clearly showed no fluorescence when cells were 
incubated without any labelled NPs (Fig. 6.15d). Compared with the images of 
monolayer by confocal (Fig. 6.12), it was found that there was a large increase in 
intracellular fluorescence intensity in the aggregates compared to the monolayer 
experiments.  The galleries of pictures show the fluorescence in different slices 
through the spheroids etc. 
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Figure 6-15 : Confocal fluorescence microscopy images of 0.1 % Tween±PGA 40%C18± IONPs incubated with C6 cells aggregates for 
different time periods. (A) 1 h (Scale bar 100 µm), (B) 4 h (Scale bars 47.2 µm), (C) 24 h (Scale bar 150 µm) and (D) control (Scale bars 150 
µm).
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Figure 6-16 :  Confocal fluorescence microscopy images gallery of 0.1 % TweeníPGA 40%C18± IONPs incubated with C6 cells 
aggregates for different time periods.  1 h (A1), 4 h (B1) and 24 h (C1); each section is 1.956 µm thick for A1, 0.767 µm thick for B1 and 
3.927 µm thick for C1 illustrates the fluorescence activity in all the sections of the cells. 
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6.3.7.2 PEGíPGA 40%C18±IONPs 
In order to analyse the cellular and subcellular localisation of the particles, confocal 
fluorescence microscopy was performed. 
The images of C6
 
cell aggregates
 
incubated with PEGíPGA  40%C18±IONPs   for 
different times of 1 h, 4 h and 24 h showed that all PEGí PGA 40%C18± IONPs were 
located intracellularly (Fig. 6.17). In the first 1 h, we observed intracellular uptake 
(red clusters inside of cells) (Fig. 6.17a). Also the gallery showed the fluorescence in 
the centre of the aggregate and the stages of the uptake level. For 4 h particles 
showed an increase in the number of particles that were taken up (Fig. 6.17b). In the 
case of 24 h incubation time (Fig. 6.17c) there is a large increase in uptake of 
particles with more particles in cells, some of them completely stuffed full of PEGí 
PGA 40%C18±IONPs. 
The gallery of confocal fluorescence microscopy images (Fig.6.18 c1) showed that 
most of the red fluorescence can be seen in the middle of the spontaneously formed 
aggregates. It was found that the red fluorescence intensity in some areas was higher 
than that of other areas. The gallery of confocal fluorescence microscopy images 
(Fig.6.18) showed that most PEGíPGA 40%C18±IONPs were localised in the middle 
of the aggregates and many PEGíPGA 40%C18±IONPs penetrate through the whole 
of the aggregates after 24 h incubation time. 
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Figure 6-17: Confocal fluoreVFHQFH PLFURVFRS\ LPDJHVRI 3(*íPGA 40%C18±IONPs incubated with C6 cells aggregates for different 
time periods. (A) 1 h (Scale bar 150 µm), (B) 4 h (Scale bar 25 µm) and (C) 24 h (Scale bar 20 µm).  
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Figure 6-18: Confocal fluorescence microscopy images gallery RI 3(*íPGA 40%C18±IONPs incubated with C6 cells aggregates for 
different time periods.  (A1) 1 h, (B1) 4 h and (C1)  24 h; each section is 0.897 µm thick  for A1, 1.197 µm thick for B1 and 0.553 µm thick for 
C1 illustrates the fluorescence activity in all the sections of the cells. 
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6.3.8 cytometry Investigation of Uptake of RBITC Labelled NPs by 
C6 Monolayer cell cultures.  
6.3.8.1 Dose-dependent uptake of RBITC labelled PGA 40%C18±IONPs 
and PEGíPGA 40%C18±IONPs by cells 
Quantitative evaluation of cellular uptake of fluorescently labelled NPs was 
performed using flow cytometry. Flow cytometry is a means of measuring certain 
physical and chemical characteristics of cells or particles as they travel in suspension 
one by one past a laser beam. Thus flow cytometry can measure the fluorescence 
intensity of every single cell or particle. As shown in (Figure 6.19), the cellular level 
of mean fluorescence intensity (MFI) progressively increased with doses of RBITC 
labelled NPs for both PGA 40%C18±IONPs and 3(*íPGA 40% C18±IONPs.  
Uptake of the PGA 40%C18±IONPs appeared lower than uptake for the 
PEG-PGA 40%C18±IONPs, but the difference was not statistically significant. While 
uptake had started to plateau due to the addition of 1 ml of particles, saturation had 
not yet been achieved using either coating. This result reflects the result of the 
labelled NPs in fluorescence microscopy. 
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Figure 6-19: RBITC labelled PGA 40%C18±IONPs and PEG±PGA 40%C18±
 IONPs taken up by C6 cells monolayer depended on dose using flow cytometry. 
 
6.3.8.2 Time-dependent uptake of RBITC labelled PGA 40%C18±IONPs 
and PEG±PGA 40%C18±IONPs by cells  
Briefly, cells were incubated with nanoparticle suspensions in tubes for different 
time periods of 1, 4 and 24 h, then cells were washed three times with PBS, they 
were fixed in 4% fresh prepared paraformaldehyde (PFA) and the last washing of 
PFA was just prior to measurement using flow cytometry. 
Figure 6.20 shows that the uptake of both RBITC labelled PGA 40%C18±IONPs and 
PEG-PGA 40%C18±IONPs were also dependent on the incubation time. Studies of 
flow cytometry in cells show the MFI increased sharply within 1h of incubation time 
and then increased gradually. In this assay the rate of uptake of PEG±PGA 40%C18 ±
IONPs was greater than that of the PGA 40%C18±IONPs (statistical significance 
P < 0.049 by Student t±test). This was particularly apparent over longer time periods 
when further uptake of PGA 40%C18±IONPs had virtually stopped increasing, but the 
PEG±PGA 40%C18±IONPs continued to accumulate. 
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Figure 6-20 : Time-dependent uptake of RBITC labelled PGA 40%C18±IONPs 
and PEG±PGA 40%C18±IONPs by cells in monolayer culture using flow 
cytometry. 
 
6.3.8.3 Time-dependent uptake of RBITC labelled PGA 40%C18±IONPs 
and PEG±PGA 40%C18±IONPs by C6 cells using flow cytometry 
studies to investigate retention of RBITC labelled nanoparticles 
within C6
 
cells  
Briefly, cells were incubated with NPs suspension for 2 h, washed and incubated in 
new culture medium with serum for up to 24 h, and then were measured by using 
flow cytometry.  
Flow cytometry studies showed a decrease in MFI with an increased incubation time 
(Fig. 6.21). Decrease in cellular fluorescence levels with long incubation time 
confirmed the pattern seen in the fluorescence microscopy studies. The percentage of 
cells that internalised RBITC-labelled NPs and their fluorescence intensity were 
quantified by flow cytometry. As shown in (Fig. 6.21), the fluorescence intensity of 
the cells was found to continuously decrease over the time up to 24 h. A similar rate 
of loss of fluorescence was seen for both PEG±PGA 40%C18±IONPs and PGA 
40%C18±IONPs. 
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Figure 6-21 : Retention study of RBITC labelled PGA 40%C18±IONPs and 
PEG±PGA 40%C18±IONPs within C6 cells using flow cytometry. 
6.3.9 Localisation NPs in C6 cells using TEM  
6.3.9.1 Time±dependence uptake of PGA 40%C18±IONPs by C6 cells and 
localisation in cells using TEM  
TEM was utilised to determine the sub-cellular localisation of coated IONPs in C6 
cells. A cumulative experimental protocol was used where cells were incubated with 
nanoparticles for varying periods up to 24 h before washing. Samples were then post-
fixed, stained, dehydrated, embedded, and sectioned (see 2.2.18.13) for TEM 
analysis. Figure 6.22 shows a high magnification image for PGA 40%C18±IONPs 
incubated with cells for different time periods of 1 h, 4 h, 12 h and 24 h.  
At 1h incubation time (Fig 6.22a1, a2, a3 and a4), numerous particles were detected 
forming clusters inside the cells and can be seen throughout the cell in nuclei and in 
mitochondria, endosomes and cytoplasm. Mostly, particles were seen in dense 
collections, but also in small groups or as individual particles. Nanoparticles can also 
be seen outside the cell. There was quite a lot of variation between cells, but a similar 
distribution and intensity of particles were seen at all the time points investigated. By 
contrast, the control image shows virtually no contrast or obvious black dots as seen 
in the experimental pictures. 
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Figure 6-22 : Electron micrographs for PGA 40%C18±IONPs.  Incubated with 
C6 for different time periods (A) 1 h, (B) 4 h, (C) 12 h, (D) 24 h and (E) untreated 
cell control.  
6.3.9.2 PEG±PGA 40%C18±IONPs 
To observe with TEM, the cells were incubated for different times of 1 h, 4 h, 12 h 
and 24 h with PEG±PGA 40%C18±IONPs and the representative TEM images are 
presented in Figure 6.23. After 1h incubation time (Fig. 6.23a1, a2, a3 and a4) PEG± 
PGA 40%C18±IONPs were seen outside the cells, near the plasma membrane and 
inside the endosome, in mitochondria, and the nanoparticles can also been seen in the 
nuclei. This phenomenon indicated that the uptake of PEG±PGA 40%C18±IONPs 
was very high and in all the compartments of the cell. After 4 h of incubation, PEG±
PGA 40%C18±IONPs were already inside the cells, while others were about to enter, 
as shown in b1, b2, b3, and b4 of Figure 6.23. The PEG±PGA 40%C18±IONPs were 
internalised and taken up as individual particles in 12 h incubation time. As shown in 
Figure 6.23 c1 and c2, interestingly some of PEG±PGA 40%C18±IONPs lined up on 
membrane surfaces in the cytoplasm in mitochondria and apparently adsorbed onto 
structures in the nucleus. Figure 6.23 c3 and c4 showed the nanoparticles
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Figure 6-23 : Electron micrographs for PEG±PGA 40%C18±IONPs.  Incubated with C6 cells for different time periods (A) 1 h, (B) 4 h, (C) 
12 h, and (D) 24 h.  
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in nuclei in very tiny groups or individually. In 24 h time incubation Figure 6.23d1, 
d2, d3 and d4 shows the particles in individual form and as groups inside the cell and 
also the many nanoparticles lined up adsorbed to various subcellular membranes. 
The control (Fig. 6.22 e) also here shown without nanoparticles for comparison to 
show the change in contrast seen with these very small IONPs.  
For both PGA 40%C18±IONPs and PEG±PGA  40%C18±IONPs, the subcellular 
biodistribution was more widespread at later times, but nanoparticles could be seen 
in many cellular compartments even at early time points.  In addition, there was no 
obvious collection of nanoparticles mainly in endosomal type compartments at early 
time points. It is therefore not clear whether initial uptake was by endosomal 
pathways. 
6.4 DISCUSSION 
The normal pathway and mechanism of drug absorption is by partition and diffusion, 
but with nanoparticles, other processes such as phagocytosis and endocytosis take 
place. 
For use of iron oxide nanoparticles in a variety of applications, studying uptake is 
very important in order to find out if the nanoparticles had been taken up by the cells, 
how long it takes and whether or not the nanoparticles are retained in the cells. Also 
the effect of time and dose on the accumulation and distribution and the way the 
nanoparticles entered into the cells. 
In this chapter, uptake of nanoparticles by cells and the effects of time or dose were 
evaluated in two types of cell models: monolayer culture and aggregate culture, using 
fluorescence microscopy and confocal microscopy. To determine where the 
nanoparticles were localised in cells, NPs were incubated with cells for different 
periods of time and TEM images acquired.  
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6.4.1 Uptake into Monolayers 
Cell culture monolayers were incubated with both PGA 40%C18±IONPs and 
PEGíPGA 40%C18±IONPs were studied using fluorescence microscopy, confocal 
microscopy and TEM. The aim of these studies was to find out the uptake of the 
nanoparticles into cells, also the sub-cellular localisation of nanoparticles, and how 
the nanoparticles entered the cells. 
The fluorescence micrographs of nanoparticles with both coatings appeared to show 
NP uptake by the cells with a broad distribution of fluorescence across the cell. The 
nanoparticles appeared to show a very fine fluorescence without strong points of 
light even after prolonged incubation. They were seen throughout the entire cell 
cytoplasm and tended to be near the nucleus where they were more concentrated, 
forming a highly fluorescent region. All of the nanoparticles with their different 
coatings and overcoatings gave a similar picture of distribution by fluorescence 
microscopy (Figs. 6.1, 6.2, 6.3 and 6.4). While the pictures are similar to most other 
particle uptake studies in showing a cytoplasmic uptake, in these studies the pictures 
were subtly different. Typically, particle uptake shows a much more punctate 
fluorescence due to the accumulation of particles in endosomes and lysosomes. Also 
at later time points (2±4 h) a typical horseshoe shaped perinuclear pattern of highly 
fluorescent spots of high concentration delineating the late endosome/lysosome 
accumulation is seen. However, unusually in this work these patterns were absent, 
suggesting some unusual features to the uptake. A further difference was the 
appearance of fluorescent patches over the nuclei. This was particularly noticeable in 
cells with high particle uptake, but it was unclear whether this represented particles 
actually in the nucleus or merely fluorescence in the cytoplasm overlying the 
nucleus. 
PGA 40%C18±IONPs and PEG±PGA 40%C18±IONPs also showed a higher uptake in 
the presence of serum and in the absence of the serum with Tween overcoated 
nanoparticles. The uptake, however, was still very strong with all the coatings. There 
were some relative differences in the level of uptake with the different coatings 
(presence and absence of serum, Tween 0.1% and PEG±PGA 40%C18±IONPs, but 
apparent differences in subcellular distribution were quite small. When particles were 
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without Tween in the presence of serum (Fig. 6.1), the accumulation was high and 
concentrated in the cytoplasmic region and showed higher uptake than with Tween in 
the presence of serum (Fig. 6.2). Using just PGA 40%C18±IONPs without Tween and 
in the absence of serum (Fig. 6.3), the uptake was high and the fine particles could be 
seen in the cytoplasm and around the nuclei. The apparently high level of 
fluorescence in these cells could have been exaggerated because the cells tended to 
be more rounded up in the absence of serum. Very high uptake was also shown with 
PEG-PGA 40%C18±IONPs (Fig. 6.4). The relative levels of uptake for the serum and 
Tween coatings was in the same order to that shown for the stability of particles in 
the presence of salt in chapter 4. However, surprisingly the PEG-PGA 40%C18±
IONPs, which showed even greater stability, do not fit this pattern. PGA particles in 
the absence of serum are hydrophobic and so should bind to cells and be taken up 
well. Incubation of PGA 40%C18±IONPs with serum should result in protein 
adsorption and a hydrophilic surface leading to lower uptake.  Tween coating could 
result in a thin layer of hydrophobic PEG on the surface of cells, reducing protein 
uptake and also reducing nanoparticle uptake. This theory fits well to the observed 
effects. However, PEG±PGA 40%C18±IONPs could result in a much more 
hydrophilic surface, with a much lower uptake of particles. This was not seen in my 
experiments. 
Confocal fluorescence micrographs of C6 monolayer appeared to show NPs within 
the cytoplasm for both PGA 40%C18±IONPs and PEG±PGA 40%C18±IONPs 
(Fig.6.10, 6.11, 6.12 and 6.13). Dark patches were also seen in the DAPI stained 
nuclei in the nanoparticle treated cells which were not apparent in the control (Fig. 
6.10 d, Fig.11d, Fig.12d and Fig.13d). In these images, the PGA 40%C18±IONPs 
appeared to be taken up better than the PEG±PGA 40%C18±IONPs. The exact 
localisation of nanoparticles with both coatings was still not clear. The majority of 
the particles were in the cytoplasm, but again not in an obvious perinuclear location 
and the nuclear localisation was still unclear. The confocal microscopy confirmed 
that nanoparticles were definitely taken up into the cells. 
The TEM studies confirmed that the nanoparticles were internalised by the cells 
(Fig. 6.22 and 6.23) confirming the above fluorescence microscopy work.  The 
subcellular localisation of the nanoparticles was surprising. Large amounts of 
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nanoparticles were seen inside the cells and particles were everywhere in the cell and 
in the nuclei even after incubation times as short as one hour. The size of 
nanoparticles was clearly very small and there were no large aggregates. A few 
nanoparticles were observed outside of the cells and which may have been 
exocytosed. Almost all of the particles appeared to have been taken up as individual 
particles rather than as aggregates. Inside the cells the particles were sometimes 
arranged as individual particles in small groups or in many cases in lines adsorbed to 
various membrane structures inside the cell. 
Looking at the results and the huge number of nanoparticles, the mechanism of entry 
into the cells was not clear. With nanoparticles in all subcellular compartments, 
nuclei, endosomes, mitochondria and cytoplasm, it is clear that particles have 
somehow been able to cross various intracellular membranes. It is only possible to 
pick out a few possible candidates for coated pits and caveolae on cell membranes, 
and these do not contain obvious accumulations of nanoparticles. Uptake could 
therefore have involved either a translocation of nanoparticles across membranes or 
could also have involved the usual endocytic pathways. A similar picture was seen 
for both the PGA 40%C18±IONPs and PEG±PGA 40%C18±IONPs. Despite the large 
numbers of nanoparticles taken up into all areas of the cells, there was no obvious 
change in the morphology of the cells observed compared with the control.  
It is difficult to find any evidence in the literature for uptake even by very small 
nanoparticles either directly into cells or passing across membranes. In this study 
there is no direct evidence that the nanoparticles were taken up by one of these 
mechanisms. But the evidence of both the fluorescence microscopy and the TEM 
suggests quite strongly that the normal endocytic mechanisms were not the main 
uptake route. 
Uptake of 200 nm particles in both serum-free and serum containing medium was 
low and could be attributed to the particle size improving the mode of nanoparticle-
cell interaction and/or a smaller particle surface area available for serum protein 
adsorption (Johnston et al., 2010). It was reported that nanoparticles with sizes 
between 100 to 200 nm size acquired the best properties for cellular uptake (Panyam 
et al., 2003). Also,Jo et al., (2010) have  reported that nanoparticles of a large size 
between 100 and 160 nm were aggregated in the culture media, therefore interaction 
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with serum proteins could cause the elimination of cell internalisation. Nanoparticles 
with a positive surface interacted with cell surfaces, which are negatively charged, 
resulting in improved cell internalisation of nanoparticles.  
It has been reported that the size has an important role in their adhesion and 
interaction with the biological cell (Foster et al., 2001). Also Zhang et al., (2008) 
have showed that better cellular uptake can be achieved by smaller particle size 
198.5 ± 131.1 nm. 
The characteristics of the nanoparticles themselves are likely to play a very important 
role in the uptake, particularly the size of nanoparticles. In this study, the particle size 
was about 20±40 nm and this is likely to have some effect on the high uptake and 
wide distribution of the nanoparticles in cells. 
In previous work within our group on larger nanoparticles made from PGA, Meng et 
al., (2006) investigated cell uptake. She showed a high uptake of these Tween-coated 
PGA nanoparticles into DAOY cells by fluorescence microscopy. This uptake 
showed a perinuclear distribution in the cells typical of lysosomal accumulation of 
particles. Uptake was time and concentration dependent. This work by Meng 
therefore demonstrates that the distribution seen with the smaller PGA nanoparticles 
results from the size, or the size in combination with the coating, rather than from the 
coating of the nanoparticles. Also, the charge of nanoparticles could be another 
factor to increase the uptake and distribution of nanoparticles. 
Jun-ichiro Jo et al., (2009) reported that nanoparticles of large size between 100 and 
160 nm were aggregated in the culture media, therefore interaction with serum 
proteins caused the elimination of cell internalisation. Nanoparticles with a positive 
surface charge interacted with the cell surface, which is negatively charged, resulting 
in improved cell internalisation of nanoparticles. 
Nam et al., (2009) reported that the formulation of nanoparticles with different 
surface properties could improve their cellular uptake and intracellular distribution.  
magnetite I nanoparticles were synthesised using spermine with a zeta potential of 
9.4 mV and magnetite II with hexanediamine with a zeta potential of -8.3 mV,  
magnetite I showed a  higher uptake than that of magnetite II when the cells were 
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incubated with cancer cells or normal cells which have negative surface charge  
(Osaka et al., 2009).  
Other factors, which may have effects on the uptake, are the type of coatings, 
particularly coatings to reduce nonspecific protein adsorption and clearance by 
macrophages. The type of coating used could indeed be directed towards cell 
interaction (Berry et al., 2004). 
Polymeric surface coats may be functional in themselves through their influence on 
particle size and in vivo properties (Sébastien et al., 2006). Nanoparticle size, shape, 
surface properties, incubation temperature and time and concentration in the medium 
influenced the uptake of nanoparticles (Torchilin, 2000a and Rowland et al., 2005).  
Yang et al., (2008) used aminopropyl triethoxysilane (APTS) modified IONPs and 
adapted a tumour-targeting nanoimmunoliposome platform technology. 
Nanoparticles were labelled with sulfo-NHS-LC-biotin. Cells grown in monolayer 
were incubated with the ligand targeted scL- superparamagnetic IONPs complex 
with a size of 157.4 ± 12.5 nm compared with either the liposome-SPIO or free SPIO 
with a size of about 10 nm at 70 nmol for 4.5 h. The result showed the NPs were 
delivered to the tumour specifically and more efficiently when incorporated into a 
complex than as free SPIO. 
Epidermal growth factor (EGF) was conjugated with carboxymethyldextran (CMD) 
coated iron oxide magnetic nanoparticles. Both CMD coated IONPs and EGF 
modified nanoparticles were incubated for 1 h with CaCo±2 cancer cells, and 
visualised using confocal microscopy. After 1 h of incubation, IONPs coated by 
CMD±EGF were present in both the cell membrane and cytoplasm. Internalised 
nanoparticles that appear in the cytoplasm seemed to accumulate in small vesicles, 
while after 1 h of incubation time, no presence of CMD coated IONPs was observed 
in the cells (Creixell et al., 2010). 
In the present work IONPs were coated with different coatings and showed high 
uptake over the whole time period studied, also showing different levels of uptake 
and different distribution.   
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The increased intracellular uptake by using PEG as coating to IONPs could result 
from the possibility that the nanoparticles with the PEGylated functionalised surface 
could interact with the cell membrane to a greater extent, because of the capability of 
PEG dissolved in both polar and non-polar solvents and having high solubility in cell 
membranes (Yamazaki and Ito, 1990). 
Many studies have reported a route of uptake of nanoparticles which did not involve 
a huge number of the nanoparticles. Wilhelm and Gazeau, (2008) have reported the 
incubation of anionic monomer-coated IONPs with cells. After 1 h incubation time, 
all the nanoparticles were confined within late endosomes or lysosomes dispersed 
throughout the cytoplasm, and did not behave as single particles, but were clustered 
into aggregates decorating the endosomal membrane and/or homogeneously 
dispersed in the endosome.  
In this study, the nanoparticles that were shown in individual particles formed as 
single particles rather than in groups, and this could be attributed to the efficiency of 
the coatings. Work done by Stroh et al., (2004) used different concentrations of 
citrate-coated small superparamagnetic iron oxide particles of 1.5 or 3.0 mM  
incubated with the rat  macrophages (RAW) cells for 90 min and viewed by CLSM. 
This work clearly demonstrated iron oxide particles seemed to be incorporated via 
endocytosis, as indicated by the observation of aggregates in vesicles and surrounded 
by membranes. 
After the adsorption of the nanoparticles on the cellular membrane, the uptake occurs 
via several possible mechanisms, like pinocytosis, non-specific or receptor-mediated 
endocytosis or phagocytosis. The attachment of the particles to the cell membrane as 
the first step seems to be most affected by the surface charge of the particles (Lorenz 
et al., 2006). 
Ge et al., (2009) used three different coatings with meso-2, 3-dimercaptosuccinic 
acid (DMSA), chitosan (CS) and (CS-DMSA) on IONPs  incubated with the KB 
cells for 24h incubation. The higher cellular uptake of CS-DMSA-MNPs compared 
with CS-MNPs results from the high surface charge (positive zeta potential) and also 
showed higher cellular uptake compared to DMSA-MNPs with negative zeta 
potential. After 24 h most of the particles were endocytosed by cells and were 
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eventually sequestered in digestive vacuoles in the cell, some of them being taken up 
as agglomerates. According to my results, the uptake was by none of these routes 
mentioned above and could be by another way altogether. It has been demonstrated 
that particles with PEG-modified surfaces cross cell membranes, in non-specific 
cellular uptake (Caliceti et al., 1989). The possible mechanism for this uptake is that 
PEG can dissolve in both polar and nonpolar solvents and have high solubility in cell 
membranes (Yamazaki and Ito, 1990 and Boni et al., 1984). 
Other studies agree with my result about the uptake of the particles located in cells 
but there is no evidence as to how the particles have been taken up. Häfeli et al., 
(2009) reported that when IONPs with size about 10 nm were coated with 
poly(ethyleneoxide) triblock copolymer (PEO±COOH±PEO) the size was increased 
to 100±200 nm. Uptake of particles was observed in three cell types: prostate cancer 
cell lines (PC3 and C4±2), human umbilical vein endothelial cells (HUVECs), and 
human retinal pigment epithelial cells (HRPEs) were investigated. The particles were 
located inside the cells after uptake, and the locations were defined by staining the 
lysosmes with LysoTracker. The result of the confocal image showed the particles 
did not locate inside these vesicles. Other results reported by Panyam et al., (2002) 
showed PLGA nanoparticles of 70 nm diameter escaped from the endo-lysosmal 
compartment, and it was postulated that this could be attributed to the selective 
surface charge reversal in acidic endo-lysosmes.   
The other finding in this project was that the PGA 40%C18±IONPs and PEG±
PGA 40%C18±IONPs showed high uptake in the presence of serum. Normally serum 
adsorption on the nanoparticles reduces uptake. Work reported by  Petri-Fink et al., 
(2008) showed the presence of serum strongly inhibited the uptake of vinyl 
alcohol/vinyl amine copolymer (A±PVA) coated iron oxide nanoparticles, because of  
adsorption of serum on the particle surface. Berry et al., (2004)  have reported that 
FITC labelled dextran-derivatised IONPs appear to be in clusters in the cell 
cytoplasm, possibly located in endocytic vesicles. Studies reported that the 
commercial dextran±IONPs, such as Feridex and Resovist, showed poor intracellular 
uptake, especially for cells lacking substantial phagocytic capacity (Dodd et al., 1999 
and Ralph et al., 1997).  
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In the presence of the serum the PGA 40%C18±IONPs and PEG±PGA 40%C18±
IONPs, however, showed wide distribution and high uptake by TEM and 
fluorescence microscopies (Figs. 6.1, 6.2, 6.4, 6.22 and 6.23).  
6.4.2 Effects of Time and Dose 
Two further factors have been investigated in this chapter, which are the time and the 
dose and how they affect the uptake. These have been determined using fluorescence 
microscopy, confocal microscopy and flow cytometry. Two coatings were used here, 
PEG±PGA 40%C18±IONPs and PGA 40%C18±IONPs. Fluorescence microscopy 
micrographs showed the uptake increased with an increase in the dose. The uptake 
was high even with a low dose of nanoparticles. Also, both of the coatings showed 
very high uptake but uptake of PEG±PGA 40%C18±IONPs was higher than 
PGA 40%C18±IONPs. The uptake was carried out in the presence of serum but this 
did not affect the uptake. 
Confocal fluorescence micrographs of cells appeared to show fluorescence intensity 
increased with an increase of nanoparticle concentration (Figs. 6.10 and 6.11). 
However, in these experiments the PGA 40%C18±IONPs appeared to be taken up 
more effectively than the PEG±PGA 40%C18±IONPs. 
The quantification of nanoparticles uptake was carried out by flow cytometry. As 
shown in Fig. 6.19, RBITC labelled uptake by C6 cells was dependent on the dose of 
NPs. The results of flow cytometry revealed that at early time points the uptake of 
PGA 40%C18±IONPs and PEG±PGA 40%C18±IONPs was very similar, but that at 
later time points PEG±PGA 40%C18±IONPs uptake was higher than PGA 40%C18±     
IONPs and continued increasing steadily. The results corresponded with the 
fluorescence microscopy dose uptake. 
The goal was to find out how time and dose had affected the uptake and the required 
time and dose that could be used for in vitro studies.  Wang et al.,( 2010)  studied the 
uptake of the poly(DL-lactic acid-co-a,b-malic acid) coated IONPs by cells incubated 
for different times: 2, 4, 8, 12, 24 and 48 h. He showed that the uptake increased with 
increasing incubation time and the highest iron uptake was obtained after 24 h 
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incubation with a medium containing 0.2 mg/mL nanoparticles. In my studies, a 
range of 0.1 to 1 ml of nanoparticles was used.  The concentration of coated IONPs 
was 0.07 M (3.92 mg/ml) and after dilution into cell culture medium was 1.96 mg/ml 
giving amounts down to 0.2 PJPOIRUWKHµ PO¶DPRXQW. This lowest amount used 
in my studies was therefore similar to the amount used in the study reported above. 
In my studies, the highest were 10x this amount, and even at this was not a saturating 
amount for uptake. 
6.4.3 Metabolism and Retention of Nanoparticles Uptake with time 
The metabolism of particles in the cells was followed by changes in fluorescence 
over time after incubation of the cells with particles for 2 h followed by washing and 
further incubation of cells. The fluorescence micrographs showed that PGA 40%C18±
IONPs  (Figs. 6.7 and 6.9) remained in the cells over the early hours, i.e. from 1 to 4 
hr, and then started to disappear after that, while with PEG±PGA 40%C18±IONPs  
the fluorescence started to disappear after 6 h incubation time. The time series 
fluorescence images over the 24 h incubation time showed that the intracellular 
fluorescence intensity level decreased with increased incubation time. The 
fluorescence had completely disappeared at 24 h.   
Flow cytometry studies of the two coatings showed the drop in MFI (Fig. 6.21) and 
agreed with the fluorescence images. By 24 h the fluorescence levels were close to 
background levels. The explanation could be attributed to the fluorescence 
disappearing but the nanoparticles still remaining in the cells. The PGA 40%C18 
could be degraded by lysosome and the RBITC diffused out of the cells, while the 
IONPs may have either been metabolised or still be in the cells. Previous studies by 
Meng et al. (2006) with 200 nm PGA nanoparticles have shown that the PGA is 
degraded rapidly in the lysosomal compartment, leading to a loss of RBITC 
fluorescence. PGA backbone is synthesised by an enzymic reaction, and so the ester 
bonds would be expected to be particularly labile in the lysosomal environment. 
The uptake of Streptavidin±fluorescein labelled iron oxide incubated with cells for 
24 h was investigated by using flow cytometry and fluorescence microscopy.  
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The particles were shown to be in the lysosomal compartment of the cells, which 
suggested a receptor-mediated uptake mechanism (Becker et al., 2007).    
Corot et al., (2006) explained the disappearance of iron oxide nanoparticles. Cells 
showed a gradual decline of intracellular iron particles with increasing time after 
incubation, which can be attributed to cell division and exocytosis or release of iron 
from non-viable cells over a period of 3 days. 
The gradual disappearance of magnetic labelling may be because of the incorporation 
of iron into metabolic pathways, which constitutes a major pathway in non-dividing 
cells. This is a longer time period than investigated in these studies. 
6.4.4 Uptake into Aggregates 
Work was carried out using 3D cell aggregates because they are a much better model 
of the in vivo environment. This matters for two reasons. Firstly, the penetration of 
small nanoparticles across tissues is very important when considering the possible in 
vivo localisation of these nanoparticles if used as contrast agents, and this cannot be 
investigated using monolayers. Secondly the uptake of nanoparticles in cells grown 
in 3D is different to that of cells grown in monolayer (Meng et al., 2007a). This work 
was carried out using confocal microscopy.  
A very high uptake of PGA 40%C18±IONPs and PEG±PGA 40%C18±IONPs was 
observed in the periphery of aggregates but there were still substantial amounts of 
nanoparticles penetrating into the centre of the aggregates (Figs. 6.15,6.16, 6.17 and 
6.18 ). Uptake, particularly penetration into the aggregates, increased with time, with 
very high levels of uptake observed at 24 h.  PEG±PGA 40%C18±IONPs appeared to 
show a higher penetration than the PGA 40%C18±IONPs. The pattern of intracellular 
uptake was more difficult to see in these lower magnification pictures, but appeared 
to be similar to that seen in monolayer culture. The amount of uptake subjectively 
looked higher than in monolayer culture as reported for larger PGA nanoparticle 
(Meng et al., 2006). 
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The percentage of carboxylated polystyrene nanoparticles that were taken up by the 
spheroid core was affected by the particle size, i.e. the uptake decreased with 
increased particle size, where particles with size 20 and 40 nm penetrated  more 
effectively than  the nanoparticles with sizes about 100 and 200 nm (Goodman et al., 
2007). With the nanoparticles in this study, which had a similar size to the smaller 
particles as reported above, the uptake and penetration was high. Also the surface 
charge has an effect on the uptake with aggregates. Liposomes with different surface 
charge were investigated. The results showed liposomes with neutral or low surface 
charge penetrated to the centre of spheroids, whereas with higher particle surface 
charge  they remained more towards the outer layer of the aggregates (Saga et al., 
1995). In chapters 4 and 5 it was shown that the IONPs coated with PGA 0%, PGA 
40%C18 and PEG±PGA 40%C18 showed low surface charge and were nearly neutral.    
Insufficient uptake of nanoparticles in solid tumours and extravasation because of the 
binding within tumour tissue increased the interstitial fluid pressure caused by leaky 
vasculature and poor lymphatic drainage, and torturosity and hindered diffusion due 
to cell packing and the extracellular matrix (ECM) (Netti et al., 2000, Jain, 2001, 
Kuppen et al., 2001,Davies et al., 2001 and Grantab et al., 2006). At Nottingham, 
previous work by Meng (2006) using PGA nanoparticles with size about 170 nm 
showed limited uptake in aggregates because of the size, while with PGA 40%C18±
IONPs and PEG±PGA 40%C18±IONPs in this project the uptake was higher. Studies 
reported that the smaller particles showed an ability to transport across and diffuse 
between organised collagen fibrils. The spacing of the fibrils was measured in poorly 
organised tumour ECM where the small space was about 20±40 nm and the larger 
spaces between 75±130 nm (Pluen et al., 2001). 
6.4.5 Overview 
Coated IONPs have been evaluated as a possible candidate for contrast agent for 
MRI by cellular uptake, distribution in the cell, retention, metabolism and 
localisation of RBITC labelled nanoparticles in cells.  
Microscopy studies illustrated that when the IONPs coated with both PGA 40%C18 
and PEG±PGA 40%C18 were taken up by the cells, the uptake was very high. 
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The nanoparticles showed a very fine distribution in cytoplasm and around the 
nuclei. The uptake of PEG±PGA 40%C18±IONPs was similar to or higher than the 
PGA 40%C18±IONPs, depending on the conditions used. Flow cytometry studies 
showed cellular uptake of PGA 40%C18±IONPs and PEG-PGA 40%C18±IONPs were 
dependent on the dose and incubation time of nanoparticles. The study showed 
agreement with the microscopy studies and the higher cellular uptake in cells was 
with PEG±PGA 40%C18±IONPs, but also the PGA 40%C18±IONPs showed very 
high uptake. This was in contrast to many other studies using IONPs reported in the 
literature where uptake was usually poor.  
The retention and metabolism of nanoparticles were studied and showed a loss of 
fluorescence with time. Further work is necessary to show whether this was a loss of 
particle coating and fluorescence or also a loss of iron oxide core. Distribution, 
penetration and intracellular uptake were studied in 3-D cell cultures and it was 
found that intracellular uptake of the nanoparticles was dependent on the incubation 
time. The confocal microscopy micrographs demonstrated that penetration of 
nanoparticles into aggregates was very effective, giving high fluorescence intensity 
even towards the centre of the aggregates.  
TEM studies demonstrated the subcellular localisation of nanoparticles. TEM images 
illustrated the massive uptake into cells and showed that the nanoparticles were 
located in nuclei and every other subcellular compartment in the cells. The 
nanoparticles did not show any aggregation after uptake, although some small groups 
of particles were seen as well as nanoparticle adsorption to membranes. This 
distribution is unusual as most studies show uptake by an endosomal route and 
confinement of nanoparticles to the endosomal/lysosomal system. TEM 
investigations were unable to determine the route of uptake that needs more 
investigation. There was no change in the morphology of the cell as a result of even 
high levels of nanoparticle uptake. The results in this chapter suggest the capability 
of these small particles to be taken up with very broad subcellular distribution and 
the power to penetrate into cell aggregates. These novel PEG±PGA 40%C18±IONPs 
and PGA 40%C18±IONPs could therefore be useful for medical applications of both 
drug delivery and as MRI contrast agents. 
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CHAPTER 7 
7. SUMMARY AND CONCLUSIONS 
7.1 Aims and objectives 
In this project, coated IONPs have been produced and their properties examined. 
IONPs with size 13 ± 9 nm in diameter as determined by TEM were synthesised by 
the co-precipitation method. The IONPs tend to aggregate and form large particles 
which can easily be eliminated by defence systems in the body. Coating particles was 
necessary to prevent aggregation and provide biological stability. 
The early stage of the research project focused on the synthesis of small 
nanoparticles coated with the most common polymers used in this field, dextran and 
carboxymethyl dextran (CMD). Characterisation of each of the products was 
investigated using the complementary techniques of DLS, zeta potential and TEM.  
Throughout this study we were also trying to understand the effect of the type of the 
polymer, the amount of polymer coating nanoparticles, the amount of solvent and the 
method on the coated particles size. Polymers such as CMD and dextran have been 
extensively used as coating for nanoparticle formulations.  
The bulk of this project has concentrated on developing coatings using biodegradable 
polymers. The idea is to exploit existing knowledge on drug delivery systems to 
deliver contrast agents. PGA was chosen for this work because this polymer 
backbone can be modified with acyl groups to give polymers with different 
properties. The 40%C18 acylated polymer has been previously shown to have 
excellent properties for this work. Particles made with these polymers have been 
shown to be taken up by cells and readily degraded within the cells. They also have 
high drug entrapment efficiency for labelling with fluorescent dyes. These polymers 
CHAPTER 7                                                                        Summary and Conclusions 
224 
were used for coating the nanoparticles. This thesis describes the development of 
suitable coatings using these polymers. 
To improve the stability of the nanoparticles, PEG was coupled to the acylated 40% 
C18 by using a monoamine PEG to couple to a terminal carboxyl group on the PEG.  
This reaction gave a yield of 77%, and the copolymer has been characterised. The 
copolymer has been used to coat the nanoparticles. 
The stability of the nanoparticles with different coatings, including overcoatings such 
as albumin and Tween 80%, has been assessed using a range of different 
concentrations of NaCl.  The coated particles show a very good stability to 
aggregation up to physiological levels. 
Intracellular uptake of RBITC labelled PGA 40%C18 and PEG±PGA 40%C18 coated 
IONPs by the C6 cell line, and C6 cell aggregates, have been carried out.  Retention 
of RBITC labelled NPs within cells was evaluated. Uptake was determined and 
confirmed using fluorescence microscopy, confocal microscopy and flow cytometry. 
Finally, cells were also used to examine the intracellular location of the uptake of 
NPs using TEM.  
7.2 Overall  Summary 
7.2.1 Iron Oxide Nanoparticle Manufacture 
We have presented a controlled co-precipitation method which produced iron oxide 
nanoparticles. The pH of IONPs was a crucial factor to control the particle size. 
Particle sizes 13 nm in diameter, a narrow size distribution, were measured by TEM 
and DLS. Small particle sizes can be prepared by changing the operational 
parameters, e.g. optimum pH, which was established at pH 0.5. The particle showed 
high stability when stored for 7 days as a formal experiment, but my records show up 
to 1 year without any change of the particle size.  
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7.2.2  Dextran±Coated Iron Oxide Nanoparticles 
7.2.2.1 Synthesis of Carboxymethyl dextran  
The carboxymethyldextran derivative was obtained by statistical substitution of the 
dextran hydroxyl groups on the glycosyl unit. The degree of substitution of 
carboxymethyl groups was determined by acidic titration. The dextran derivative 
with high degree of substitution with carboxymethyl group was 0.49, a result similar 
to that reported by other groups for this reaction. 
CMD±IONPs and dextran±IONPs about 40 nm in size with narrow distribution 
measured by TEM have been synthesised using a co-precipitation method, either in 
the presence of the polymer or in the absence of the polymer. The two methods for 
coating nanoparticles gave a similar final nanoparticle size. Zeta potential was 
negative for all preparations of CMD nanoparticles made. This could be attributed to 
the carboxyl group on the polymer. 
7.2.3 Different Substitutions of PGA±coated IONPs using two 
different Methods 
This chapter has examined coated nanoparticles with PGA polymer backbone and its 
substituted acylated 40% variant. Particles were coated with Tween 80 (0.1%) and 
albumin in order to increase the stability. The purification of nanoparticles was also 
investigated. 
 
On comparing the particles prepared by the IDP and sonication methods, the 
modified interfacial deposition method allowed us easily to obtain PGAs±coated 
IONPs nanoparticles with a good yield and with a smaller size than particles 
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prepared by the sonication method. The nanoprecipitation method is more flexible 
and can be modified (Alonso, 1996). 
Using PGA polymers with acyl groups of varying chain lengths, it was observed that 
the chain length of the acyl group and the degree of acylation seemed to be less 
important for enhanced coatings. The preparation of coated nanoparticles under 
optimum conditions is important in terms of the physicochemical properties of 
nanoparticles. The polymer and solvent ratios were two of the parameters with the 
greatest effect on size. 
By choosing the right method, small PGA 0% coated IONPs can be produced with a 
small amount of polymers (0.2 mg) and 2 ml of acetone. The small particles were 
found be under about 20 nm, which is smaller than other formulations reported in the 
literature with biodegradable hydrophobic polymers. Transmission electron 
micrographs showed nanoparticles were spherical and with very little aggregates and 
in the nanometre size range 16 ± 5 nm. 
Poly(glycerol adipate) is a water insoluble polyester. The presence of hydrophilic 
groups confers some hydrophilic characteristics on the backbone. The addition of 
acyl groups led to an increase in polymer hydrophobicity by decreasing the number 
of free OH groups on the backbone. Substituting the pendant hydroxyl groups of the 
backbone with hydrophobic acyl groups (C18) increases the stability of the 
nanoparticles. The acyl groups and the chain lengths were determined using the 
traditional, analysis techniques such as FTIR, NMR and GPC and confirmed the 
acylation of PGA backbone with high yield. The acylation of PGA backbone is 
simple, flexible and efficient. 
Polymer was substituted by C18 chains, and coated IONPs with small size were still 
obtained using the nanoprecipitation method. The iron oxide particles were clearly 
detected in the polymer by TEM. Many nanoparticles were separately coated with 
the polymer and some polymer-coated aggregates were also found. These TEM 
results correlate very well with the data obtained by dynamic light scattering. 
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Treatment of coated nanoparticles with a low concentration of NaCl followed by a 
brief centrifugation removed large and poorly coated nanoparticles. This technique 
seems to be suitable for the purification of coated nanoparticles.  
7.2.4 PEGylated PGA 40%C18 
An easy and favourable approach had been developed to prepare PEGylated PGA 
40%C18 by activating the COOH group on the PGA by the CDI and bio-orthogonal 
reaction of the N terminus of the monoamine PEG molecule. The coupling of 
monoamine group on the PEG to the PGA 40%C18 was successful and gave a yield 
of 78%. The coupling between the polymers has been confirmed by GPC, NMR and 
FTIR. 
7.2.4.1 PEGylated PGA 40%C18 coated iron oxide nanoparticles 
In this work demonstrated the possibility of synthesising PEGylated±PGA 40%C18. 
PEGylation with PEG 2000 gave surface modified layer with PGA 40%C18 
precipitated around the surface of the nanoparticles. On the basis of the result, it is 
concluded that the physicochemical characteristics of PGA±IONPs could be 
controlled by altering several experimental conditions, such as the amount of the 
polymer and the amount of the solvent. 
IONPs coated with a layer of PEG±PGA 40%C18 were prepared using our modified 
ID method to determine the optimum conditions for preparing small nanoparticles. 
The best conditions were found to be using 0.2 mg of polymer and 2 ml of acetone 
which gave clean and smooth particles with only very rare aggregates with average 
size 16 ± 4 nm. Decreasing the amount of the polymer to 0.1 mg caused an increase 
of the particle size. The TEM images indicated that the optimised nanoparticles with 
0.2 mg of  polymers (PGA  0% ,PGA 40%C18 and PEG±PGA 40%C18) with 2 ml of 
acetone coated IONPs  were spherical in shape without any aggregation, and smooth, 
and that the particle size was small 16 ± 5 nm, 23 ± 7 nm and 16 ± 4 nm respectively. 
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Zeta potential showed a positive charge. In any case, for all the formulations the 
smallest size was with 0.2 mg of polymer addition for all the polymers (PGA, PGA 
40%C18 and PEG±PGA 40%C18) with 2 ml of acetone coated IONPs.  
7.2.5 Stability of Coated Iron Oxide Nanoparticles. 
The investigation on the stability of NPs coated with different polymers and 
overcoating showed differences in the turbidity of NP suspensions with different 
concentrations of NaCl before the critical flocculation point occurred. To increase 
the stability of the nanoparticles in a biological medium, the surface of nanoparticles 
was coated with either 0.1% Tween or 0.1% albumin. 
The PGA±IONPs were remarkably stable even in high sodium chloride concentration 
and showed more stability than dextran-coated IONPs. It was shown that the stability 
of the coated nanoparticles increased after overcoating with either Tween or albumin. 
The overcoatings were found to be stable under conditions mimicking the 
physiological medium. Thus, 0.2 mg of polymers (PGA 0%
 
and PGA 40%C18) 
coated IONPs and 0.1% Tween and albumin would be useful to stabilise the 
nanoparticles in vivo. Overcoating with albumin would be equivalent to providing 
the surface characteristics which would be expected by putting the particles into 
serum. PEGylated PGA 40%C18±IONPs were also effectively stabilised at high 
concentrations of NaCl, making these particles suitable for in vitro and in vivo use. 
7.2.6 Coated IONPs Uptake by Cells 
To evaluate IONPs as a useful delivery system for medical applications, cellular 
uptake, intracellular distribution and localisation, the retention and metabolism of 
RBITC labelled NPs have been examined in C6 cells. NP uptake has been 
determined over different time periods and with different doses. Both the quantitative 
and qualitative evaluation of NP uptake was performed by using flow cytometry and 
fluorescence microscopy following the uptake of fluorescently labelled NPs. Uptake 
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has also been investigated in cell aggregates. Observation of cultures by confocal 
microscope and TEM images have confirmed the uptake and the localisation into 
cells. 
Firstly, studies of NP distribution and intracellular distribution were carried out in 
monolayer culture mode using fluorescence microscopy. Those studies demonstrated 
that, in contrast to many other studies, the uptake was very high and dependent on 
both time and dose. Both in the presence and absence of serum the nanoparticles also 
showed high uptake. Similarly, PGA 40%C18 coatings based on either Tween or 
PEGylation of PGA 40%C18 also showed high uptake of particles into cells. In all of 
these conditions there was a surprising intracellular distribution. These findings were 
confirmed by confocal fluorescence microscopy. Uptake studies were also performed 
by using flow cytometry studies. Intracellular uptake of NPs was dependent on the 
incubation time and NP concentration. Flow cytometry studies also showed cells had 
high nanoparticle uptake.  
From the TEM images can be concluded that the nanparticles were internalised in 
cells entering the cytoplasm, subcellular organelles and nuclei. The number of 
individual nanoparticles taken up was huge, and nanoparticles were found to be 
present in nuclei and in all subcellular compartments throughout the cell. The 
invasion of nanoparticles into all areas of the cell was very surprising. As transport 
across membranes has clearly taken place, it is unclear whether or not uptake is 
mediated by endocytosis or direct uptake. This unusual behaviour must be attributed 
to two factors: the small size of the particles and the high protection to stability given 
by the coatings. 
The time-series fluorescence images of cells incubated with both NPs showed that 
the intracellular fluorescence intensity level decreased with the incubation time of 
cells with fresh culture medium. These results were confirmed with quantitative flow 
cytometry, suggesting either loss of nanoparticle coating or disappearance of the 
nanoparticles from cells. Further experiments are needed to resolve this question.   
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Uptake of nanoparticles into spherical aggregates was evaluated by confocal 
microscopy studies in 3-D cell aggregates which were formed spontaneously by 
using a high individual cell concentration. The penetration of NPs in aggregates was 
rapid and occurred deep into the aggregates. These aggregate models have not so far 
been used much by other workers in this field, but they supply very important 
information that may help us with further future research into medical applications 
such as drug delivery. 
7.3 FUTURE WORK 
In this thesis, a new system of manufacturing small coated IONPs with unmodified 
PGA, C18 acylated PGA and PEGylated PGA has been established.  This work has 
helped in understanding and identifying a range of key factors that primarily 
contributed to the successful production of small monodisperse coated nanoparticles. 
Use of analytical techniques like DLS, Zeta potential and TEM was sufficient to find 
out the important properties of the nanoparticles, but needs to be explored further in 
order to quantify other important properties using X-ray diffraction techniques and 
magnetic measurements. More study is needed to capture further information about 
the zeta potential of the particles using a range of buffers. 
The excellent results in cell work showed a different uptake behaviour by these very 
small coated nanoparticles. Further investigation of the uptake of nanoparticles in 
different types of cell and different cultures, such as co-culture models, would be 
particularly useful. Also, further investigation into the effects of different surface 
coatings would be valuable. Further work is also required on the uptake of the 
nanoparticles into cellular aggregates examined by TEM. 
PGA has a very flexible chemistry, and these coated nanoparticles could be very 
useful for more research in the development of drug delivery systems. In addition to 
loading with conventional drugs, loading with DNA, siRNA and binding with a 
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range of ligands and incorporating different types of proteins, enzymes, antibodies, 
or nucleotides on the particle surfaces is possible.  
With the preparation and characterisation of these coated nanoparticles almost 
completed, in vivo studies would now be useful to determine their biodistribution and 
in the assessment of the effects of the nanoparticles as contrast agents to detect 
defective and diseased cells. Also for the possible tracking of stem cells in vitro and 
in vivo. 
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